Some pages of this thesis may have been removed for copyright restrictions.

If you have discovered material in Aston Research Explorer which is unlawful e.g. breaches copyright, (either yours or that of a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity, defamation, libel, then please read our [Takedown policy](mailto:openaccess@aston.ac.uk) and contact the service immediately.
METHYLGLOYXAL, GLYOXALASES AND CELL PROLIFERATION

NIGEL IRA HOOPER

Doctor of Philosophy

THE UNIVERSITY OF ASTON IN BIRMINGHAM

October 1987

This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without the author's prior, written consent.
SUMMARY

The metabolic function of the glyoxalase system was investigated in (a) the differentiation and proliferation of human tumour cells in vitro, (b) the cell-free assembly of microtubules and (c) in the red blood cells during hyperglycaemia associated with Diabetes Mellitus.

Chemically-induced differentiation of human promyelocytic HL60 leukaemia cells to neutrophils, and K562 erythroleukaemia cells, was accompanied by a decrease and an increase in the activity of glyoxalase I, respectively. Growth-arrest of Burkitt's lymphoma Raji cells and GM892 lymphoblastoid cells was accompanied by an increase and a decrease in the activity of glyoxalase I respectively. However, differentiation and growth arrest generally proceeded with an increase in the activity of glyoxalase II. Glyoxalase I activity did not consistently correlate with cell differentiation or proliferation status; hence, it is unlikely that glyoxalase I activity is either an indicator or a regulator of cell differentiation or proliferation. Conversely, glyoxalase II activity consistently increased during cell differentiation and growth-arrest and may be both an indicator and regulator of cell differentiation or proliferation. This may be related to the control of cellular microtubule assembly.

S-D-Lactoylglutathione potentiated the cell-free, GTP-promoted assembly of microtubules. The effect was dose-related and was inhibited by glyoxalase II. During assembly, S-D-lactoylglutathione was consumed. This suggests that the glyoxalase system, through the influence of S-D-lactoylglutathione, may regulate the assembly of microtubules in cellular systems.

The whole blood concentrations of methylglyoxal and S-D-lactoylglutathione were increased in Diabetes Mellitus. There was no significant difference between red blood cell glyoxalase activities in diabetics, compared to healthy controls. However, insulin-dependent diabetic patients with retinopathy had a significantly higher glyoxalase I activity and a lower glyoxalase II activity, than patients without retinopathy. Diabetic retinopathy correlated with high glyoxalase I activity and low glyoxalase II activity and suggests the glyoxalase system may be involved in the development of diabetic complications.

Keywords: Glyoxalase, S-D-lactoylglutathione, microtubules, differentiation, proliferation.
TO TERRY.
ACKNOWLEDGEMENTS

First of all, I would like to thank my supervisor, Dr Paul Thornalley, for his constant help, advice and enthusiasm over the past three years.

I would also like to thank my associate supervisor, Dr Mike Tisdale, for his advice at various times and for providing the many cell cultures I've used throughout this work.

My thanks are also due to Drs P. Jennings, C. Florkowski and A. Barnett at the Diabetic clinic, East Birmingham Hospital for providing the clinical samples used in the diabetic study.

Grateful thanks are extended to the various members, past and present, of 636 for putting up with three years of my "humour" and occasional moods without complaining too much.

Finally, Miss Beci Holt deserves special thanks for providing a sympathetic ear and endless advice on the one subject I shall probably never understand.
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>DEDICATION</td>
<td>3</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>4</td>
</tr>
<tr>
<td>CONTENTS</td>
<td>5</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>10</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>12</td>
</tr>
<tr>
<td>ABBREVIATIONS</td>
<td>14</td>
</tr>
<tr>
<td>CHAPTER 1. INTRODUCTION</td>
<td>15</td>
</tr>
<tr>
<td>1.1 The Glyoxalase System - A Definition</td>
<td>15</td>
</tr>
<tr>
<td>1.1.1 Historical</td>
<td>16</td>
</tr>
<tr>
<td>1.2 Glyoxalase I</td>
<td>19</td>
</tr>
<tr>
<td>1.2.1 Distribution and Molecular Characteristics</td>
<td>19</td>
</tr>
<tr>
<td>1.2.2 Substrate Specificity</td>
<td>21</td>
</tr>
<tr>
<td>1.2.3 The Rate of the Glyoxalase I Reaction</td>
<td>24</td>
</tr>
<tr>
<td>1.2.4 Probing the Active Site</td>
<td>26</td>
</tr>
<tr>
<td>1.2.5 Catalytic Mechanism of Glyoxalase I</td>
<td>29</td>
</tr>
<tr>
<td>1.2.6 Inhibition</td>
<td>33</td>
</tr>
<tr>
<td>1.2.7 Genetics and Polymorphism</td>
<td>35</td>
</tr>
<tr>
<td>1.3 Glyoxalase II</td>
<td>38</td>
</tr>
<tr>
<td>1.3.1 Distribution and Molecular Characteristics</td>
<td>38</td>
</tr>
<tr>
<td>1.3.2 Substrate Specificity</td>
<td>40</td>
</tr>
<tr>
<td>1.3.3 The Rate of the Glyoxalase II Reaction</td>
<td>40</td>
</tr>
<tr>
<td>1.3.4 Probing the Active Site</td>
<td>41</td>
</tr>
<tr>
<td>1.3.5 Inhibition</td>
<td>42</td>
</tr>
<tr>
<td>1.3.6 Genetics and Polymorphism</td>
<td>43</td>
</tr>
</tbody>
</table>
1.4 Methylglyoxal
   1.4.1 Formation 44
   1.4.2 Metabolism 45
   1.4.3 The Concentration of Methylglyoxal in Biological Tissues 46
   1.4.4 Other Reactions 47
1.5 S-D-Lactoylglutathione 49
1.6 D-Lactate 49
1.7 Physiological Role of the Glyoxalase System 50

CHAPTER 2. BACKGROUND TO THIS WORK. 54

2.1 The Modification of the Glyoxalase System in Cell Proliferation and Maturation 54
   2.1.1 The Activity of Glyoxalase I and Glyoxalase II 54
   2.1.2 The Concentration of Methylglyoxal and S-D-Lactoylglutathione 57
   2.1.3 Research Objectives and Plan of Action 57

2.2 The Glyoxalase System in Hyperglycaemia: Possible Involvement in Diabetic Pathogenesis 60
   2.2.1 Diabetic Pathogenesis: Defining the Pathology 60
   2.2.2 Classification of Diabetes Mellitus 61
   2.2.3 The Biochemical Basis for Diabetic Pathogenesis 62
   2.2.3 The Red Blood Cell as a Model for Hyperglycaemic Metabolism in Diabetic Pathogenesis 62

CHAPTER 3. MATERIALS AND METHODS. 65

3.1 Materials 65
3.1.1 Cell Culture 65
3.1.2 Enzymes, Co-factors and Substrates 65
3.1.3 Buffers and Miscellaneous Agents 65
3.1.4 Miscellaneous 66
3.2 The Characterisation of the Glyoxalase System 66
  3.2.1 The Assay of the Activity of Glyoxalase I in Cell Extracts 66
  3.2.2 The Assay of the Activity of Glyoxalase II in Cell Extracts 69
  3.2.3 The Assay of Reduced Glutathione and S-D-Lactoylglutathione in Whole Human Blood 70
  3.2.4 The Assay of Methylglyoxal In Whole Human Blood 71
3.3 Modification of the Glyoxalase System During the Differentiation of Human Leukaemia Cells In Vitro 73
3.4 Changes in Glyoxalase Activities During Growth Arrest of Raji and GM892 Cells 76
3.5 The Potentiation of Cell-Free Microtubule Assembly by S-D-Lactoylglutathione 77
  3.5.1 The Purification of Microtubular Protein from Porcine Brain 77
  3.5.2 The Measurement of Microtubular Assembly by Turbidity 80
  3.5.3 The Consumption of S-D-Lactoylglutathione on Assembly 80
3.6 The Red Blood Cell Glyoxalase System in Diabetic Patients 81
  3.6.1 Patients 81
  3.6.2 The Assay of Red Blood Cell Glyoxalase Activities 81
  3.6.3 The Assay of Methylglyoxal and S-D-Lactoylglutathione 82
3.7 Instrumentation

3.7.1 Spectrophotometry

3.7.2 High Pressure Liquid Chromatography

CHAPTER 4. RESULTS.

4.1 Changes in Glyoxalase Activity During the Differentiation of Human Leukaemia Cells In Vitro

4.1.1 Human Promyelocytic Leukaemia HL60 Cells

4.1.2 Human Erythroleukaemia K562 Cells

4.1.3 The Substrate - Reaction Velocity Relationship For Glyoxalase Enzymes During the Differentiation of Human Promyelocytic Leukaemia Cells to Neutrophils

4.2 Changes in Glyoxalase Activity During the Growth Arrest of GM892 Lymphoblastoid and Raji Burkitt's Lymphoma Cells In Vitro

4.2.1 Growth Arrest of GM892 Lymphoblastoid Cells

4.2.2 Growth Arrest of Raji Burkitt's Lymphoma Cells

4.3 S-D-Lactoylglutathione and the Cell-Free Assembly of Microtubules

4.3.1 The Potentiation of Microtubule Assembly by S-D-Lactoylglutathione

4.3.2 The Consumption of S-D-Lactoylglutathione on Assembly of Microtubules

4.4 The Red Blood Cell Glyoxalase System During Hyperglycaemia In Vivo

4.4.1 Glyoxalase Activities

4.4.2 The Concentration of Methylglyoxal in Whole Human Blood
CHAPTER 5. DISCUSSION.

5.1 The Glyoxalase Enigma

5.2 Modification of the Glyoxalase System During the Differentiation of Human Leukaemia Cells In Vitro

5.3 Modification of the Glyoxalase System During Changes in Cell Proliferation Status

5.4 The Effect of S-D-Lactoylglutathione on Cell-Free Assembly of Microtubules

5.4.1 The Cell-Free Assembly of Microtubules

5.4.2 The Effect of S-D-Lactoylglutathione on the Kinetics of Cell-Free Assembly of Microtubules

5.4.3 The Consumption of S-D-Lactoylglutathione During the Cell-Free Assembly of Microtubules

5.5 The Red Blood Cell Glyoxalase System During Hyperglycaemia In Vitro

5.5.1 Diabetes Mellitus and Retinopathy

5.5.2 Age and Duration of Diabetes

5.5.3 Glyoxalase Activities

5.5.4 The Concentration of Methylglyoxal and S-D-Lactoylglutathione in Whole Human Blood

CHAPTER 6. CONCLUSION.

CHAPTER 7. REFERENCES.
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The Environment of the Metal Ion in the Active Site of Glyoxalase I</td>
<td>30</td>
</tr>
<tr>
<td>2</td>
<td>The Proposed Reaction Mechanism of Glyoxalase I</td>
<td>32</td>
</tr>
<tr>
<td>3</td>
<td>A Typical Calibration Curve for the Assay of Reduced Glutathione and S-D-Lactoylglutathione</td>
<td>72</td>
</tr>
<tr>
<td>4</td>
<td>A Typical HPLC Trace for the Assay of Methylglyoxal</td>
<td>74</td>
</tr>
<tr>
<td>5</td>
<td>Flow Diagram for the Purification of Microtubular Protein from Porcine Brain</td>
<td>79</td>
</tr>
<tr>
<td>6</td>
<td>The Glyoxalase I and Glyoxalase II Activities in HL60 Cells Treated with N-Methylformamide (NMF)</td>
<td>85</td>
</tr>
<tr>
<td>7</td>
<td>The Relationship Between Changes in the Activities of the Glyoxalase Enzymes and the Percentage of Differentiated HL60 Cells after Treatment with NMF and CCRG 81045 for 4 Days</td>
<td>88</td>
</tr>
<tr>
<td>8</td>
<td>The Activity of Glyoxalase I and Glyoxalase II in HL60 Cells Treated with CCRG 81045 for 6 Days</td>
<td>91</td>
</tr>
<tr>
<td>9</td>
<td>The Glyoxalase I and Glyoxalase II Activities in K562 Cells Treated with N-Methylformamide</td>
<td>98</td>
</tr>
<tr>
<td>10</td>
<td>The Glyoxalase I and Glyoxalase II Activities in K562 Cells Treated with CCRG 81045</td>
<td>102</td>
</tr>
<tr>
<td>11</td>
<td>The Substrate Concentration - Reaction Velocity Relationship for the Glyoxalase I-Catalysed Reaction During the Differentiation of HL60 Cells to Neutrophils</td>
<td>106</td>
</tr>
<tr>
<td>12</td>
<td>The Substrate Concentration - Reaction Velocity Relationship for the Glyoxalase II-Catalysed Reaction During the Differentiation of HL60 Cells to Neutrophils</td>
<td>107</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>13</td>
<td>The Effect of Proliferation Rate on the Activity of Glyoxalase Enzymes in GM892 Cells</td>
<td>110</td>
</tr>
<tr>
<td>14</td>
<td>The Effect of Proliferation Rate on the Activity of Glyoxalase Enzymes in Raji Cells</td>
<td>112</td>
</tr>
<tr>
<td>15</td>
<td>The Effect of S-D-Lactoylglutathione on the Assembly of Microtubules</td>
<td>114</td>
</tr>
<tr>
<td>16</td>
<td>The Effect of the Concentration of S-D-Lactoylglutathione on Microtubule Assembly</td>
<td>116</td>
</tr>
<tr>
<td>17</td>
<td>Frequency Distribution Curves for the Glyoxalase I Activity of Red Blood Cells</td>
<td>119</td>
</tr>
<tr>
<td>18</td>
<td>Frequency Distribution Curves for the Glyoxalase II Activity of Red Blood Cells</td>
<td>120</td>
</tr>
<tr>
<td>19</td>
<td>Frequency Distribution Curves of Glyoxalase I Activity in Red Blood Cells from Insulin-Dependent Diabetic Patients</td>
<td>126</td>
</tr>
<tr>
<td>20</td>
<td>Frequency Distribution Curves of Glyoxalase II Activity in Red Blood Cells from Insulin-Dependent Diabetic Patients</td>
<td>127</td>
</tr>
<tr>
<td>21</td>
<td>Frequency Distribution Curves of the Concentration of Methyglyoxal in Whole Human Blood</td>
<td>133</td>
</tr>
<tr>
<td>22</td>
<td>Frequency Distribution Curves of the Concentration of S-D-Lactoylglutathione in Whole Human Blood</td>
<td>135</td>
</tr>
<tr>
<td>23</td>
<td>The Relationship Between the Degree of Differentiation of HL60 Cells and the Decrease in the Glyoxalase I/Glyoxalase II Activity Ratio</td>
<td>142</td>
</tr>
<tr>
<td>Table</td>
<td>LIST OF TABLES</td>
<td>Page</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>1</td>
<td>The Activity of the Glyoxalase Enzymes in Different Tissues.</td>
<td>20</td>
</tr>
<tr>
<td>2</td>
<td>Molecular Properties of Glyoxalase I.</td>
<td>22</td>
</tr>
<tr>
<td>3</td>
<td>Molecular Properties of Glyoxalase II.</td>
<td>39</td>
</tr>
<tr>
<td>4</td>
<td>The Activity of Glyoxalase I and Glyoxalase II in Untreated HL60 Leukaemia Cells in Culture.</td>
<td>86</td>
</tr>
<tr>
<td>5</td>
<td>The Glyoxalase I/Glyoxalase II Activity Ratio (A\text{I}/A\text{II}) in N-Methylformamide Treated HL60 Leukaemia Cells in Culture.</td>
<td>90</td>
</tr>
<tr>
<td>6</td>
<td>The Effect of N-Methylformamide and CCRG 81045 on Glyoxalase I Activity in Cell-Free Systems.</td>
<td>93</td>
</tr>
<tr>
<td>7</td>
<td>The Effect of N-Methylformamide and CCRG 81045 on Glyoxalase II Activity in Cell-Free Systems.</td>
<td>94</td>
</tr>
<tr>
<td>8</td>
<td>The Stability of Hemimercaptal and S-D-Lactoylglutathione in the Presence of 185 mM NMF and 103 \text{pM} CCRG 81045.</td>
<td>95</td>
</tr>
<tr>
<td>9</td>
<td>The Stability of Glyoxalase I and Glyoxalase II from HL60 and K562 Cells</td>
<td>96</td>
</tr>
<tr>
<td>10</td>
<td>The Activity of Glyoxalase I and Glyoxalase II in Untreated K562 Erythroleukaemia Cells in Culture.</td>
<td>99</td>
</tr>
<tr>
<td>11</td>
<td>The Glyoxalase I/Glyoxalase II Activity Ratio (A\text{I}/A\text{II}) in N-Methylformamide Treated K562 Erythroleukaemia Cells in Culture.</td>
<td>101</td>
</tr>
<tr>
<td>12</td>
<td>The Glyoxalase I/Glyoxalase II Activity Ratio (A\text{I}/A\text{II}) in CCRG 81045 Treated K562 Erythroleukaemia Cells in Culture.</td>
<td>104</td>
</tr>
<tr>
<td>13</td>
<td>The Apparent Michaelis-Menten Kinetic Constants for the Glyoxalase Enzymes During the Differentiation Of HL60 Promyelocytes to Neutrophils by N-Methylformamide.</td>
<td>108</td>
</tr>
<tr>
<td>Table</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>The Consumption of S-D-Lactoylglutathione During Tubulin Assembly.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>121</td>
<td></td>
</tr>
<tr>
<td>The Activity of Glyoxalase I and Glyoxalase II in Control and Diabetic Patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>122</td>
<td></td>
</tr>
<tr>
<td>Statistical Analysis of the Data from the Diabetic Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>The Age and Duration of Diabetes for Subjects in the Diabetes Study.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>130</td>
<td></td>
</tr>
<tr>
<td>The Activity of the Glyoxalase Enzymes in Age-Matched Non-Insulin-Dependent Type II Diabetics With and Without Complications.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>131</td>
<td></td>
</tr>
<tr>
<td>The Activity of the Glyoxalase Enzymes in Age-Matched Insulin-Dependent Type I Diabetes With and Without Complications.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>134</td>
<td></td>
</tr>
<tr>
<td>The Concentration of Glyoxalase Metabolites in Whole Venous Human Blood.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>155</td>
<td></td>
</tr>
<tr>
<td>The Distribution of Glyoxalase I and Glyoxalase II Activity in 1 ml of Whole Blood.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ABBREVIATIONS

CCRG 81045 : 8-carbamoyl-3-methylimidazo-[5,1-d]-1,2,3,5-tetrazin-4(3H)-one

BL : Burkitt's Lymphoma

DMSO : Dimethyl Sulphoxide

EGTA : 1,2-Di(2-aminoethoxy)ethane-NNN'N'-tetra-acetic acid

GSH : Reduced Glutathione

GTP : Guanosine 5'-Triphosphate

HEPES : N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid

HL60 : Human Promyelocytic Leukaemia - 60 Cell Line

HPLC : High Pressure Liquid Chromatography

MES : 2-(N'-Morpholino)ethanesulfonic acid

NMF : N-Methylformamide

RPMI 1640 : Roswell Park Memorial Institute 1640

TRIS : Tris(hydroxymethyl)aminomethane
1. INTRODUCTION

1.1 The Glyoxalase System - A Definition

The glyoxalase system catalyses the conversion of methylglyoxal to D-lactic acid, via the intermediate S-D-lactoylglutathione. It comprises two enzymes, glyoxalase I and glyoxalase II, plus a catalytic amount of reduced glutathione (1) - Scheme 1.

MeCOCHO

\[ \xrightarrow{\text{Glyoxalase I}} \]

\[ \xrightarrow{\text{Glyoxalase II}} \]

GSH

MeCH(OH)CO-SG

\[ \xrightarrow{\text{Glyoxalase I}} \]

MeCH(OH)CO₂H

\[ \xrightarrow{\text{Glyoxalase II}} \]

\[ \xrightarrow{\text{o-Lactic acid}} \]

**SCHEME 1**

THE GLYOXALASE PATHWAY.

Glyoxalase I [E.C.4.4.1.5, lactoylglutathione lyase] catalyses the formation of S-D-lactoylglutathione from the hemimercaptal formed non-enzymatically between methylglyoxal and reduced glutathione (2).

\[ \text{MeCOCHO} + \text{GSH} \xrightarrow{\text{Glyoxalase I}} \text{MeCOCH(OH)-SG} \xrightarrow{\text{Glyoxalase I}} \text{MeCH(OH)CO-SG} \]
Glyoxalase II [E.C.3.1.2.6, hydroxyacylglutathione hydrolase] catalyses the hydrolysis of S-D-lactoylglutathione to D-lactic acid and regenerates the reduced glutathione consumed in the glyoxalase I-catalysed reaction (2).

\[
\text{MeCH(OH)CO-SG} \xrightarrow{\text{GLYOXALASE II}} \text{MeCH(OH)COOH} + \text{GSH}
\]

The glyoxalase II-catalysed reaction is generally found to be the rate-limiting step of the glyoxalase metabolic pathway. Glyoxalase II is the pacemaking enzyme (2). The glyoxalase system is present in the cytosolic fraction of cells and cellular organelles (3). It is found throughout biological life and is thought to be ubiquitous: Hopkins and Morgan considered the glyoxalase system to be present in the cells of all life forms (4).

1.1.1 Historical.

The glyoxalase system was discovered in 1913 by Dakin and Dudley (5) and by Neuburg (6). It was initially thought to consist of only one enzyme catalysing the conversion of methylglyoxal to lactic acid and phenylglyoxal to mandelic acid. "Glyoxalase activity" was assayed as the rate of production of lactic acid upon the addition of methylglyoxal to cell extracts. At this time, the formation of lactic acid was measured either by the manometric determination of carbon dioxide released by acidification of a
bicarbonate buffer (1,4) or by optical rotation measurements (5,7).

In 1932 Lohmann (1) found that reduced glutathione was an essential cofactor required for "glyoxalase activity". This disclosure stimulated interest in the chemical interaction between methylglyoxal and reduced glutathione. In 1933 Jowett and Quastel (8) reported that reduced glutathione and methylglyoxal combine non-enzymatically to form a complex which, they hypothesised, was converted to lactic acid by "glyoxalase". By 1936 Yamazoye (9) was able to demonstrate that methylglyoxal was converted to an intermediate in liver extracts which was distinct from the non-enzymatic adduct of methylglyoxal and reduced glutathione. The structure of this intermediate remained a mystery for a further 15 years.

In 1951 Racker (2) recognised that the glyoxalase system was comprised of two discrete and consecutive reaction steps, catalysed by two separable enzymes which he called glyoxalase I and glyoxalase II — as defined above. The product of the first enzymatic step was the substrate of the second step; with methylglyoxal, this glyoxalase intermediate was found to be S-D-lactoylglutathione. He developed a direct spectrophotometric method for the assay of S-D-lactoylglutathione and, thereby, measured the activity of glyoxalase I by determining the rate of formation of S-D-lactoylglutathione from methylglyoxal
and reduced glutathione, and the activity of glyoxalase II by determining the rate of disappearance of added synthetic S-D-lactoylglutathione; in the presence of cell extract. This formed the basis of the protocol for the spectrophotometric assay of the activities of the glyoxalase enzymes which is in use today.

In 1954 Racker (10) reported the crucial observation that D-lactic acid is the product of metabolism of methylglyoxal by the glyoxalase system. This fundamentally divorced the glyoxalase system from mainstream glycolytic metabolism which produces L-lactic acid. It was then concluded that the glyoxalase pathway is a minor pathway of non-glycolytic glucose metabolism.

In 1966 it was reported that glyoxalase I is a metalloprotein (11). Initial investigations, studying the loss of enzymatic activity with metal ion chelators and re-constitution of the apoenzyme with restoration of enzymatic activity, suggested the prosthetic metal ion was magnesium (11). However, later studies (12,13) analysing metal content of the purified enzyme defined zinc (II) ions as the physiological metal component of glyoxalase I.
The Glyoxalase Enzymes

1.2. Glyoxalase I.

1.2.1 Distribution and Molecular Characteristics.

Glyoxalase I activity appears to be present in all tissues of prokaryotic and eukaryotic organisms (4). It has been detected in: mammals, birds, fish, amphibians, plants, bacteria, fungi, and invertebrates (4,14-16). In mammals, the highest activities are found in the liver, kidney and brain (4,14,17). Typical activities of glyoxalase I are presented in Table 1. Recent comparison of glyoxalase I activities with radioimmunoassay of the enzyme protein suggest that there may be active and inactive forms of the enzyme in cells (18). Glyoxalase I is present at a concentration of approximately 0.2 μg/mg protein in most human tissues (18).

Mammalian glyoxalase I is a dimer with two identical subunits of molecular weight 20-23,000 daltons (19) whereas, from yeast and some strains of bacteria, glyoxalase I is a monomer with molecular weight 31-34,000 daltons (17). For most species, glyoxalase I is present in only one genetically determined form. However, the mammalian enzyme is found as a mixture of three separable forms (19,20). No differences in the catalytic and binding properties of these isozymes has been detected, indicating that the three subunit combinations (aa, ab, bb) are probably very similar.

In naturally occurring glyoxalase I, each subunit
<table>
<thead>
<tr>
<th>Source</th>
<th>Glyoxalase I mU/mg protein</th>
<th>Glyoxalase II mU/mg protein</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Brain</td>
<td>138</td>
<td>245</td>
<td>3</td>
</tr>
<tr>
<td>Human Liver</td>
<td>26</td>
<td>108</td>
<td>3</td>
</tr>
<tr>
<td>Human Heart</td>
<td>71</td>
<td>80</td>
<td>3</td>
</tr>
<tr>
<td>Human Muscle</td>
<td>120</td>
<td>108</td>
<td>3</td>
</tr>
<tr>
<td>Pig Brain</td>
<td>274</td>
<td>80</td>
<td>3</td>
</tr>
<tr>
<td>Ox Brain</td>
<td>268</td>
<td>69</td>
<td>3</td>
</tr>
<tr>
<td>Rabbit Brain</td>
<td>117</td>
<td>86</td>
<td>3</td>
</tr>
<tr>
<td>Rat Brain</td>
<td>328</td>
<td>77</td>
<td>3</td>
</tr>
<tr>
<td>Yeast (Saccharomyces cerevisiae)</td>
<td>2040</td>
<td>nd</td>
<td>152</td>
</tr>
</tbody>
</table>

U = μmoles of S-D-lactoylglutathione produced (glyoxalase I) or decomposed (glyoxalase II) per minute at 25°C.

nd = Activity not determined
contains one equivalent of prosthetic zinc (II) ions - the apoenzyme is catalytically inactive. Metal ion substitution experiments have demonstrated that similar specific enzymatic activities can be maintained with magnesium Mg$^{2+}$, manganese Mn$^{2+}$, cobalt Co$^{2+}$ and nickel Ni$^{2+}$ ions (21,22).

Mammalian glyoxalase I has an isoelectric point of 4.7 - 4.8, an acidic protein (23) whereas the yeast enzyme is neutral with an isoelectric point of 7.0 (17). These diverse properties are reflected in a dissimilar amino acid composition for glyoxalase I from mammalian and yeast origin (17). There are two free thiol groups per molecule for all of the enzymes except the human one, which contains four, and 5 - 12 disulphide bridges (17). The molecular properties of glyoxalase I from bacterial, yeast and mammalian sources are summarised in Table 2.

Antibodies raised against glyoxalase I from one mammalian species will cross-react with other mammalian glyoxalase I enzymes but not with yeast glyoxalase I (18). The substantial differences in the physical, molecular and immunological properties of glyoxalase I from mammalian and yeast sources suggests that the two enzymes may have originated from different ancestral proteins (17).

1.2.2. Substrate Specificity

The natural cofactor for glyoxalase I is reduced glutathione [γ-L-glutamyl-L-cysteinylglycine] (1). A
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subunits</td>
<td>1 (Yeast) (17)</td>
</tr>
<tr>
<td></td>
<td>1 (Bacteria) (196)</td>
</tr>
<tr>
<td></td>
<td>2 (Mammalian) (23)</td>
</tr>
<tr>
<td>Molecular Weight (daltons)</td>
<td>30,000 (Yeast) (17)</td>
</tr>
<tr>
<td></td>
<td>20,000 (Bacteria) (196)</td>
</tr>
<tr>
<td></td>
<td>46,000 (Mammalian) (17)</td>
</tr>
<tr>
<td>Isoelectric Point at 4°C</td>
<td>7.0 (Yeast) (17)</td>
</tr>
<tr>
<td></td>
<td>4.7 - 4.8 (Mammalian) (23)</td>
</tr>
<tr>
<td>Metal Content</td>
<td>1 zinc atom per subunit</td>
</tr>
<tr>
<td></td>
<td>(Yeast (17) and Mammalian (12))</td>
</tr>
<tr>
<td>Molecular Activity ( k_{cat} ) for</td>
<td>109,000 min(^{-1}) (Yeast) (17)</td>
</tr>
<tr>
<td>Methyglyoxal</td>
<td>68,000 min(^{-1}) (Mammalian) (17)</td>
</tr>
<tr>
<td>( K_m ) for Methyglyoxal</td>
<td>0.53 mM (Yeast) (17)</td>
</tr>
<tr>
<td>(at 2mM free glutathione)</td>
<td>0.12 - 0.14 mM (Mammalian) (17)</td>
</tr>
<tr>
<td></td>
<td>3.50 mM (Bacteria) (196)*</td>
</tr>
</tbody>
</table>

* Free Glutathione Concentration Not Known
number of glutathione analogues have been investigated as cofactors (24). L-Cysteine, oxidised glutathione [GSSG], L-cysteinylglycine and γ-L-glutamyl-L-cysteine have all been shown to be inactive as cofactors. L-cysteinylglycine and L-cysteine were inhibitory. Homoglutathione [γ-L-glutamyl-L-cysteinyl-β-alanine] (25), isoglutathione [α-L-glutamyl-L-cysteinylglycine] and some N-acyl derivatives of glutathione (26) have been found to be active as cofactors. The apparent Km values for these glutathione analogues are significantly higher than that of glutathione (the Km for glutathione is \(7.4 \times 10^{-4}\) M; for isoglutathione, it is \(1.2 \times 10^{-2}\) M) (27), while the maximal velocity is changed very little, indicating a lower binding affinity for the analogues than for reduced glutathione.

Glyoxalase I has a broad substrate specificity for α-oxoaldehydes. Substrates of glyoxalase I include methylglyoxal (7), hydroxypyruvaldehyde (28), phosphohydroxypyruvaldehyde (29), and several aromatic derivatives of glyoxal (30,31). The Km for the α-oxoaldehyde substrate decreases as the polarity of the side chain of the α-oxoaldehyde decreases. The trend in the \(V_{\text{max}}\) data parallels that of the Km for a series of alkyl α-oxoaldehyde homologues. Overall, methylglyoxal has the lowest Km and highest \(V_{\text{max}}\) for glyoxalase I, for enzymes from all known sources, and thus methylglyoxal is considered to be the physiological substrate.
1.2.3. The Rate of the Glyoxalase I Reaction.

From the kinetic analysis of the glyoxalase I reaction, it is generally accepted that the hemimercaptal adduct of reduced glutathione and methylglyoxal is the substrate of glyoxalase I (32,33,34). The hemimercaptal is formed in a non-enzymatic pre-equilibrium.

A neutral aqueous solution of methylglyoxal contains a complex equilibrium mixture of hydrates and oligomers of the α-oxoaldehyde with only a minor component existing in the free α-oxoaldehyde form (32). In the presence of reduced glutathione, the α-oxoaldehyde component reacts rapidly with the cysteinyi thiol of glutathione to form a hemimercaptal -residual methylglyoxal hydrate undergoes dehydration as hemimercaptal formation continues.

\[
\text{MeCOCH(OH)}_2 \quad \overset{-\text{H}_2\text{O}}{\Rightarrow} \quad \text{MeCOCHO} \quad \overset{+\text{GSH}}{\Rightarrow} \quad \text{MeCOCH(OH)-SG}
\]

When the reduced glutathione concentration is equal to or greater than the concentration of methylglyoxal, the initial rate of formation of the hemimercaptal is dependent on the concentration of methylglyoxal and is independent of the concentration of reduced glutathione (32). The rate expression for the formation of hemimercaptal, \( \text{HM} \), is therefore:

\[
\frac{d[\text{HM}]}{dt} = k \cdot [\text{methylglyoxal}]
\]
where \( k = 0.01 \text{ s}^{-1} \) at pH 6.6 and 20°C (32). Eventually equilibrium is attained,

\[
\text{MeCOCHO} + \text{GSH} \rightleftharpoons \text{MeCOCH(OH)-SG}
\]

The equilibrium constant, \( K_{HM} \), is 333 M\(^{-1}\) in the pH range 5-9 (34). The hemimercaptal is the molecular species which binds to the active site of glyoxalase I (34). The rate of S-D-lactoylglutathione formation from methylglyoxal and reduced glutathione cannot be increased above the rate of hemimercaptal formation by addition of glyoxalase I, indicating that there is no significant contribution from other (two substrate) reaction pathways (35).

The reaction kinetics of the conversion of hemimercaptal to S-D-lactoylglutathione catalysed by glyoxalase I approximate to Michaelis-Menten kinetics over a restricted substrate concentration range below saturation conditions. The initial-velocity saturation behaviour is non-Michaelian with apparent inhibition by reduced glutathione. With purified enzymes, Mannervik found the true kinetic behaviour was best described by the relationship:

\[
v = \frac{V_{\text{max}} [\text{HM}]}{K_m (1 + [\text{GSH}] / K_i) + [\text{HM}]}
\]

where \( v \) was the reaction velocity, \([\text{HM}]\) was the
concentration of hemimercaptal and $K_i$ was the constant describing the competitive inhibition by reduced glutathione, GSH (36). The Michaelis constant, $K_m$, for the hemimercaptal with purified enzyme is 120-140 $\mu$M from mammalian sources and 530 $\mu$M from yeast (17). The molecular activity (turnover number), $k_{cat}$, is 59-71,000 min$^{-1}$ for mammalian enzymes and 109,000 min$^{-1}$ for the yeast enzyme (17). The molecular activity per subunit for mammalian enzymes is only ca. 30% of the activity of the yeast enzyme. The values of $k_{cat}/Km$ are usually of the order $10^6 - 10^7$ M$^{-1}$s$^{-1}$ which is close to the theoretical diffusion limit maximum, indicating that glyoxalase I is a very efficient enzyme (17).

The glyoxalase I-catalysed conversion of hemimercaptal to S-D-lactoylglutathione may be reversed under conditions where liberated reduced glutathione is trapped and removed from the equilibrium. For the human red blood cell enzyme, kinetic parameters for this reverse reaction are $k_{cat} = 3.6$ s$^{-1}$ and $K_m = 1.9$ mM, which combined with parameters for the forward reaction, give an equilibrium constant of $1.1 \times 10^4$ for the isomerisation of hemimercaptal to S-D-lactoylglutathione (37).

1.2.4 Probing the Active Site

Glyoxalase I from yeast is inactivated by sulphydryl antagonists (38) whereas mammalian enzymes are resistant to a variety of oxidising, alkylating and mercaptide-forming sulphydryl-blocking agents (36,39).
Glyoxalase I from all sources is inhibited by the amino reagents 1-fluoro-2,4-dinitrobenzene, 5-dimethylaminonaphthalene-1-sulphonyl chloride and 2,4,6-trinitrobenzenesulphonate (36,39), and by arginine-specific reagents, 2,3-butanedione and camphorquinone-10-sulfonic acid (40). Modification of only two of the 10 - 17 arginine residues in the enzyme causes complete inactivation. One arginine residue is protected by glutathione; the hemimercaptal and S-D-lactoylglutathione may also provide substantial protection (40).

Nitration of the tyrosine residues of yeast glyoxalase I with tetranitromethane causes complete inactivation of the enzyme (41). The competitive inhibitor S-(p-bromobenzyl)glutathione provides very effective protection against inactivation, indicating that at least one residue must be in or near the active site of the enzyme.

Circular dichroism studies on yeast glyoxalase I show that the binding of S-(p-bromobenzyl)glutathione changes the electronic environment of the tyrosine residue(s) (42). This indicates that there is at least one tyrosine residue in close proximity to the active site. Although tyrosine residues may have an important structural role, they may also be acting as ligands for the zinc atom; it has been proposed that the ligands involved in the binding of the metal ion are probably nitrogen and oxygen (43).
Modification of the three tryptophan residues per subunit of human glyoxalase I with 2-hydroxy-5-nitrobenzyl bromide produces an almost total loss of activity (13). Studies with the competitive inhibitor S-p-bromobenzylglutathione have shown that one tryptophan residue is located in the active site of each subunit of glyoxalase I and may be involved in the binding of the substrate. Binding of the zinc ions to the apoenzyme changes the intrinsic fluorescence of the tryptophan residues, indicating a conformational change and, possibly, the close proximity of at least one tryptophan to the metal ion (13).

The activity of mammalian glyoxalase I is not markedly changed following the replacement of zinc ions with some other divalent cations (21,22), although the presence of zinc or other metal ion is essential for activity. This indicates that the prosthetic metal ion is not directly interacting with the substrate and may, rather, have an important structural role within the locus of the active site. The structural role for the metal ion is supported by the conformational changes occurring during metal ion binding by the apoenzyme, as judged by changes in tryptophan fluorescence (13).

The chemical properties of the metal ion binding site in yeast and mammalian glyoxalase I are very different. When the yeast apoenzyme is formed by removal of the zinc ions with the chelator 1-hydroxy-2,3-propanedithiol, the enzymatic activity
cannot be restored with zinc or other metal ions (44); whereas, with the human red blood cell enzyme, reconstitution of the enzyme can occur with a decrease in activity of only a few percent. This may be related to the particular sensitivity of the yeast enzyme to sulphhydryl agents.

Metal ion replacement studies of glyoxalase I have been used to provide a paramagnetic metal ion derivative which is amenable to electron paramagnetic resonance spectroscopy (EPR). These studies have indicated that the metal ion environment in cobaltous (Co\(^{2+}\))-glyoxalase I is octahedral (21). Direct extended X-ray absorption fine structure (EXAFS) measurements on native human glyoxalase I suggest a distorted octahedral, or perhaps heptahedral coordination to the zinc ion – see Figure 1 (45). Both EXAFS and nuclear magnetic resonance (NMR) studies confirm that there is no coordination of the substrate sulphur atom to the metal ion. NMR studies have indicated that there are one or more water molecules coordinated with the zinc ion, and the carbonyl groups of the substrate and product reside in the second coordination sphere of the zinc ion (46,47) – probably held there by hydrogen bonding to the associated water. These structural characteristics proximate to the prosthetic metal ion may facilitate the isomerisation of the substrate.

1.2.5. Catalytic Mechanism of Glyoxalase I.

The reaction catalysed by glyoxalase I is an
Figure 1. The Environment of the Metal Ion in the Active Site of Glyoxalase I.
isomerisation of the methyglyoxal-glutathione hemimercaptal adduct to S-D-lactoylglutathione. Experimental observations suggest the role of the glutathione in this process is: (a) to provide specific binding to the active site, and (b) to activate the C1 proton of the aldehydic group of the methyglyoxal by hemimercaptal formation. The zinc ion is thought to be important in the maintenance of optimum structure of the active site for catalysis.

The mechanism proposed for the isomerisation involves a shielded-proton transfer from C1 to C2 of the hemimercaptal bound in the active site of the enzyme - see Figure 2, (I). The resulting bound ene-diolate species (II) ketonises to form S-D-lactoylglutathione. Further substantiation of this mechanism has been provided by evidence of the formation of the ene-diolate species. This intermediate has been trapped by oxidative reaction with flavinoid compounds (48,49).

The existence of a cis-dihydroxy intermediate has been detected by NMR studies. As the temperature of the reaction mixture is increased, the incorporation of deuterium atoms into S-D-lactoylglutathione increases from ca. 15% at 25°C to ca. 22% at 35°C (50). This is consistent with a reaction mechanism involving an ene-diol proton transfer. Glutathiohydroxyacetone (GS-CH₂COCHO), which is a substrate for glyoxalase I, can be synthesised as two monodeuterated diastereomers which differ very slightly in their NMR signals (51).
Figure 2. The Proposed Reaction Mechanism of Glyoxalase I.
Investigation using the thiohemiacetals derived from the reaction of the diastereomers with glutathione strongly suggest that only one diastereomer reacts with glyoxalase I and that the reaction proceeds via a cis-ene-diol intermediate. Ene-diol analogues have also proven to be good inhibitors of glyoxalase I - see below.

The role of the enzyme protein in the isomerisation is important for specificity of substrate binding and stereo-selectivity, and also for the provision of the basic group which is the putative initiator of the enolisation. The identity of this crucial basic component is not known.

1.2.6 Inhibition.

A large number of compounds have been investigated as potential inhibitors of glyoxalase I, some of them with a view to their prospective use as anti-cancer and anti-inflammatory agents.

**Competitive Inhibitors.**

S-Alkylglutathiones are competitive inhibitors of glyoxalase I. The relative inhibitory power increases with increase in alkyl chain length (52). This indicates that there is a non-polar region on glyoxalase I which plays an important part in the formation of the enzyme-inhibitor complex (52,53). The most potent reversible inhibitor of glyoxalase I known is S-p-bromobenzylglutathione $[K_i = 9 \mu M]$ (53). However, this inhibition decreases 10-20 fold if the
zinc atom is replaced by other divalent metal ions (13).

Glutathione derivatives formed by modification of the N- and S-terminals are competitive inhibitors of glyoxalase I (54,55). The $K_i$ values of these compounds, with glyoxalase I from human erythrocytes, indicate that there is no specific binding of the N-site of glutathione to the enzyme. This is in contrast with the yeast enzyme where a weak interaction between the N-site of glutathione and glyoxalase I is observed.

Yeast glyoxalase I is competitively inhibited by a number of porphyrin derivatives (56,57). The $K_i$ value for these compounds is pH dependent, the inhibition being stronger at lower pH.

**Mechanism-based Inhibitors.**

The proposal that the glyoxalase I reaction proceeds via an ene-diol intermediate has prompted several investigators to test ene-diol analogues for inhibitory activity. Examples are: lapachol (the $K_i$ is dependent on the source of the enzyme - yeast = 37.5 $\mu$M, rat liver = 0.16 mM and human erythrocyte = 9.5 $\mu$M) (58), flavones (myricetin, taxifolin, quercetin) (59) and substituted coumarins (4-methylesculetin, isoesculetin) (60). Modification of the ene-diol moiety greatly reduces the extent to which these compounds bind to glyoxalase I (61).

**Miscellaneous inhibitors.**

An inhibitor has been isolated from *Streptomyces griseoporeus* -
2-Crotyloxyomethyl-4(R),5(R),6(R)-trihydroxycyclohex-2-enone. Its inhibitory action is potentiated by pre-incubation with glutathione (62). Some nucleic acid bases, nucleosides and nucleotides, and tryptophan have been proposed as potential inhibitors of glyoxalase I (63,64). The $I_{50}$ for tryptophan with mouse liver glyoxalase I is 0.9 mM and for GTP is 0.15 mM (63).

1.2.7 Genetics and Polymorphism.

The mammalian glyoxalase I gene is located on chromosome 6 and exists in the form of two alleles, GLO*1 and GLO*2. These alleles are autosomal ly inherited in a simple 2-allele codominant manner. The alleles code for two slightly different monomers, GLO$^1$ and GLO$^2$. These can be separated by their electrophoretic mobility: GLO$^1$ is electrophoretically "slow" and GLO$^2$ is electrophoretically "fast".

Glyoxalase I can exist in the form of three isozymes - GLO$^{11}$ and GLO$^{22}$ homodimers and a GLO$^{12}$ heterodimer. These three isozymes appear to be functionally identical but can be separated by means of their different chromatographic and electrophoretic properties (19).

In lymphocytes stimulated with phytohemagglutinin and in lymphoblastoid cell lines, a third glyoxalase I allele (GLO*3) has been found (65). This allele codes for a GLO$^3$ monomer that is electrophoretically similar to GLO$^1$, but is catalytically inactive. Enzyme dimers that are homozygous for this monomer are inactive, while
heterozygous dimers have decreased enzymatic activity 
(approx 50% or less of normal activity). The GLO\(^3\) 
monomer has not been detected in red blood cells or 
circulating lymphocytes either because the cell is 
unable to resynthesize it after it has been broken down 
by natural processes or because it is more unstable in 
these cells than it is in the stimulated lymphocytes and 
lymphoblastoid cell lines. A glyoxalase I monomer with 
very low activity has been detected in some species of 
chicken (66).

The glyoxalase I gene has been shown to exist in 
the form of two alleles in the human (67), rat (68) and 
mouse (69) genome. Experiments in the rat indicate that 
the glyoxalase I gene is located on the same chromosome 
as the genes for the Major Histocompatibility Complex 
(MHC) (68). It has also been linked to the H-2 gene 
complex of the mouse (69). Both the MHC of the rat and 
the H-2 gene complex of the mouse are equivalent to the 
Human Leukocyte System A (HLA) gene complex in man. The 
mammalian glyoxalase I gene is linked to the HLA gene 
complex (70). The proposed order of the genes on 
chromosome 6 is shown below:

![HLA Gene Complex Diagram](image-url)
The glyoxalase I gene has been assigned to chromosome 1 of the Chinese hamster. It is not known where the HLA complex is situated in this animal (71).

Tissue typing of the HLA system in man has shown that the different glyoxalase I alleles are associated with different HLA haplotypes. In a French survey (72), GLO$^1$ was found to be mainly associated with the BW6 allele, while GLO$^2$ was mainly associated with the BW4 allele. A Spanish survey (73) has shown a significant association between the DR4 allele and GLO$^2$. The DR3 and DR4 alleles were also found to be associated with GLO$^2$ in Insulin-Dependent Diabetes Mellitus patients (73). Investigation of one family indicated the possible existence of a glyoxalase I "null" allele (GLO*0) that was associated with the A(10)-B16-DW7 haplotype (74). In a different family, this GLO*0 allele was associated with the AW30-CW4-BW35 haplotype (75).

Glyoxalase I polymorphism has been suggested as a possibly useful tool in the study of human population genetics. The GLO$^1$ allele frequency has been measured in a large number of different populations. The frequency is highest in Caucasoid populations (0.42-0.45) (76), lower in Negroid populations (0.25) (77) and it is rare or non-existent in Asiatic populations (78,79).

Glyoxalase I polymorphism has been used forensically (80). The blood glyoxalase I phenotype in
a human individual is identical with the glyoxalase I phenotype in as many as 23 different tissue sites (81), including semen, muscle, skin and hair root tissue. If the existence of a silent allele is taken into account, the heredity pattern of glyoxalase I, and the frequency with which it deviates from this pattern, is such that the glyoxalase system can be used to exclude suspects in paternity cases (82).

1.3 Glyoxalase II

1.3.1 Distribution and Molecular Characteristics

Glyoxalase II activity is found throughout biological life in association with the activity of glyoxalase I. Typical glyoxalase II activities in biological tissues are presented in Table 1. Glyoxalase II has been isolated from several different vertebrates (83). The molecular weight of the enzyme varies between 18,000 and 29,000 daltons. The protein is normally isolated as a monomer but a recent report (84) suggests that it may exist in dimeric, trimeric and tetrameric forms in rat hepatocytes. Glyoxalase II is a basic protein, with an isoelectric point above pH 7.0. The typical amino acid composition, primary sequence and crystal structure of glyoxalase II have not yet been reported. The molecular properties of glyoxalase II from yeast and mammalian sources are summarised in Table 3.
<table>
<thead>
<tr>
<th><strong>Table 3  Molecular Properties of Glyoxalase II</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of Subunits</strong></td>
</tr>
<tr>
<td><strong>Molecular Weight</strong></td>
</tr>
<tr>
<td>(daltons)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Isoelectric Point</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Km for</strong></td>
</tr>
<tr>
<td>S-D-Lactoylglutathione</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Molecular Activity</strong></td>
</tr>
<tr>
<td>(x&lt;sub&gt;cat&lt;/sub&gt; for S-D-Lactoylglutathione)</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
1.3.2 Substrate Specificity

Glyoxalase II can catalyse the hydrolysis of a wide range of S-2-hydroxyacylglutathiones. With S-lactoyl-, S-glycoloyl-, S-mandeloyl-, S-glyceroyl- and S-acetoacetoyl glutathiones, the relative kinetic activity of glyoxalase II is maintained during purification (85). In contrast, the activity of glyoxalase II with S-formyl-, S-succinoyl-, S-acetyl- and S-propionoyl glutathione is lost during purification, suggesting that there may be other S-acylglutathione hydrolases (85). Purified glyoxalase II is inactive with S-formyl-, S-acetyl-, S-propionyl-, S-succinoyl- and S-acetoacetoyl thioglycolate, acetyl-CoA, succinyl-CoA and carboxyl esters, indicating a high specificity for the glutathione moiety of the substrate (85).

1.3.3 The Rate of the Glyoxalase II Reaction.

The hydrolysis of S-acylglutathiones to carboxylic acid and reduced glutathione, catalysed by glyoxalase II, follows Michaelis-Menten kinetics in the substrate range 5-500 µM, except under some experimental conditions. Competitive inhibition by the substrate may be observed at high substrate concentrations (85). For the S-acylglutathione derivatives studied, S-D-lactoylglutathione has the highest relative $V_{\text{max}}$ and a relatively low $K_m$ (200-300 µM) in the glyoxalase II-catalysed reaction (85,86). There is also a well-defined biological source of S-D-lactoylglutathione
- the glyoxalase I-catalysed reaction. Therefore, S-D-lactoylglutathione is considered to be the physiological substrate of glyoxalase II.

It has recently been reported that glyoxalase II from liver and brain of Wistar rats exists in two forms, designated α and β. There was no significant difference in the kinetic activity of these two forms (87).

1.3.4 Probing the Active Site

Glyoxalase II does not require an active site metal ion for its activity (85). Several studies have shown that the activity of glyoxalase II is unaffected by serine modifying reagents (phenylmethanesulphonic acid, diisopropyl phosphofluoridate), indicating that there are no serine residues in the active site and glyoxalase II is not a serine-type thiolesterase (85,86,88). The activity of glyoxalase II is also not affected by treatment with 2-hydroxy-5-nitrobenzylbromide, indicating that there are no tryptophan residues in the active site (86). The effect of thiol antagonists is equivocal: N-ethyimaleimide is a weak inhibitor (86), mercuric chloride and p-hydroxymercuribenzoate produce strong inhibition only at high concentrations which is not reversible with dithiothreitol (85), and 5,5'-dithiobis(2-nitrobenzoic acid) is without effect (85). These observations are not typical of a enzyme with an active site cysteinyI residue, although there may be a cysteine group adjacent to the active site.
The arginine reagent phenylglyoxal produces a partial inhibition (86), the histidine reagents diethylpyrocarbonate and photo-oxidation with methylene blue produce a strong inhibition (86), and the amine reagent 2,4,6-trinitrobenzenesulphonic acid produces a strong inhibition (85), of glyoxalase II. This indicates that there are arginine and histidine residues, and possibly lysyl residues, in the active site which are essential for the catalytic function of the enzyme. The arginine residue is probably located in the active site and appears to be involved in binding the substrate's carboxyl group (86). The $K_m$ and $V_{max}$ data suggests that the active site contains a hydrophobic pocket on the side which binds the acyl moiety of the substrate (86).

1.3.5 Inhibition

Mouse liver glyoxalase II is inhibited by nucleosides, nucleotides and tryptophan (63). The $I_{50}$ for tryptophan is 0.8 mM and for GTP is 0.16 mM (63). Both methylglyoxal and reduced glutathione are weak competitive inhibitors of glyoxalase II (for reduced glutathione with human liver glyoxalase II, $K_i = 4$ mM) (85). Their effects are increased in combination, possibly due to the formation of the hemimercaptal. Studies on the hemimercaptal show that it is a competitive inhibitor of glyoxalase II, but the $K_i$ depends on the source of the enzyme ($K_i = 0.3$ mM (mouse liver glyoxalase II) (89) and 0.12 mM (human liver

42
glyoxalase II) (85)).

S-(Nitrocarbobenzoxy)glutathiones are the most potent competitive inhibitors of glyoxalase II known ($K_i$ of the para isomer = 6.5 $\mu$M) but are very weak inhibitors of glyoxalase I. This selective inhibition of glyoxalase II facilitates their use in experiments to investigate the function of glyoxalase II (90).

1.3.6 Genetics and Polymorphism

Experiments involving the fusion of human and rodent cells have shown the location of the human glyoxalase II gene to be on chromosome 16 (91). In man, there is normally only one phenotype for the glyoxalase II gene. However, in one Micronesian population, a second phenotype of glyoxalase II has been identified (92). When the blood glyoxalase enzymes from this population were separated by electrophoresis, they showed a band of activity at the normally expected position for glyoxalase II and a second, electrophoretically faster band of activity, suggesting the presence of an allele variant at the glyoxalase II locus. Investigation of family data showed that the allele variant was genetically transmitted in an autosomal codominant manner. This variant was restricted to only one Micronesian population, suggesting that it is a relatively recent mutation. Dimorphic forms of glyoxalase II have also been isolated from human erythrocytes (93) and the liver and brain of
Wistar rats (87). In each case, the two forms of glyoxalase II differed in their isoelectric points, suggesting that they were structurally distinct. Although glyoxalase II polymorphism is rare in man, it has been found to be common in anthropoid primates (94).

An heredity deficiency of glyoxalase II activity has been demonstrated in a patient suffering from heredity elliptocytosis (95). The occurrence of the two conditions was not related. The glyoxalase II deficiency was inherited by an autosomal recessive mechanism. The activity was deficient in the erythrocytes but not leukocytes of the affected subjects, suggesting that there may be a varying pattern of isozymes in different tissues. This deficiency of glyoxalase II activity was not associated with any clinical or haematological abnormalities.

1.4. Methylglyoxal

1.4.1 Formation

The formation of methylglyoxal in biological tissues occurs by several different routes. Dihydroxyacetone phosphate is converted to methylglyoxal by the action of methylglyoxal synthetase (E.C. 4.2.99.11). This enzyme has been isolated from goat liver (96) and bacteria (97,98). An alternative source of methylglyoxal in some bacteria is 1-hydroxyacetone (acetol), an intermediate in the catabolism of isopropanol and acetone (99). The enzyme involved in
the conversion of 1-hydroxyacetone to methylglyoxal is acetol dehydrogenase (E.C. 1.1.1.7), which uses NAD$^+$ as a co-factor.

In mammals, methylglyoxal is also formed from aminoacetone catalysed by amine oxidase, which has been isolated from goat plasma (100). Aminoacetone can be formed from L-threonine catalysed by L-threonine dehydrogenase (E.C. 1.1.1.103.) or from glycine and acetyl coenzyme A catalysed by aminoacetone synthase. Methylglyoxal exerts feedback inhibition on L-threonine dehydrogenase (101), binding to a site other than the active site, thus providing a route by which methylglyoxal can regulate its own rate of production.

1.4.2 Metabolism

Glyoxalase I and three other enzymes may catalyse the metabolism of methylglyoxal; 2-oxoaldehyde dehydrogenase, S-formylglutathione hydrolase, and methylglyoxal reductase.

2-Oxoaldehyde dehydrogenase (E.C. 1.2.1.23.) has been isolated from mammalian liver (102,103) and micro-organisms (104). This enzyme catalyses the direct oxidation of methylglyoxal to pyruvate. It requires NAD$^+$ or NADP$^+$ as a cofactor, but does not require glutathione. The Km of the mammalian enzyme for methylglyoxal is 4.5 mM with NAD$^+$ and 0.4 mM with NADP$^+$ (105).

Formaldehyde dehydrogenase (E.C. 1.2.1.1) is present in yeast, several other micro-organisms and
mammalian liver (105,106). This enzyme requires glutathione and NAD\(^+\) for activity. Its normal function is to convert the adduct formed between formaldehyde and glutathione (107) to S-formylglutathione (105). A second enzyme, S-formylglutathione hydrolase (E.C. 3.1.2.12), metabolises S-formylglutathione to formate and glutathione (108). Although formaldehyde dehydrogenase will readily convert the methylglyoxal-glutathione adduct to S-pyruvoylglutathione (109) (the Km of methylglyoxal is 1.2 mM; Km for glutathione = 0.13 mM) (105), pyruvoylglutathione is not a substrate acceptable to S-formylglutathione hydrolase (110). The role of formaldehyde dehydrogenase in the metabolism of methylglyoxal is therefore unclear.

The third enzyme involved in methylglyoxal metabolism is methylglyoxal reductase. This enzyme, isolated from goat liver (111), converts methylglyoxal to lactaldehyde. It uses NADH as a co-substrate and has a Km value for methylglyoxal of 0.4 mM.

1.4.3 The Concentration of Methylglyoxal in Biological Tissues.

Methylglyoxal is generally assayed by determination of a chromophoric adduct of methylglyoxal with an amine (112,113). The major interference associated with this procedure is the prospect of the chromophoric amine catalysing the formation of methylglyoxal or other \(\alpha\)-oxoaldehydes from monosaccharides (114) in the cell
extract during the analytical extraction procedure. This artifact, if unrecognised, greatly over-estimates the concentration of \( \alpha \)-oxoaldehyde. The recent development of a rapid high pressure liquid chromatography (HPLC) method for the adduct of methylglyoxal with o-phenylene diamine, 2-methylquinoxaline, has improved the accuracy and precision of the assay of methylglyoxal in biological material (115).

The concentration of methylglyoxal in the liver and muscle of young Wistar rats is 0.88 and 0.90 \( \mu \)g/g wet weight respectively. The concentration in the heart is higher (1.10 \( \mu \)g/g wet weight) (115). The concentration of methylglyoxal in the liver is higher in mice than the rat (3.69 \( \mu \)g/g) (116).

1.4.4 Other Reactions

Methylglyoxal binds to DNA and RNA undergoing replication and transcription, through adduct formation with guanine residues (117,118).

It may express mutagenic or carcinogenic activity through this interaction with DNA (119,120) e.g. acting as a direct mutagen in *Salmonella typhimurium* TA100. Cells treated with methylglyoxal may develop DNA crosslinks but these are usually repaired within 24 hours of removal of the \( \alpha \)-oxoaldehyde (121).

Methylglyoxal also binds and crosslinks proteins through adduct formation with arginyl residues. These reactions may mediate the inactivation of enzymes,
particularly those with arginine residues essential for enzymatic activity in the active site, and the denaturation of proteins. However, relatively high concentrations of methylglyoxal are required to exert this inhibitory effect. For example, the glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase, phosphoglyceromutase, phosphoglycerate kinase and phosphofructokinase are inhibited by 50% within 50 minutes of incubation at 30°C and pH 7.6 with 2.5 mM methylglyoxal (122), and the assembly of microtubules from purified tubulin at pH 6.6 and 37°C is inhibited by 1 - 5 mM methylglyoxal (123).

Methylglyoxal inhibits the cellular synthesis of proteins (124,125). The inhibition is most marked during the S and G2 phases of the cell cycle (126). During these phases, RNA and DNA synthesis is inhibited much less than protein synthesis. The inhibition of protein synthesis does not involve an effect on mRNA (127) but may involve an inactivation of ribosomal enzymes which contain arginine residues essential for their function (128). Alternatively, this inhibitory effect may be due to methylglyoxal binding to tRNA and preventing its participation in protein synthesis.

All of these biological effects of methylglyoxal are observed under conditions which are extremely favourable for their occurrence; 1 - 5 mM methylglyoxal treatment, for example. It is unlikely that such concentrations of methylglyoxal (and biological
consequences) are ever maintained in normal physiological circumstances because of the efficiency of the glyoxalase system.

1.5. S-D-Lactoylglutathione.

S-D-Lactoylglutathione is considered to be the physiological intermediate of the glyoxalase system. It is stable in neutral or acid solution, but undergoes a slow decomposition in alkali solution to give D-lactate and reduced glutathione (9). S-D-Lactoylglutathione expresses some remarkable bioactivities: (i) it potentiates the GTP-promoted assembly of microtubules from purified tubulin and microtubule-associated proteins in vitro (129); (ii) it potentiates the secretion of histamine from human leukocytes (130); and it inhibits the proliferation of tumour cells in culture (131). The mechanism of expression of these effects and the normal cellular concentration of S-D-lactoylglutathione is not known.

1.6. D-Lactate.

D-Lactate is the end product of the glyoxalase system. It is very poorly metabolised by mammals (132) and is normally excreted in the urine (133,134). It may, however, be used by bacteria, such as Escherichia coli, as part of the amino acid and β-galactoside transport mechanism (135,136).

In man, the normal concentration of D-lactate in
plasma is 0.023 mM (137). This is only a small fraction (1.5%) of the concentration of L-lactate. The excretion, and presumably the production, of D-lactate in man appears to be unaffected by the presence or absence of disease - although this may deserve further and more thorough investigation (134). In vitro, D-lactate formation has been demonstrated in blood following inhibition of glycolysis (138), presumably due to an increased flux of glycolytic intermediates through the glyoxalase system.

1.7. Physiological Role of the Glyoxalase System.

Although the existence of the glyoxalase system has been known for over 70 years and the enzyme activity found to be ubiquitous, the role of this system in normal cellular metabolism still remains to be fully elucidated. Several theories for the function of the glyoxalase system have been proposed.

1) Glycolytic bypass in micro-organisms. Cooper and Anderson have demonstrated that the micro-organism E. coli can convert dihydroxyacetone phosphate to pyruvate, via methylglyoxal and D-lactate (139). This reaction sequence bypasses the normal glycolytic route for the formation of pyruvate from dihydroxyacetone phosphate. They proposed this may be a regulatory mechanism to prevent the accumulation of a high concentration of phosphorylated glycolytic intermediates, which are known to inhibit bacterial growth (140). Alternatively, it
may be a means of producing D-lactate, via the glyoxalase system, which may be important in *E. coli* for amino acid and β-galactoside transport (135,136)

2) Detoxification of α-oxoaldehydes. Methylglyoxal is a potentially noxious compound, if permitted to accumulate to high concentrations in biological tissue. The formation of methylglyoxal by methylglyoxal synthase has been found in several strains of bacteria, including enterobacteria (98). Mannervik and Aronsson have proposed that methylglyoxal, released by enterobacteria, enters the body and is transported to the liver, where it is metabolised by glyoxalase I (23). It has also been suggested that the major role of this system in micro-organisms may be the removal of methylglyoxal formed during metabolism (97)

3) Control of Cell Growth. In the 1960's, Szent-Györgyi, Együd and others proposed that there was a universal mechanism in multi-cellular organisms that regulated growth (cell division). This mechanism would involve a factor which existed in all living systems which could permanently promote growth and would be controlled in its action by an antagonist. The growth status would depend on the equilibrium between the growth factor and the antagonist. They also proposed there was a common receptor which regulated all the changes occurring in the cell during division. The receptor would involve sulphydryl groups, since their indispensibility for cell division had been known for
some time (141).

The inhibitory factor, called "retine" was considered to be a glyoxal derivative (142, 143), as partial purification of tissue extracts capable of inhibiting tumour growth had revealed the presence of α-oxoaldehydes. It was already known that methylglyoxal (and all α-oxoaldehydes) would react readily with thiol groups (144), supporting the assumption that the growth inhibiting action of "retine" depended on blocking sulphydryl groups important for growth.

The accelerating factor, called "promine", was thought to involve the glyoxalase system, which converts the α-oxoaldehydes to the biologically much less reactive α-hydroxycarboxylic acids.

4) Control of microtubule assembly. Gillespie made the seminal observation that S-D-lactoylglutathione potentiates (and glyoxalase II inhibits) the cell-free GTP-promoted assembly of microtubules in vitro (129), although the data presented was equivocal - S-D-lactoylglutathione was shown to both potentiate and inhibit microtubule assembly. She later observed that the activity of glyoxalase I increased and the activity of glyoxalase II decreased during the functional activation (phagocytosis and degranulation) of neutrophils (145), and S-D-lactoylglutathione potentiated anti-IgE-induced secretion of histamine from basophils (130) - which is known to be a
microtubule-mediated process. Gillespie proposed that the glyoxalase system may regulate the assembly of microtubules through the influence of S-D-lactoylglutathione.
2. BACKGROUND TO THIS WORK

2.1 The Modification of the Glyoxalase System in Cell Proliferation and Maturation

2.1.1. The Activity of Glyoxalase I and Glyoxalase II.

The Szent-Györgyi hypothesis predicted that methylglyoxal was a growth-inhibiting (or anti-proliferative) substance and glyoxalase I, the physiological antagonist of methylglyoxal, was a growth-promoting substance; the conflict between these two species was the putative mechanism of growth control (142,143). This hypothesis was substantiated by a wealth of literature demonstrating the carcinostatic properties of relatively high doses of methylglyoxal (146,147,148,149). Therefore, rapidly proliferating tissue was expected to have a high activity of glyoxalase I and a low cellular concentration of methylglyoxal.

In 1978, Jerzykowski et al (3) reported the results of a survey of the glyoxalase activities in murine, rat and human tumours. In the majority of tumours, they found the activity of glyoxalase I was lower than in normal tissues and the activity of glyoxalase II was very small or undetectable. Despite this, the tumours exhibited rapid tissue growth kinetics. These observations contradicted the Szent-Györgyi hypothesis and stymied advance in this area of glyoxalase research.
In 1982, Principato et al published the first report in a series of investigations into glyoxalase activities in proliferating and maturing tissues. They studied glyoxalase activities in the maturing chick embryo, before and after hatching (150). They found that the activity of glyoxalase I decreased and the activity of glyoxalase II increased markedly from five days before to fifteen days after hatching. This demonstrated a major change in glyoxalase activities during embryo maturation. A further investigation by this group found that regenerating rat liver (after hepatectomy) had a higher activity of glyoxalase I and a lower activity of glyoxalase II than the sham control liver (151). From these data, it appears that during cell maturation (differentiation), there was a decrease in the activity of glyoxalase I and an increase in the activity of glyoxalase II.

Tissue maturation reflects both changes in the differentiation status and the proliferation status of cells. Therefore, it is still not clear if the changes observed in glyoxalase activities during maturation reflect changes in proliferation status or differentiation status.

Studies on non-differentiating, growth-arrested cells show no consistent relationship between proliferation status and glyoxalase activities. In a study with exponentially growing and G₁ arrested temperature-sensitive cell division cycle mutants of
Saccharomyces cerevisiae, the activity of glyoxalase I was found to be substantially (35 - 75%) decreased in growth-arrested cells (152). The activity of glyoxalase I in mouse spleen was monitored during regeneration following radiation-induced damage: the activity of glyoxalase I was found to correlate with the increased rate of DNA synthesis and cell proliferation during regeneration (153). However, in a study of quiescent and proliferating human fibroblasts, Bruschelli et al (154) found no significant change in the activity of glyoxalase I or glyoxalase II between growth-arrested and rapidly proliferating cells. Further studies are necessary before any firm conclusions can be made.

The glyoxalase system is a primary and important feature of mammalian foetal development. The glyoxalase I phenotype is one of the first to be developed and is present, fully formed by the sixth-seventh week of foetal life (155). The activity of both enzymes increases as gestation proceeds. Overall, the cell proliferation and maturation studies to date indicate that the activity of the glyoxalase enzymes are linked to the mitotic activity of the cell. As the mitotic activity increases, the activity of glyoxalase I increases and the activity of glyoxalase II decreases.

The regulatory mechanism by which these changes in glyoxalase activity occur and why these changes occur during proliferation and maturation is not known. Similar changes in glyoxalase activities in
functionally-activated neutrophils are associated with the control of the cellular concentration of S-D-lactoylglutathione and the putative regulation of microtubule assembly (129,145,156). The changes in glyoxalase activities during proliferation and maturation may also be related to the control of S-D-lactoylglutathione for the regulation of the microtubular cytoskeleton.

2.1.2. The Concentration of Methylglyoxal and S-D-Lactoylglutathione.

The concentration of methylglyoxal and S-D-lactoylglutathione in tumour cells is not known.

2.1.3. Research Objectives and Plan of Action.

Objective 1) To study the modification of the glyoxalase system during the differentiation of human leukaemia cells in vitro.

Two well-established human leukaemia cell lines were used for this study: the HL60 human promyelocytic leukaemia line and the K562 human erythroleukaemia line.

A. Human Leukaemia - 60 Cells.

Human leukaemia - 60 (HL60) cells are a human promyelocytic leukaemia cell line initially established from peripheral blood leukocytes from a patient with acute promyelocytic leukaemia (157). HL60 cells can be induced to differentiate into two different types of mature cells. Exposure to dimethylsulphoxide (158) and N-methylformamide (159) induces differentiation to cells
which are morphologically and functionally similar to human neutrophils, although HL60-derived neutrophils have been shown to be deficient in some characteristic neutrophilic enzyme activities e.g. myeloperoxidase (160). However, the characteristic NADPH oxidase activity of neutrophils is present (161) and is a convenient marker of differentiation of HL60 cells. Alternatively, exposure of HL60 cells to 12-O-tetradecanoylphorbol-13-acetate induces their differentiation into macrophages or monocyte-like cells (162). After treatment with dimethylsulphoxide, the cells are committed to differentiation within 8 - 18 hours (163). The initiation of the maturation of HL60 cells to neutrophils is not a cell-cycle related event (164).

**B. K562 - Erythroleukaemia Cell Line.**

The K562 human erythroleukaemia cell line was originally established in 1975. It was derived from the pleural effusion of a patient with chronic myelogenous leukaemia in terminal blast crisis (165). The K562 cell is thought to be an early differentiated stage of the granulocyte lineage (166). However, it shows clear differences from benign and malignant cells representing various stages of the myeloblast to granulocyte differentiation sequence: it lacks the normal B-cell markers of immunoglobulin and T-cell antigens, and does not phagocytose or mediate antibody-dependent cytolysis or phagocytosis (166). Moreover, the K562 cell exhibits
several features common to human erythrocytes: the cell surface antigens are very similar to those of normal erythrocytes with the major red blood cell sialoglycoprotein, glycophorin, on its surface (167); K562 cells contain spectrin (a red blood cell protein) and may synthesise haemoglobin which is electrophoretically similar to haemoglobin from embryonic erythroblasts (168).

Objective 2) To study the modification of the glyoxalase system during changes in the proliferation status of the cell, in the absence of differentiation.

Two cell lines were used in this study: the GM892 transformed human lymphoblast and the Raji (Mer +) Burkitt's lymphoma cell lines.

A. The Raji (Mer +) Cell Line.

The Raji cell line was initially established in 1964 (169). It was derived from material obtained from a Burkitt's lymphoma (BL) tumour, and has many characteristics in common with other BL-derived tumour cell lines. Burkitt's lymphoma is characterised by the presence of a rapidly growing solid tumour (170) and is defined as a B-cell tumour of mucosa-associated lymphoid tissue (171). The origin of BL is unknown, but all BL-derived cell lines, including Raji, contain at least one copy of an Epstein-Barr virial (EBV) genome and express EBV membrane and nuclear antigens (170).
B. The GM892 Cell line

The GM892 cell line is a human lymphoblastoid cell line, which has been shown to be O\textsuperscript{6}-alkylguanine repair deficient (131).

Objective 3) To study the effect of S-D-lactoylglutathione on the cell-free assembly of microtubules

Following the pioneering work of Weisenberg (172), the GTP-dependent assembly of microtubules from purified tubulin (with microtubule-associated proteins) can be studied in cell-free systems in vitro using a calcium-deficient medium with sulphonic acid buffers at pH 6.6. This was exploited to study the effect of S-D-lactoylglutathione on the kinetics of microtubule assembly and disassembly.

2.2. The Glyoxalase System in Hyperglycaemia: Possible Involvement in Diabetic Pathogenesis

2.2.1 Diabetic Pathogenesis: Defining the Pathology

Diabetic pathogenesis is the development of complications arising from chronic periodic hyperglycaemia, associated with Diabetes Mellitus. Diabetes Mellitus is a metabolic disorder in which there is a relative, or absolute deficiency, of insulin. The relative or absolute lack of insulin action produces a substantial change in carbohydrate, lipid and protein metabolism (173). Tissues with insulin-dependent glucose uptake (e.g. skeletal muscle) cannot utilise
glucose and the plasma glucose level rises from 5 mM to 10 - 50 mM. Tissues with insulin-independent glucose uptake (red blood cell, endothelial cells of the small capillaries - especially in the retina and kidney glomeruli, lens fibre cells, red blood cells, peripheral neurones) become hyperglycaemic. With insulin injections, the diabetic individual experiences periodic hyperglycaemia, particularly in the hours immediately prior to the insulin supplement. The toxicity arising from this managed, periodic hyperglycaemia produces a characteristic profile of clinical pathology: cataract, retinopathy, neuropathy, nephropathy and renal failure, generalised microangiopathy and arteriosclerosis (174).

2.2.2 Classification of Diabetes Mellitus

There are two main types of Diabetes Mellitus:

Type 1 Diabetes Mellitus (Insulin-Dependent Diabetes).

This form of diabetes normally occurs in children or young adults. The classification is based on a dependence on insulin and a disposition towards ketoacidosis. These patients usually have a short history of the symptoms of hyperglycaemia (polydipsia, polyuria, lethargy and weight loss) and, if not recognised quickly, may develop ketoacidosis. The amount of insulin remaining in the pancreas is extremely small and circulating levels are very low. Carbohydrate metabolism is extremely abnormal, producing a fasting hyperglycaemia and a marked abnormality of glucose tolerance (173).
Type 2 Diabetes Mellitus (Non-Insulin-Dependent Diabetes).

This is the normal "clinical" type of diabetes that occurs in middle or late life. Insulin is not usually required and ketoacidosis rarely arises (173). The plasma insulin levels are normal or elevated and the subjects are often obese (175,176).

The diagnosis of Diabetes Mellitus is made on the criterion of plasma glucose level. A plasma glucose level greater than 200mgs/100mls is usually indicative of diabetes, irrespective of other factors. A basal plasma glucose level of 115 - 129mgs/100mls is the boarderline for the diagnosis of diabetes. Values greater than 129mgs/100mls require the diagnosis of diabetes to be confirmed by other tests.

2.2.3 The Biochemical Basis for Diabetic Pathogenesis.

It is generally considered that the biochemical basis of the development of diabetic complications is expressed through pathways of non-glycolytic glucose metabolism which are enhanced during hyperglycaemia. Particularly pertinent examples are: (i) the characteristic formation of sorbitol from glucose (177,178), catalysed by aldose reductase (alditol : NADP⁺ 1-oxidóreductase, E.C. 1.1.1.21), and (ii) the non-enzymatic glycosylation of protein (179). Recent reports (114,180) proposed that the formation of α-oxoaldehydes may be enhanced during hyperglycaemia.
and \( \alpha \)-oxoaldehyde metabolism may be an aetiological factor in the development of diabetic microangiopathy.

To test and substantiate this hypothesis, a human cell type is required which has an active glyoxalase system and suffers hyperglycaemic metabolism in Diabetes Mellitus, and is readily isolable for carefully-controlled in vitro experiments.

2.2.4 The Red Blood Cell as a Model For Hyperglycaemic Metabolism in Diabetic Pathogenesis.

The red blood cell has an insulin-independent glucose uptake mechanism and operates only the Embden-Meyerhof glycolytic pathway (181). In periods of hyperglycaemia, the intracellular concentration of glucose, normally ca. 5 mM, may rise to 20 - 30 mM, depending on the quality of glycaemic control (182,183). In the red blood cell suffering periodic hyperglycaemia: sorbitol is produced from glucose, catalysed by red blood cell aldose reductase (184); haemoglobin (185) and other proteins (179) are glycosylated, forming fructosamine adducts by Amadori rearrangement of the initial Schiff's base adduct, and chromophoric and fluorophoric pigments by further rearrangement and oxidation (186,187); the concentration of reduced glutathione is significantly decreased (188,189); and there are decreases in \( Ca^{2+} \)-ATP-ase activity (190) and membrane deformability (191,192). Although these metabolic changes do not produce measurable haemolysis, the circulatory lifetime of the red blood cell is
significantly decreased in Diabetes Mellitus (193,194). The red blood cell is typical of many other hyperglycaemic tissues in producing these characteristic metabolic changes in hyperglycaemia.

The red blood cell has an active glyoxalase system. Both glyoxalase I and glyoxalase II have been purified from human red blood cells (93,195). The cellular concentrations of methylglyoxal and S-D-lactoylglutathione are not known.

Objective 4. To study the effect of hyperglycaemia on the red blood cell glyoxalase system in diabetic patients in vivo.

Glyoxalase activities and the concentrations of glyoxalase metabolites may be assayed in clinical blood specimens taken routinely from diabetic patients.
3. MATERIALS AND METHODS

3.1 Materials.

3.1.1 Cell Culture

Human promyelocytic leukaemia HL60, erythroleukaemia K562, Burkitt's lymphoma Raji, and GM892 lymphoblastoid cells were incubated at 37°C in RPMI 1640 media containing 10% foetal calf serum under an atmosphere of 10% CO₂ in air, 100% humidity for the times stated. Tissue culture medium RPMI 1640, foetal calf serum, and newborn calf serum were purchased from Gibco Europe Ltd. (Paisley, Scotland).

3.1.2 Enzymes, Co-factors and Substrates

Glyoxalase I (Grade X, from yeast, specific activity 1645 units/mg protein), glyoxalase II (from beef liver, specific activity 10.3 units/mg protein) and glutathione S-transferase (from equine liver, specific activity 65 units/mg protein) were purchased from Sigma Chem. Co. Ltd, (Poole, Dorset, U.K). Methylglyoxal, reduced glutathione GSH, S-D-lactoylglutathione (free acid), 1-chloro-2,4-dinitrobenzene, guanosine 5-triphosphate (GTP, Type II-S) and nocodazole (methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl] carbamate) were purchased from Sigma. 5-(³H-Methyl)thymidine (specific activity 5.0 Ci/mmcl) was purchased from Amersham International plc (Buckinghamshire, U.K).

3.1.3 Buffers and Miscellaneous Agents

2-(N'-Morpholino)ethanesulfonic acid (MES),

65
tris(hydroxymethyl)aminomethane (TRIS),
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
(HEPES) and
1,2-di(2-aminoethoxy)ethane-NNN'N'-tetra-acetic acid
(EGTA) were purchased from Sigma. Dimethyl sulphoxide
(DMSO), N-methylformamide and N-ethylmaleimide were
obtained from Aldrich Chem. Co. Ltd. (Poole, Dorset).
The imidazotetrazinone,
8-carbamoyl-3-methylimidazo-[5,1-d]-1,2,3,5-
tetrazin-4(3H)-one (CCRG 81045), was kindly donated by
May and Baker Ltd. (Dagenham, Essex, U.K). OPTIPHASE
scintillation fluid was purchased from LKB Instruments
Ltd, (Croydon, Surry, U.K).

3.1.4 Miscellaneous

All other chemicals were purchased from BDH Ltd
(Poole, Dorset) and were the highest grade available.

3.2 The Characterisation of the Glyoxalase System.

3.2.1 The Assay of the Activity of Glyoxalase I in
Cell Extracts.

The activity of glyoxalase I was determined by
measuring the initial rate of formation of
S-D-lactoylglutathione from the hemimercaptal formed
non-enzymatically from methylglyoxal and reduced
glutathione. The formation of S-D-lactoylglutathione
was followed spectrophotometrically at 240 nm,
\[ \Delta \epsilon_{240} = 2.86 \text{ mM}^{-1}\text{cm}^{-1} \] (34). Nominal concentrations of
hemimercaptal were calculated assuming, for the
equilibrium, MeCOCHO + GSH $\rightleftharpoons$ MeCOCH(OH)-SG, $K_{eq} = 333 \text{ M}^{-1}$ (34). For routine estimates of tissue activities of glyoxalase I, the initial hemimercaptal concentration was nominally 1.33 mM. For investigation of the substrate - reaction velocity relationship, initial hemimercaptal concentrations were 0.2, 0.285, 0.5, and 2.0 mM. The hemimercaptal was prepared by incubating equimolar mixtures of reduced glutathione and methylglyoxal in 100 mM sodium phosphate, pH 6.6, at 37°C for 30 minutes.

It has been reported by Hall et al that the hemimercaptal formed between methylglyoxal and reduced glutathione undergoes a non-enzymatic conversion to S-lactoylglutathione (199). For this study, the activity of glyoxalase I was determined under standard conditions. A temperature of 37°C was used for physiological relevance, and an incubation time, for hemimercaptal formation, of 30 minutes. The incubation time of 30 minutes was chosen to allow effective thermal equilibrium of the incubation mixture to 37°C and because the absorbance change in the blank was found to be sufficiently linear and accurately reproducible at this time. Some of the hemimercaptal may be converted to S-lactoylglutathione during the incubation period and, therefore, the hemimercaptal concentrations are only nominal values, but the conditions used gave accurately reproducible determinations for glyoxalase I activity. It is
critical that the preincubation times are kept exactly the same throughout the study.

After incubation of the hemimercaptal and reference (buffer only) solutions, an aliquot of cell extract was added to both reference and sample cuvettes and the initial rate of change of absorbance at 240 nm was measured. Blanks were assayed by the addition of an aliquot of sonication buffer only. The activity of glyoxalase I is given in units per $10^6$ cells (or per ml of packed red blood cells) where one unit of activity is defined as the amount of enzyme required to catalyse the formation of one μmol of S-D-lactoylglutathione per minute under assay conditions.

Stock solutions of methylglyoxal were prepared by diluting commercial methylglyoxal solutions with water to ca. 20 mM. The concentration of methylglyoxal was calibrated by end-point assay with commercial glyoxalase I (grade X). Sufficient of the methylglyoxal solution was added to 2 mM reduced glutathione in 100 mM sodium phosphate, pH 6.6, in a quartz cuvette to make the final methylglyoxal concentration of ca. 0.3 mM. Glyoxalase I (5 units) was added to sample and reference cuvettes. The absorbance at 240 nm was followed until a steady maximum was reached. The mean increase in absorbance was used to calculate the concentration of S-D-lactoylglutathione at the end-point assuming $\Delta \varepsilon_{\text{SLG}} = 3.10 \text{ mM}^{-1}\text{cm}^{-1}$, and hence the concentration of methylglyoxal in the stock solution.
3.2.2 The Assay of the Activity of Glyoxalase II in Cell Extracts

The activity of glyoxalase II was determined by measuring the initial rate of hydrolysis of S-D-lactoylglutathione in 50 mM Tris/HCl buffer, pH 7.4, at 37°C. The decrease in the concentration of S-D-lactoylglutathione was followed spectrophotometrically at 240 nm; \[ \Delta e_{240} = 3.10 \text{ mM}^{-1}\text{cm}^{-1} \] (34). The initial concentration of S-D-lactoylglutathione was 300 \( \mu \)M for routine estimates of tissue activities of glyoxalase II, and 25, 33, 50, 100 and 300 \( \mu \)M where the substrate - reaction velocity relationship was investigated. The blank was the spontaneous rate of hydrolysis of S-D-lactoylglutathione after addition of an aliquot of sonication buffer only. The activity of glyoxalase II is given in units per 10^6 cells (or per ml of packed red blood cells) where one unit of activity is defined as the amount of enzyme required to catalyse the hydrolysis of one \( \mu \)mol of S-D-lactoylglutathione per minute under assay conditions.

The concentration of S-D-lactoylglutathione in stock solutions was calibrated by assaying the S-D-lactoylglutathione using commercial glyoxalase II in an end-point spectrophotometric assay. A stock solution of ca. 3 mM S-D-lactoylglutathione (free acid) in water was prepared and a portion was diluted 10 fold in a quartz cuvette containing 50 mM Tris/HCl, pH 7.4, with
buffer only in the reference cuvette. One unit of glyoxalase II (Sigma) was added to both sample and reference cuvettes and the absorbance at 240 nm was followed until a steady minimum absorbance was reached. The concentration of S-D-lactoylglutathione was calculated from the mean decrease in absorbance using the extinction coefficient given above.

3.2.3 The Assay of Reduced Glutathione and S-D-Lactoylglutathione in Whole Human Blood

The concentration of S-D-lactoylglutathione in whole blood was assayed by a modification of the method of Thornalley et al (156). S-D-Lactoylglutathione was determined as the reduced glutathione released on the addition of glyoxalase II to de-proteinised extracts of whole blood samples; reduced glutathione was measured by the method of Davies et al (200), which determines glutathione as the chromophore S-2,4-dinitrophenyl-glutathione, formed from 1-chloro-2,4-dinitrobenzene in the presence of glutathione S-transferase.

2 mls of whole blood were treated with 1 mM N-ethylmaleimide for 10 minutes at room temperature to remove native reduced glutathione (201). 1 ml of ice-cold 20% trichloroacetic acid was added to the sample and mixed thoroughly. After keeping the samples on ice for 20 minutes, the precipitate was sedimented by centrifugation (500g, 10 minutes). The supernatant was removed and neutralised by extraction with 5 x 4
of water-saturated diethyl/ether. Residual ether was dispersed with nitrogen gas. This procedure produced a de-proteinised extract depleted of native reduced glutathione.

An aliquot of de-proteinised extract was incubated with 100 µM 1-chloro-2,4-dinitrobenzene and 10 units of glutathione S-transferase for 1 hour in 50 mM Tris/HCl, pH 7.4 and 37°C. The absorbance at 340 nm was recorded. 1 Unit/ml of glyoxalase II was added to the assay and reference samples and incubated for a further hour at 37°C. The final absorbance at 340 nm was recorded. The concentration of S-D-lactoylglutathione was calculated from the glyoxalase II-dependent increase in absorbance. Assays were calibrated and controlled by assaying standard solutions of S-D-lactoylglutathione and blanks (phosphate-buffered saline) respectively.

A typical calibration curve for reduced glutathione and S-D-lactoylglutathione is presented in Figure 3.

3.2.4 The Assay of Methylglyoxal in Whole Human Blood

The concentration of methylglyoxal in whole blood was assayed by a modification of the high pressure liquid chromatography (HPLC) method of Ohmori et al (115), which determines α-oxoaldehydes as quinoxalines formed by the incubation of α-oxoaldehydes with o-phenylene diamine. Whole blood samples were treated with two volumes of absolute ethanol, mixed thoroughly and incubated on ice for 10 minutes. The precipitate was sedimented by centrifugation (500g, 10 minutes).
Figure 3. A Typical Calibration Curve for the Assay of Reduced Glutathione and S-D-Lactoylglutathione. Standard solutions of reduced glutathione and S-D-lactoylglutathione were assayed as described in the Materials and Methods section.
The clear aqueous ethanol supernatant was incubated with 100 µM o-phenylene diamine for two hours in the dark at room temperature, and then extracted 5 times with 4 volumes of chloroform. The chloroform extracts were pooled and evaporated to dryness under vacuum at room temperature. The residue was dissolved in 0.5 ml HPLC mobile phase and analysed for quinoxaline content.

HPLC analysis was performed on a Radial-PAK µBondapak C_{18} reverse-phase column (8 mm internal diameter x 10 cm) with a mobile phase of 10 mM potassium dihydrogen phosphate pH 2.1 : acetonitrile (80 : 20). Quinoxalines were detected by flow spectrophotometry at 312 nm. The internal standard was 2,3-dimethylquinoxaline. The assay was calibrated by assaying solutions of known methylglyoxal concentration. 200 µl of sample was injected per assay. The recovery of methylglyoxal was approximately 60%. A typical HPLC trace for the methylglyoxal assay is shown in Figure 4.

3.3 Modification of the Glyoxalase System During the Differentiation of Human Leukaemia Cells In Vitro.

HL60 and K562 cell cultures were grown in the absence and presence of 130, 150 and 185 mM N-methylformamide, and 13, 26, 51.5, 77 and 103 µM CCRG 81045 dissolved in DMSO such that the final concentration of DMSO in the culture medium did not exceed 0.001% - this concentration does not induce differentiation of HL60 or K562 cells (202). Cells were
Figure 4. A Typical HPLC Trace for the Assay of Methylglyoxal. A standard methylglyoxal solution was prepared and assayed as described in the Materials and Methods section. Key: IJ - Injection point, MQ - Methylquinoxaline peak (10 μM), IS - Internal Standard peak (10 μM).
seeded at an initial density of $5 \times 10^4$ cells/ml and incubated for 3 - 6 days. The development of HL60 maturation-dependent superoxide-forming NADPH oxidase activity was measured by the reduction of nitro blue tetrazolium (NBT) to formazan by the method of Mendelsohn et al (203). Erythroid differentiation of K562 cells was scored by benzidine staining (204).

For the assay of glyoxalase activities, the cells were sedimented by centrifugation (300g, 5 minutes), re-suspended in sonication buffer (10 mM sodium phosphate, pH 7.4) at 4°C and ruptured by sonication (100 W, 20 seconds). The membranes were sedimented by centrifugation (50,000g, 30 minutes) and the supernatant assayed for glyoxalase I and glyoxalase II activity.

The intrinsic effect of NMF and CCRG 81045 on the glyoxalase enzyme activities, defined as the effect of these compounds on the activity of glyoxalase I and glyoxalase II in a cell-free system, was investigated by studying the effect of adding NMF and CCRG 81045 to sonicated cell extracts from HL60 and K562 cells. An aliquot of cell extract was incubated, in the presence or absence of 185 mM NMF or 103 μM CCRG 81045 (the highest concentration of each drug used in the differentiation study), for 10 minutes at 37°C. After incubation, the residual activity of glyoxalase I and glyoxalase II in the sample was determined at a high and a low substrate concentration (0.2 and 2.0 mM hemimercaptal, 25 and 300 μM S-D-lactoylglutathione).
The effect of NMF and CCRG 81045 on the stability of the glyoxalase substrates, hemimercaptal and S-D-lactoylglutathione, was also investigated. Solutions of substrate were incubated with or without 185 mM NMF or 103 μM CCRG 81045 and the rate of decrease in substrate concentration was monitored at 240 nm, as described above.

The stability of glyoxalase I and glyoxalase II in the cell-free extract was also determined. The activity of both enzymes was measured when the cell extract was prepared. The cell extract was then stored overnight at 4°C and the activity of glyoxalase I and glyoxalase II re-measured, as described above. The stability of both enzymes was determined from the change in activity of glyoxalase I and glyoxalase II following overnight storage.

3.4 Changes in Glyoxalase Activities During Growth Arrest Of Raji and GM892 Cells.

GM892 and Raji cell cultures were incubated as described. Growth arrest was achieved by decreasing the concentrations of foetal calf serum to 0.1%, 0.5%, 2.0% and 5.0% from the normal 10%. Cells were seeded at an initial density of $2 \times 10^5$ cells/ml and incubated for 2 days. For assay of glyoxalase activities, the cells were sedimented by centrifugation (300g, 5 minutes), re-suspended in sonication buffer (10 mM HEPES with 0.02% Triton X-100, pH 7.4) at 4°C and ruptured by
sonication (100 W, 20 seconds). The membranes were sedimented by centrifugation (50,000g, 30 minutes) and the supernatant assayed for glyoxalase activity.

The rate of cell proliferation was assessed by the rate of incorporation of tritiated thymidine (131). An aliquot (1 ml) of cell suspension was added to 2.5 μCi of tritiated thymidine and gassed with 5% carbon dioxide. The tubes were capped and incubated at 37°C for 1 hour. The solution was filtered, under vacuum, through a WHATMAN GF/C filter and washed once with physiological saline (0.9% sodium chloride), followed by three washes with ice cold 5% trichloroacetic acid, and a final wash with absolute ethanol. The filter was dried in air and placed in a scintillation vial containing 5 mls of OPTIPHASE scintillation fluid for counting. The amount of tritiated thymidine in the cell extract was measured with a Tricarb 2000CA liquid scintillation counter.

3.5 The Potentiation of Cell-Free Microtubule Assembly by S-D-Lactoylglutathione.

3.5.1 The Purification of Microtubular Protein from Porcine Brain

Microtubular protein (tubulin + microtubule-associated proteins, MAPS) was prepared by a modification of the method of Gaskin et al (205). Pig brains from 4 - 6 pigs, freshly killed at a local slaughter house, were chilled on ice and the meninges
and superficial blood vessels removed. The brains were homogenized at 0°C in assembly buffer (0.1 M MES, 1 mM EGTA, 0.5 mM MgCl₂, 1 ml of buffer per gram wet weight of tissue). Homogenization was performed with a Waring blender (4 seconds at low speed) and then in a PotterElvejhem Teflon pestle homogenizer. Cellular debris was sedimented by centrifugation (90 minutes, 12,000g, 0°C). Tubulin was purified from the supernatant by three assembly - disassembly cycles. One volume of 8 M glycerol in assembly buffer was added to the supernatant and the solution was made 1 mM with respect to GTP and incubated at 37°C for 45 minutes. Assembled microtubules were sedimented by centrifugation (60 minutes, 39,000g, 37°C) and re-suspended in assembly buffer by homogenization. The re-suspended microtubules were disassembled by incubation at 0°C for 30 minutes, the solution was then centrifuged (60 minutes, 39,000g, 0°C) to produce a tubulin-rich supernatant. The supernatant was purified by a further two assembly - disassembly cycles, the last purification cycle being performed immediately prior to the microtubule assembly experiments, as shown in the purification scheme - Figure 5. Purified tubulin solution was stored at -20°C. Electrophoretic analysis has shown that protein purified by this method contains greater than 80% tubulin, the remainder being microtubule-associated proteins (205).
Figure 5. Flow Diagram for the Purification of Microtubular Protein from Porcine Brain. Microtubular protein was purified by the method of Gaskin et al (205).
3.5.2 The Measurement of Microtubular Assembly by Turbidity.

Microtubular formation was measured turbidometrically by following the absorbance of assembly incubations at 350 nm (205). The incubation mixture contained 1 mg/ml microtubular protein in assembly buffer, with and without 0.02 - 1.00 mM S-D-lactoylglutathione, at 37°C. The assembly of microtubules was initiated by the addition of 20 μM GTP. After incubation for one hour, the disassembly properties of the microtubules were investigated by:
(i) the addition of calcium chloride (final concentration 1.05 mM), (ii) the addition of 0.1 mg/ml of the anti-tubulin nocodazole, and (iii) incubation of assembled microtubules in suspension at 0°C. The decrease in absorbance at 350 nm was followed for a further 30 minutes.

3.5.3 The Consumption of S-D-Lactoylglutathione on Assembly

Microtubular protein (1 mg/ml) was assembled at 37°C for 30 minutes in the presence of 1 mM S-D-lactoylglutathione. The incubation was centrifuged (30 minutes, 37°C, 20,000g) and the supernatant removed. The concentration of S-D-lactoylglutathione in the supernatant was estimated from the decrease in absorbance after addition of glyoxalase II - as described in section 3.2.2. Controls were S-D-lactoylglutathione incubated with assembly buffer
and GTP, and assembly buffer with microtubular protein without GTP.


3.6.1. Patients.

Eighty-five diabetic patients, 40 with retinopathy and 45 clinically uncomplicated (no retinopathy by fundoscopy of the dilated eye and no "Albustix" positive proteinuria) were studied together with 45 healthy non-diabetic controls attending the same outpatients clinic with minor complaints. Venous blood samples taken by venupuncture were drawn into tubes containing lithium heparine at the West Midland Regional Health Authority Diabetic Clinic, East Birmingham Hospital, by Drs P. Jennings and C. Florkowski. Samples were transported to the laboratory, arriving within 1 hour of taking the blood sample. Retinopathy examinations and blood glucose measurements were performed by the staff of East Birmingham Hospital.

3.6.2. The Assay of Red Blood Cell Glyoxalase Activities

Red blood cells were sedimented from 4 mls blood by centrifugation (10 minutes, 2,000g). The plasma and white cells were removed and the red cells washed four times with 5 volumes of phosphate-buffered saline (0.9% sodium chloride : 0.1 M potassium phosphate buffer pH 7.4; 9 : 1). 1 ml of washed packed red blood cells was
lysed in four volumes of distilled water and vortexed to ensure complete lysis of the cells. The membrane fragments were sedimented by centrifugation (10 minutes, 2,000g). The supernatant was assayed for glyoxalase activity as described above.

In the glyoxalase I assay, the coefficient of variance for the intrabatch assay was 2.7% (n = 6) and 6.7% for the interbatch assay (n = 6). In the glyoxalase II assay, the coefficient of variance for the intrabatch assay was 1.5% (n = 6) and 3.2% for the interbatch assay (n = 6).


The concentration of methylglyoxal in whole blood was determined in 32 diabetic patients with and without complications and in 17 healthy control subjects by the methods described above. The concentration of S-D-lactoylglutathione in whole blood was determined in 28 diabetic patients with and without complications and in 24 healthy control subjects by the methods described above.

In the methylglyoxal assay, the coefficient of variance for the controls was 5.8% for the intrabatch assay (n = 4) and 14.7% for the interbatch assay (n = 6). In the S-D-lactoylglutathione assay, the coefficient of variance for the controls was 11.4% for the intrabatch assay (n = 4) and 12.1% for the interbatch assay (n = 6).
3.7 Instrumentation.

3.7.1 Spectrophotometry.

All spectrophotometric assays were performed on a CECIL CE5095 High Performance Scanning spectrophotometer equipped with a CECIL CE500 Control-record module (Series II) and a Gallenkamp 85 thermostirrer.

3.7.2 High Pressure Liquid Chromatography.

The HPLC system employed comprised an ALTEX 420 microprocessor controller/programmer, two ALTEX 100A pumps, a WATERS Lambda-Max model 480 LC spectrophotometer, a WATERS RCM-100 Radial Compression Module and an LKB 1-Channel recorder. The HPLC column (Type 8MBC 180μ) was purchased from Waters Associates (Harrow, U.K.)
4. RESULTS.

4.1 Changes in Glyoxalase Activities During the Differentiation of Human Leukaemia Cells In Vitro.

4.1.1 Human Promyelocytic Leukaemia HL60 Cells.

Incubating HL60 cells with N-methylformamide (NMF) for 3 to 6 days results in a dose- and time- dependent increase in the formation of mature granulocytes, as determined by an increase in the percentage of cells reducing nitroblue tetrazolium (NBT) (159). During the incubation period, there were marked changes in the HL60 glyoxalase activities - the activity of glyoxalase I decreased and the activity of glyoxalase II increased (Figure 6). The activities of the glyoxalase enzymes in untreated HL60 cells was relatively constant throughout the 6-day period (Table 4). There was no reduction in the viability of NMF-treated cells, as judged by trypan blue exclusion (159). However, there was a dose-dependent decrease in cell growth, as indicated by the decrease in the final cell number.

The decrease in the activity of glyoxalase I was dependent on the concentration of NMF in the incubation media. Maximal inhibition of 40, 58 and 64% of control values occurred after incubation for 4 days with 130, 150 and 185 mM NMF, respectively. In contrast, the activity of glyoxalase I in the untreated cells varied by only 10% of the mean value throughout the 6 day incubation period (Table 4). The number of
Figure 6. The Glyoxalase I and Glyoxalase II Activities in HL60 Cells Treated with N-Methylformamide (NMF). Drug treatment: (△ ▲) 130 mM NMF, (○ ●) 150 mM NMF and (□ ■) 185 mM NMF. Closed symbols - glyoxalase I, open symbols - glyoxalase II. Data is the mean ± standard deviation of three independent experiments. The activities of the glyoxalase enzymes were determined as described in the Materials and Methods section.
Table 4. The Activity of Glyoxalase I and Glyoxalase II in Untreated HL60 Leukaemia Cells in Culture.

<table>
<thead>
<tr>
<th>Culture Time (Days)</th>
<th>Glyoxalase I (mU/10^6 cells)</th>
<th>Glyoxalase II (mU/10^6 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>37.9 ± 6.9</td>
<td>1.96 ± 0.33</td>
</tr>
<tr>
<td>4</td>
<td>34.1 ± 1.2</td>
<td>2.24 ± 0.05</td>
</tr>
<tr>
<td>5</td>
<td>29.4 ± 0.7</td>
<td>1.96 ± 0.08</td>
</tr>
<tr>
<td>6</td>
<td>31.5 ± 1.6</td>
<td>1.92 ± 0.03</td>
</tr>
</tbody>
</table>

Glyoxalase activities were determined as described in the Materials and Methods section. Data is the mean ± standard deviation of a minimum of 7 experiments.
differentiated cells reached a maximum at 4 days after drug administration and remained relatively constant during days 5 and 6 (159). After the fourth day of incubation, the decrease in the activity of glyoxalase I showed a direct correlation with the percentage of cells reducing NBT (Figure 7). On continued incubation of the cells with 185 mM NMF, there was no further decrease in the activity of glyoxalase I, although by day 6 the activity of glyoxalase I in the cells treated with 130 and 150 mM NMF had increased by 10-15%. The data suggests that the general features of the change in glyoxalase I activity in NMF treated HL60 cells are: (a) a decrease in activity of approximately 50-60% within the first 4 days of treatment, and (b) the approximate maintenance of this decreased glyoxalase I activity thereafter.

During the 6-day incubation period, the activity of glyoxalase II in NMF-treated HL60 cells increased by between 110 and 210% of the control levels (Figure 6). The activity of glyoxalase II in untreated HL60 cells changed by only about 8% of the mean value during this period (Table 4). The activity of glyoxalase II in the NMF-treated cells showed a time- and dose-dependent increase throughout the 6 day incubation period, as was observed with glyoxalase I. In general, incubation of the cells with 130 mM NMF produced a smaller response than was seen with the higher concentrations. There is a smaller difference between the curves for 150 and 185
Figure 7. The Relationship Between Changes in the Activities of the Glyoxalase Enzymes and the Percentage of Differentiated HL60 Cells after Treatment with NMF and CCRG 81045 for 4 Days. Key: ○ - NMF, □ - CCRG 81045. Closed symbols - glyoxalase I, open symbols - glyoxalase II.
mM NMF than between the curves for 130 and 150 mM NMF. This difference in the effect of NMF is reflected in the percentage of cells which could reduce NBT. On day 4 of treatment, there was a linear relationship between the increase in the activity of glyoxalase II and the number of differentiated cells (Figure 7). To compare the relative activities of the glyoxalase enzymes, the unit ratio of the activity of glyoxalase I to the activity of glyoxalase II ($^\text{A}_{\text{GI}}/^\text{A}_{\text{GII}}$) was calculated. This unit ratio decreased during the first 4 days of incubation and then remained relatively constant (Table 5).

When HL60 cells were incubated with CCRG 81045, the changes in the activities of glyoxalase I and glyoxalase II were similar to those seen with NMF. After a 6 day incubation, when the percentage of differentiated cells was maximal (203), there was a dose-dependent decrease in the activity of glyoxalase I and a dose-dependent increase in the activity of glyoxalase II (Figure 8). The decrease in glyoxalase I activity and the increase in glyoxalase II activity was maximal at CCRG 81045 concentrations greater than 70 μM. Moreover, there was a linear relationship between the changes in glyoxalase activities and the percentage of cells reducing NBT (Figure 7). The data for the differentiation of HL60 cells by CCRG 81045 has the same linear relationship as that obtained for the differentiation of HL60 cells by NMF.

When a crude preparation of glyoxalase enzymes,
Table 5. The Glyoxalase I/Glyoxalase II Activity Ratio (AGI/AGII) in N-Methylformamide Treated HL60 Leukaemia Cells in Culture

<table>
<thead>
<tr>
<th>Culture Time [NMF] (Days)</th>
<th>AGI/AGII (unit ratio)</th>
<th>ΔAGI/AGII (% Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>19.3 ± 6.7</td>
<td>--------</td>
</tr>
<tr>
<td>130</td>
<td>10.2 ± 1.6</td>
<td>-47 ± 51</td>
</tr>
<tr>
<td>150</td>
<td>7.8 ± 1.6</td>
<td>-60 ± 56</td>
</tr>
<tr>
<td>185</td>
<td>9.4 ± 1.7</td>
<td>-51 ± 53</td>
</tr>
<tr>
<td>Control</td>
<td>15.2 ± 0.8</td>
<td>--------</td>
</tr>
<tr>
<td>130</td>
<td>5.9 ± 0.9</td>
<td>-61 ± 23</td>
</tr>
<tr>
<td>150</td>
<td>3.3 ± 0.5</td>
<td>-78 ± 21</td>
</tr>
<tr>
<td>185</td>
<td>2.7 ± 0.5</td>
<td>-82 ± 24</td>
</tr>
<tr>
<td>Control</td>
<td>15.0 ± 1.0</td>
<td>--------</td>
</tr>
<tr>
<td>130</td>
<td>5.7 ± 0.5</td>
<td>-68 ± 14</td>
</tr>
<tr>
<td>150</td>
<td>4.2 ± 0.4</td>
<td>-77 ± 15</td>
</tr>
<tr>
<td>185</td>
<td>4.1 ± 0.3</td>
<td>-77 ± 14</td>
</tr>
<tr>
<td>Control</td>
<td>16.4 ± 1.7</td>
<td>--------</td>
</tr>
<tr>
<td>130</td>
<td>5.6 ± 0.3</td>
<td>-72 ± 15</td>
</tr>
<tr>
<td>150</td>
<td>3.2 ± 0.2</td>
<td>-84 ± 16</td>
</tr>
<tr>
<td>185</td>
<td>2.6 ± 0.2</td>
<td>-87 ± 18</td>
</tr>
</tbody>
</table>

The glyoxalase activity ratio, AGI/AGII, was calculated as the ratio of the activity of glyoxalase I/glyoxalase II, where the glyoxalase activities are expressed in units/10^6 cells as defined in the Materials and Methods section. Significance was determined using the Student's two-tailed "t" test: a - P > 0.10; b - 0.01 > P > 0.002; c - P < 0.002.
Figure 8. The Activity of Glyoxalase I and Glyoxalase II in HL60 Cells Treated with CCRG 81045 for 6 Days. Closed symbols - glyoxalase I, open symbols - glyoxalase II. Data is the mean ± standard deviation of three independent experiments. The activities of the glyoxalase enzymes were determined as described in the Materials and Methods.
prepared from the cytosol of HL60 cells, was incubated with either 185 mM NMF or 103 μM CCRG 81045 for 10 minutes, there was no significant change in the activities of glyoxalase I and glyoxalase II (Tables 6 and 7). This excludes the possibility that the presence of NMF or CCRG 81045 in the assay systems for glyoxalase activities produced the observed inhibitory and stimulatory effects. Therefore, the changes in glyoxalase activities observed during the 6 day incubations with both NMF and CCRG 81045 may be due to changes in enzyme synthesis, metabolic regulatory modification, or to a longer term interaction between NMF and CCRG 81045 with the glyoxalase enzymes.

When the glyoxalase substrates, 1.33 mM hemimercaptal and 0.3 mM S-D-lactoylglutathione, were incubated with 185 mM NMF and 103 μM CCRG 81045, there was no significant change in the stability of S-D-lactoylglutathione in the presence of NMF or CCRG 81045, or hemimercaptal in the presence of CCRG 81045. However, NMF caused a significant increase in the rate of change of absorbance of the hemimercaptal (Table 8). This did not affect the activity of glyoxalase I. In all cases, the rate of change of the blank was less than 10% of the rate of change of the enzyme catalysed reaction.

When the HL60 cell extract was stored overnight at 4°C, there was no significant decrease in the activity of glyoxalase I or glyoxalase II (Table 9). This
Table 6. The Effect of N-Methylformamide and CCRG 81045 on Glyoxalase I Activity in Cell-Free Systems

<table>
<thead>
<tr>
<th></th>
<th>[Hemimercaptal]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.2 mM</td>
</tr>
<tr>
<td><strong>HL60 Cell Extract</strong></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>18.1 ± 0.1</td>
</tr>
<tr>
<td>+ 185 mM NMF</td>
<td>18.5 ± 0.1</td>
</tr>
<tr>
<td>+ 103 µM CCRG 81045</td>
<td>20.3 ± 2.3</td>
</tr>
<tr>
<td><strong>K562 Cell Extract</strong></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>18.6 ± 1.0</td>
</tr>
<tr>
<td>+ 185 mM NMF</td>
<td>14.2 ± 8.6</td>
</tr>
<tr>
<td>+ 103 µM CCRG 81045</td>
<td>19.5 ± 2.9</td>
</tr>
</tbody>
</table>

Glyoxalase I activity is expressed as mU/10⁶ cells as defined in the Materials and Methods section. Data is the mean ± standard deviation from two independent experiments. All data gives P > 0.10 in the Student's two-tailed "t" test.
Table 7. The Effect of N-Methylformamide and CCRG 81045 on Glyoxalase II Activity in Cell-Free Systems

<table>
<thead>
<tr>
<th></th>
<th>[S-D-Lactoylglutathione]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>25 µM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>HL60 Cell Extract</th>
<th></th>
<th>K562 Cell Extract</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>+ 185 mM NMF</td>
<td>+ 103 µM CCRG 81045</td>
<td>Control</td>
</tr>
<tr>
<td></td>
<td>0.285 ± 0.025</td>
<td>0.235 ± 0.023</td>
<td>0.250 ± 0.028</td>
<td>0.510 ± 0.074</td>
</tr>
<tr>
<td></td>
<td>2.02 ± 0.13</td>
<td>1.72 ± 0.04</td>
<td>1.98 ± 0.02</td>
<td>2.80 ± 0.13</td>
</tr>
</tbody>
</table>

Glyoxalase II activity is expressed as mU/10^6 cells as defined in the Materials and Methods section. Data is the mean ± standard deviation from two independent experiments. All data gives P > 0.10 in the Student's two-tailed "t" test.
Table 8. The Stability of Hemimercaptal and S-D-Lactoylglutathione in the Presence of 185 mM NMF and 103 μM CCRG 81045.

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>+ 185 mM NMF</th>
<th>+ 103 μM CCRG 81045</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3 mM S-D-Lactoylglutathione</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0.38 ± 0.02</td>
<td>0.41 ± 0.03</td>
<td></td>
</tr>
<tr>
<td>+ 185 mM NMF</td>
<td></td>
<td>0.31 ± 0.04</td>
<td></td>
</tr>
<tr>
<td>+ 103 μM CCRG 81045</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.33 mM Hemimercaptal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>3.36 ± 0.26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ 185 mM NMF</td>
<td>11.73 ± 0.19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ 103 μM CCRG 81045</td>
<td>3.39 ± 0.31</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The stability of S-D-lactoylglutathione and hemimercaptal was determined as described in the Materials and Methods section. Statistical analysis was performed using a one-tailed Student's "t" test. * = P > 0.05, ** = P < 0.001.
Table 9. The Stability of Glyoxalase I and Glyoxalase II from HL60 and K562 Cells.

<table>
<thead>
<tr>
<th></th>
<th>Activity (% of Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 0</td>
</tr>
<tr>
<td>HL60 Cells</td>
<td></td>
</tr>
<tr>
<td>Glyoxalase I</td>
<td>100 ± 4</td>
</tr>
<tr>
<td>Glyoxalase II</td>
<td>100 ± 1</td>
</tr>
<tr>
<td>K562 Cells</td>
<td></td>
</tr>
<tr>
<td>Glyoxalase I</td>
<td>100 ± 7</td>
</tr>
<tr>
<td>Glyoxalase II</td>
<td>100 ± 4</td>
</tr>
</tbody>
</table>

The activity of glyoxalase I and glyoxalase II was determined as described in the Materials and Methods section. The activity of both enzymes on the day the samples were prepared (Day 0) is taken as the control activity. The activity of glyoxalase I and glyoxalase II was remeasured after storage for 24 hours (Day 1). Data is the mean ± standard deviation of two determinations.
indicates that both glyoxalase enzymes are stable for the time-period over which the experiment was conducted.

4.1.2 Human Erythroleukaemia K562 Cells

Unlike HL60 cells, K562 cells are not induced to differentiate by NMF at any of the concentrations used (202). Although NMF has no effect on either the proliferative activity or the expression of haemoglobin in these cells, it did induce an increase in the activity of both glyoxalase I and glyoxalase II over the 6 day period (Figure 9). The activities of the glyoxalase enzymes in untreated K562 cells showed a small fluctuation throughout this period (less than 5% of the mean value - Table 10). There was an inverse relationship between the increase in the activity of glyoxalase I in NMF-treated K562 cells and the concentration of NMF - after five days of treatment with 130 mM NMF, the glyoxalase I activity was increased by 70% of the control value, whereas, after treatment for five days with 185 mM NMF, the activity of glyoxalase I had increased by only 25% of the control value. After incubation for six days, the glyoxalase I activity, at all the NMF concentrations studied, was increased by 80 - 90% of the control value.

The activity of glyoxalase II in NMF-treated K562 cells increased during the 5-6 day incubation period (Figure 9), except for an anomalous decrease with 130 mM NMF between days 5 and 6. In contrast to the glyoxalase I data, NMF had a dose-dependent effect on glyoxalase II
Figure 9. The Glyoxalase I and Glyoxalase II Activities in K562 Cells Treated with N-Methylformamide. Key:
(△ ▲) 130 mM NMF, (○ ●) 150 mM NMF and
(□ ■) 185 mM NMF. Closed symbols – glyoxalase I, open symbols – glyoxalase II. Data is the mean ± standard deviation of three independent experiments. The activities of the glyoxalase enzymes was determined as described in the Materials and Methods.
### Table 10. The Activity of Glyoxalase I and Glyoxalase II in Untreated K562 Erythroleukaemia Cells in Culture.

<table>
<thead>
<tr>
<th>Culture Time (Days)</th>
<th>Glyoxalase I (mU/10^6 cells)</th>
<th>Glyoxalase II (mU/10^6 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>82.2 ± 5.5</td>
<td>2.83 ± 0.08</td>
</tr>
<tr>
<td>5</td>
<td>90.3 ± 4.3</td>
<td>2.78 ± 0.06</td>
</tr>
<tr>
<td>6</td>
<td>88.0 ± 6.9</td>
<td>2.93 ± 0.18</td>
</tr>
</tbody>
</table>

Glyoxalase activities were determined as described in the Materials and Methods section. Data is the mean ± standard deviation of a minimum of 8 experiments.
activity. The maximum increase in the activity of glyoxalase II observed was about 100% of the control value. The unit ratio of the activity of glyoxalase I to the activity of glyoxalase II showed only a minor change after 6 days of incubation of K562 cells with NMF (Table 11).

Unlike NMF, incubating K562 cells with CCRG 81045 produces a time- and dose-dependent increase in the number of haemoglobin-producing cells, although no functional alteration is apparent until after 3 days of treatment (204). After treatment with CCRG 81045, there was no significant change in K562 glyoxalase activities for the first three days, but thereafter the activity of both glyoxalase I and glyoxalase II increased (Figure 10). The glyoxalase activities in untreated cells showed only a relatively small fluctuation throughout this period (Table 10). The increases in the activities of glyoxalase I and glyoxalase II were not markedly dependent on the dose of CCRG 81045. Except for the curve for glyoxalase I activity in cells treated with 26 μM CCRG 81045, most of the glyoxalase activity curves are extraordinarily similar. There was a marked increase in the activity of both glyoxalase I and glyoxalase II during the sixth day of incubation. The percentage increase in the activity of glyoxalase II is approximately twice the percentage increase in the activity of glyoxalase I. Therefore, the unit ratio of the activity of glyoxalase I to the activity of
Table 11. The Glyoxalase I/Glyoxalase II Activity Ratio (\(A_GI/A_{GII}\)) in N-Methylformamide Treated K562 Erythroleukaemia Cells in Culture

<table>
<thead>
<tr>
<th>Culture Time (Days)</th>
<th>[NMF] (mM)</th>
<th>(A_GI/A_{GII}) (unit ratio)</th>
<th>(\Delta A_GI/A_{GII}) (% Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>NOT DETERMINED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td>30.8 ± 1.5(^a)</td>
<td></td>
</tr>
<tr>
<td>130</td>
<td></td>
<td>36.3 ± 1.7(^a)</td>
<td>+18 ± 10</td>
</tr>
<tr>
<td>5</td>
<td>150</td>
<td>28.9 ± 0.8(^a)</td>
<td>-7 ± 8</td>
</tr>
<tr>
<td></td>
<td>185</td>
<td>22.7 ± 0.4(^b)</td>
<td>-26 ± 7</td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td>29.6 ± 0.8(^b)</td>
<td></td>
</tr>
<tr>
<td>130</td>
<td></td>
<td>41.0 ± 1.1(^b)</td>
<td>+39 ± 6</td>
</tr>
<tr>
<td>6</td>
<td>150</td>
<td>30.5 ± 0.8(^a)</td>
<td>+3 ± 5</td>
</tr>
<tr>
<td></td>
<td>185</td>
<td>27.4 ± 0.4(^b)</td>
<td>-7 ± 4</td>
</tr>
</tbody>
</table>

The glyoxalase activity ratio, \(A_GI/A_{GII}\), was calculated as the ratio of the activity of glyoxalase I/glyoxalase II, where the glyoxalase activities are expressed in units/10\(^8\) cells as defined in the Materials and Methods section. Significance was determined using the Student's two-tailed "t" test: \(^a\) - \(P > 0.10\); \(^b\) - \(P < 0.05\).
Figure 10. The Glyoxalase I and Glyoxalase II Activities in K562 Cells Treated with CCRG 81045.
Key: (△ ▲) 26.0 μM CCRG 81045, (○ ●) 51.5 μM CCRG 81045 and (□ ■) 77.0 μM CCRG 81045. Closed symbols - glyoxalase I, open symbols - glyoxalase II. Data is the mean ± standard deviation of three independent experiments. The activities of the glyoxalase enzymes was determined as described in the Materials and Methods.
glyoxalase II falls sharply as differentiation ensues (Table 12).

When a crude preparation of glyoxalase I and glyoxalase II, prepared from the cytosol of K562 cells, was incubated with either 185 mM NMF or 103 μM CCRG 81045 for 10 minutes, there was no significant change in the activities of either enzyme (Tables 6 and 7). This excludes the possibility that the presence of NMF or CCRG 81045 in the assay systems for glyoxalase activities produced the observed inhibitory and stimulatory effects. The changes in glyoxalase activities during the 6 day incubation period with both NMF and CCRG 81045 may be due to changes in enzyme synthesis, metabolic regulatory modification, or a longer term interaction between NMF and CCRG 81045 with the glyoxalase enzymes in K562 cells.

The effect of overnight storage on the activity of glyoxalase I and glyoxalase II in the K562 cell extract is shown in Table 9. There was no significant decrease in the activity of either enzyme. Therefore, glyoxalase I and glyoxalase II can be regarded as stable over the time period used for the experiment.

4.1.3 The Substrate - Reaction Velocity Relationship for Glyoxalase Enzymes During the Differentiation of Human Promyelocytic Leukaemia Cells to Neutrophils.

Incubation of HL60 promyelocytic leukaemia cells with NMF induced their differentiation to neutrophil-like cells with an accompanying decrease in
Table 12. The Glyoxalase I/Glyoxalase II Activity Ratio (AGI/AGII) in CCRG 81045 Treated K562 Erythroleukaemia Cells in Culture

<table>
<thead>
<tr>
<th>Culture Time (Days)</th>
<th>[CCRG81045] (µM)</th>
<th>AGI/AGII (unit ratio)</th>
<th>ΔAGI/AGII (% Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>29.0 ± 2.8</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>26.0</td>
<td>29.0 ± 1.3\textsuperscript{a}</td>
<td>0 ± 14</td>
</tr>
<tr>
<td></td>
<td>51.5</td>
<td>27.5 ± 2.1\textsuperscript{a}</td>
<td>- 5 ± 17</td>
</tr>
<tr>
<td></td>
<td>77.0</td>
<td>27.5 ± 0.8\textsuperscript{a}</td>
<td>- 5 ± 12</td>
</tr>
<tr>
<td>Control</td>
<td>34.2 ± 1.3</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>26.0</td>
<td>41.0 ± 3.6\textsuperscript{a}</td>
<td>+20 ± 13</td>
</tr>
<tr>
<td></td>
<td>51.5</td>
<td>31.6 ± 1.0\textsuperscript{a}</td>
<td>- 8 ± 7</td>
</tr>
<tr>
<td></td>
<td>77.0</td>
<td>30.9 ± 1.6\textsuperscript{a}</td>
<td>-10 ± 9</td>
</tr>
<tr>
<td>Control</td>
<td>30.4 ± 2.7\textsuperscript{b}</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>26.0</td>
<td>22.3 ± 0.8\textsuperscript{b}</td>
<td>-27 ± 12</td>
</tr>
<tr>
<td></td>
<td>51.5</td>
<td>18.8 ± 0.8\textsuperscript{c}</td>
<td>-38 ± 12</td>
</tr>
<tr>
<td></td>
<td>77.0</td>
<td>19.7 ± 1.7\textsuperscript{c}</td>
<td>-35 ± 15</td>
</tr>
</tbody>
</table>

The glyoxalase activity ratio, AGI/AGII, was calculated as the ratio of the activity of glyoxalase I/glyoxalase II, where the glyoxalase activities are expressed in units/10\textsuperscript{6} cells as defined in the Materials and Methods section. Significance was determined using the Student's two-tailed "t" test: \textsuperscript{a} - P > 0.10; \textsuperscript{b} - 0.10 > P < 0.05; \textsuperscript{c} - P < 0.05.
the activity of glyoxalase I and an increase in the activity of glyoxalase II (Section 4.1.1). When the experimental activity data was analysed by the Lineweaver - Burk method, the substrate concentration (S) - reaction velocity (V) profiles for both glyoxalase I (Figure 11) and glyoxalase II (Figure 12) indicate that the changes in glyoxalase activity, during differentiation, were reflected by changes in the parameters of the apparent Michaelis-Menten kinetics. The apparent Michaelis constant, $K_m$, and the relative maximum velocities, $V_{\text{max}}$, calculated from the experimental data are presented in Table 13. During differentiation, the apparent $K_m$ of both glyoxalase I and glyoxalase II remained constant, within the limits of experimental error. However, there was a 60% decrease in the apparent $V_{\text{max}}$ of the glyoxalase I-catalysed reaction and an approximately 140% increase in the apparent $V_{\text{max}}$ for the glyoxalase II-catalysed reaction, relative to the control HL60 promyelocyte values. These changes in the kinetic parameters of glyoxalase I and glyoxalase II indicate that the activity of glyoxalase I was non-competitively decreased during differentiation and the activity of glyoxalase II was non-competitively increased during differentiation.
Figure 11. The Substrate Concentration - Reaction Velocity Relationship for the Glyoxalase I-Catalysed Reaction During the Differentiation of HL60 Cells to Neutrophils. Symbols: 1 - 0% (Control), 2 - 35%, 3 - 50% and 4 - 80% differentiation. The activity of glyoxalase I was determined as described in the Materials and Methods section. Data is the mean ± standard deviation for six independent experiments.
Figure 12. The Substrate Concentration - Reaction Velocity Relationship for the Glyoxalase II-Catalysed Reaction During the Differentiation of HL60 Cells to Neutrophils. Symbols: 1 - 0% (Control), 2 - 35%, 3 - 50% and 4 - 80% differentiation. The activity of glyoxalase II was determined as described in the Materials and Methods section. Data is the mean ± standard deviation for six independent experiments.
Table 13. The Apparent Michaelis-Menten Kinetic Constants for the Glyoxalase Enzymes During the Differentiation of HL60 Promyelocytes to Neutrophils by N-Methylformamide

<table>
<thead>
<tr>
<th>NMF Treatment (mM)</th>
<th>Percent Different. (%)</th>
<th>Glyoxalase I</th>
<th>Glyoxalase II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>App. Km (µM)</td>
<td>Rel. Vmax (%)</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>241±9</td>
<td>100±9</td>
</tr>
<tr>
<td>130</td>
<td>34±5</td>
<td>250±12</td>
<td>91±18</td>
</tr>
<tr>
<td>150</td>
<td>50±5</td>
<td>256±22</td>
<td>60±14</td>
</tr>
<tr>
<td>185</td>
<td>80±5</td>
<td>260±34</td>
<td>43±12</td>
</tr>
</tbody>
</table>
4.2 Changes in Glyoxalase Activity During the Growth Arrest of GM892 Lymphoblastoid and Raji Burkitt's Lymphoma Cells In Vitro.

4.2.1 Growth Arrest of GM892 Lymphoblastoid Cells.

When cultures of GM892 cells, grown in media containing 10% foetal calf serum, were incubated in media containing decreased concentrations (5 - 0.1%) of foetal calf serum, there was a decrease in the rate of cell proliferation, as judged by a decrease in the rate of uptake of tritiated thymidine. The growth arrest of GM892 cells was accompanied by changes in the cellular glyoxalase activities: there was a decrease in the activity of glyoxalase I and an increase in the activity of glyoxalase II with progressive growth arrest (Figure 13). There was an approximately linear correlation between the activity of both enzymes and thymidine incorporation (correlation coefficients: glyoxalase I = 0.91; glyoxalase II = - 0.98). An approximately 100% increase in the rate of cell proliferation produced an approximately 200% increase in the activity of glyoxalase I and an approximately 20% decrease in the activity of glyoxalase II.

Growth-arrested GM892 cells had a relatively low activity of glyoxalase I and a relatively high activity of glyoxalase II, whereas rapidly proliferating GM892 cells had a relatively high activity of glyoxalase I and a relatively low glyoxalase II activity.
Figure 13. The Effect of Proliferation Rate on the Activity of Glyoxalase Enzymes in GM892 Cells.
GM892 cells were incubated for two days in media containing 5%, 2%, 0.5% and 0.1% foetal calf serum. 
H-Thymidine incorporation and the activity of glyoxalase I and glyoxalase II were measured as described in the Materials and Methods section.
4.2.2 Growth Arrest of Raji Burkitt's Lymphoma Cells.

Serum-deprivation of Raji cells produced a decrease in the cell proliferation status, as judged by the decrease in the rate of tritiated thymidine uptake. The activities of both glyoxalase I and glyoxalase II increased when Raji cells were growth-arrested (Figure 14). Therefore, growth-arrested Raji cells had relatively high activities of glyoxalase I and glyoxalase II, whereas, rapidly proliferating Raji cells had relatively low activities of glyoxalase I and glyoxalase II. Unlike GM892 cells, there was no linear correlation between the rate of proliferation and the glyoxalase activities in Raji cells. There does, however, appear to be a reciprocal (hyperbolic) relationship between glyoxalase activity and rate of cell proliferation in growth arrested Raji cells (Figure 14).

4.3 S-D-Lactoylglutathione and the Cell-Free Assembly of Microtubules.

4.3.1 The Potentiation of Microtubule Assembly by S-D-Lactoylglutathione.

When microtubular protein (1 mg/ml) was incubated in microtubule assembly buffer with 20 μM GTP at 37°C, the assembly of microtubules was initiated. The resulting increase in turbidity, due to the formation of microtubular fibres of greater than 1 μm in length in suspension, may be conveniently assessed by following
Figure 14. The Effect of Proliferation Rate on the Activity of Glyoxalase Enzymes in Raji Cells. Raji cells were incubated for two days in media containing 5%, 2%, 0.5% and 0.1% foetal calf serum. $^3$H-Thymidine incorporation and the activity of glyoxalase I and glyoxalase II were measured as described in the Materials and Methods section.
the absorbance at 350 nm. For the initial 1 - 2 minutes of the incubation, there was no increase in absorbance (Figure 15, curve d). This reflects the lag period during which nucleation centres for microtubule assembly were formed and microtubular assembly begins (205). After the nucleation lag phase, there was a rapid increase in absorbance over the next 10 minutes when the microtubules grow out from the nucleation centres. The light scattering measurement of the assembly of microtubules is responsive to microtubules greater than 1 \( \mu m \) long increasing in length (205). Therefore, this rapid change in absorbance reflects nucleating microtubules growing from 1 \( \mu m \) up to a typical length of 4 - 5 \( \mu m \) (206). During the following 50 minutes, there was a slow decrease in absorbance at 350 nm, representing a slow disassembly of the microtubules formed. This is thought to be due to phosphorylation of microtubule protein (207,208). The GTP-promoted cell-free assembled microtubules may be rapidly disassembled by treatment with 1.05 mM calcium chloride, 1 mg/ml of the anti-tubulin nocodazole, or by incubation at 0\(^\circ\)C on ice. All these features of cell-free microtubule assembly have been well-documented (172,209).

When 20 - 1000 \( \mu M \) S-D-lactoylglutathione was included in the incubation, there was a dose-related decrease in the nucleation lag phase and an increase in the maximum absorbance (Figure 15, curves a, b and c).
Figure 15. The Effect of S-D-Lactoylglutathione on the Assembly of Microtubules. Microtubules were assembled in the presence of increasing concentrations of S-D-lactoylglutathione as described in the Materials and Methods section. Key: d - 0 μM (control), c - 200 μM, b - 100 μM, a - 1000 μM S-D-lactoylglutathione. Dashed line - 500 μM S-D-lactoylglutathione and 1 unit glyoxalase II.
These effects were inhibited by glyoxalase II (Figure 15, dashed line). S-D-Lactoylglutathione did not stimulate the assembly of microtubules in the absence of GTP. Therefore, S-D-lactoylglutathione potentiated the GTP-promoted assembly of microtubules. The slow phosphorylation-associated disassembly of microtubules was unaffected by S-D-lactoylglutathione. A plot of maximum absorbance at 350 nm versus the concentration of S-D-lactoylglutathione suggests that, as a result of the potentiation of microtubule assembly by S-D-lactoylglutathione, the assembly of tubulin approaches a maximum, saturation level at high S-D-lactoylglutathione concentrations (Figure 16).

Microtubules assembled in the presence of S-D-lactoylglutathione were disassembled by treatment with 1.05 mM calcium chloride, 0.1 mg/ml nocodazole and by incubation on ice, at an identical rate to microtubules assembled in the absence of S-D-lactoylglutathione.

4.3.2 Consumption of S-D-Lactoylglutathione on Assembly of Microtubules.

When microtubular protein was assembled in the presence of 1 mM S-D-lactoylglutathione, there was a significant decrease in the S-D-lactoylglutathione concentration in the solution after assembly (P < 0.001 - Table 14). During assembly, 0.39 μmoles of S-D-lactoylglutathione were consumed. This indicates that approximately 20 μmoles of S-D-lactoylglutathione
Figure 16. The Effect of the Concentration of S-D-Lactoylglutathione on Microtubule Assembly. Microtubule assembly was measured as described in the Materials and Methods section. The concentrations of S-D-lactoylglutathione in the incubation mixture were 0, 20, 100 and 1000 μM.
Table 14. The Consumption of S-D-Lactoylglutathione During Tubulin Assembly

<table>
<thead>
<tr>
<th>Incubation</th>
<th>S-D-lactoylglutathione consumed (μmoles)</th>
<th>Microtubule Assembly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubulin, GTP</td>
<td>0.39 ± 0.01</td>
<td>+</td>
</tr>
<tr>
<td>S-D-lactoylglutathione</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tubulin,</td>
<td>0.00</td>
<td></td>
</tr>
<tr>
<td>S-D-lactoylglutathione</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>GTP,</td>
<td>0.02 ± 0.01</td>
<td></td>
</tr>
<tr>
<td>S-D-lactoylglutathione</td>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

The initial concentration of S-D-lactoylglutathione was 1 mM and the initial tubulin concentration was 20 μM. Samples were incubated for 1 hour at 37°C. S-D-Lactoylglutathione concentration was determined by the decrease in absorbance on the addition of glyoxalase II. Data is the mean ± standard deviation of 3 determinations.
were consumed per nmole of tubulin during assembly. If either microtubular protein or GTP was absent, there was no loss of S-D-lactoylglutathione from the solution. This indicates that a significant decrease in the concentration of S-D-lactoylglutathione only occurs under conditions necessary for the assembly of microtubules.


4.4.1 Glyoxalase Activities.

The activities of glyoxalase I and glyoxalase II were examined in red blood cells from 45 normal healthy control individuals and from 85 patients with Diabetes Mellitus (40 with retinopathy and 45 uncomplicated). The diabetic patients were classified as either insulin-dependent (Type I) or non-insulin-dependent (Type II) diabetics. The results are presented as frequency diagrams in Figures 17 and 18 (the thickened envelope in each diagram represents the distribution of glyoxalase activities in the controls). The statistical analysis of the data is presented in Tables 15 and 16.

The distribution of the activity of glyoxalase I in the red blood cells from diabetic patients and from normal healthy controls was very similar (Figure 17). Inspection of Figure 17 shows that, although the frequency distributions for glyoxalase I in the red blood cells from diabetics with and without
Figure 17. Frequency Distribution Curves for the Glyoxalase I Activity of Red Blood Cells. Key:
thickened line envelope - normal healthy controls,
(-O-O-) - diabetic patients without complications,
(-●●-) - diabetic patients with complications, (-θ-θ-) -
mean of all diabetic patients.
Figure 18. Frequency Distribution Curves for the Glyoxalase II Activity of Red Blood Cells. Key: thickened line envelope - normal healthy controls, (-O-O-) - diabetic patients without complications, (-●-●-) - diabetic patients with complications, (-○-○-) - mean of all diabetic patients. The mean activity for diabetic patients without complications > the mean activity for patients with complications (P < 0.05).
Table 15. The Activity of Glyoxalase I and Glyoxalase II in Control and Diabetic Patients

<table>
<thead>
<tr>
<th>Subjects (n)</th>
<th>Complications (+ or -)</th>
<th>Glyoxalase I (U/mlRBC)</th>
<th>Glyoxalase II (U/mlRBC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (45)</td>
<td></td>
<td>47.8 ± 8.2</td>
<td>19.1 ± 4.0</td>
</tr>
<tr>
<td>All Diabetics (85)</td>
<td>±</td>
<td>48.7 ± 11.3</td>
<td>19.5 ± 4.0</td>
</tr>
<tr>
<td>Type I Diabetics (36)</td>
<td>±</td>
<td>48.0 ± 11.2</td>
<td>20.6 ± 4.0</td>
</tr>
<tr>
<td>Type II Diabetics (44)</td>
<td>±</td>
<td>49.3 ± 11.6</td>
<td>18.8 ± 4.1</td>
</tr>
<tr>
<td>All Diabetics (45)</td>
<td>-</td>
<td>47.6 ± 9.3</td>
<td>20.2 ± 3.7</td>
</tr>
<tr>
<td>All Diabetics (40)</td>
<td>+</td>
<td>49.9 ± 13.4</td>
<td>18.7 ± 4.5</td>
</tr>
<tr>
<td>Type I Diabetics (19)</td>
<td>-</td>
<td>45.0 ± 10.8</td>
<td>21.9 ± 3.2</td>
</tr>
<tr>
<td>Type I Diabetics (17)</td>
<td>+</td>
<td>51.4 ± 11.0</td>
<td>19.2 ± 4.4</td>
</tr>
<tr>
<td>Type II Diabetics (21)</td>
<td>-</td>
<td>48.9 ± 7.3</td>
<td>19.2 ± 3.7</td>
</tr>
<tr>
<td>Type II Diabetics (23)</td>
<td>+</td>
<td>49.7 ± 14.7</td>
<td>18.5 ± 4.6</td>
</tr>
</tbody>
</table>

Glyoxalase I and Glyoxalase II activity was measured as described in the Materials and Methods section and expressed as units/ml packed red blood cells. Data is the mean ± standard deviation from n individuals.
Table 16. Statistical Analysis of the Data from the Diabetic Study

<table>
<thead>
<tr>
<th>Comparison Groups</th>
<th>Data</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls: All</td>
<td>Glyoxalase I Activity</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Glyoxalase II Activity</td>
<td>&gt;0.1</td>
</tr>
</tbody>
</table>

There is no significant difference in the red blood cell glyoxalase activities in control and diabetic subjects.

| All               | Glyoxalase II Activity   | <0.05   |
| Diabetics(+) :Diabetics(-) | Duration of Diabetes   | <0.001  |

Red blood cell glyoxalase II activity was significantly lower in diabetic patients with complications.

| Type I            | Type I                  | Glyoxalase I Activity | <0.05 |
| Diabetics(-):Diabetics(+) | Glyoxalase II Activity | <0.05 |
|                   | Duration of Diabetes    | <0.001              |

Red blood cell glyoxalase I activity was significantly higher and glyoxalase II activity lower in Type I diabetics with complications.

| Type II           | Type II                 | Glyoxalase I Activity | >0.1  |
| Diabetics(-):Diabetics(+) | Glyoxalase II Activity | >0.1  |
|                   | Duration of Diabetes    | <0.01               |

There was no significant difference in the red blood cell glyoxalase I or glyoxalase II activities in diabetics with or without complications.

Significance was assessed using the Student's one-tailed "t" test. Actual values for the different groups are given in Table 17 (age of subjects and duration of diabetes) and Table 15 (activity of glyoxalase I and glyoxalase II). The presence or absence of complications is indicated by + or -.
complications diverged at several points across the glyoxalase activity range, they converged and crossed at the next data point. This indicates that there was no consistent difference between the activity of glyoxalase I in red cells from diabetic patients with and without complications.

The statistical analysis of the glyoxalase I activity data (Table 16) confirms the observations from Figure 17. The activity of glyoxalase I in the red blood cells from diabetic patients was not significantly different from the glyoxalase I activity in the red cells from normal healthy controls. In addition, there was no significant difference between the glyoxalase I activity in the red blood cells of diabetic patients with complications, and the glyoxalase I activity in the red blood cells of diabetic patients without complications.

The frequency distributions for the glyoxalase II activities in red blood cells from diabetic patients and normal controls are similar (Figure 18). The curve for diabetic patients has a higher maximum frequency than the curve for the controls. There was a consistent difference in the frequency distribution curves of glyoxalase II activity in red blood cells from diabetics with and without complications. At relatively low glyoxalase II activities, the frequency distribution curve for patients without complications was below the curve for patients with complications. At relatively
high glyoxalase II activities, the reverse was true—the frequency distribution curve for patients without complications was higher than the curve for patients with complications. This data suggests that the frequency distribution curve for diabetic patients without complications is skewed to relatively high activities of glyoxalase II, and the frequency distribution curve for diabetic patients with complications is skewed to relatively low activities of glyoxalase II.

The statistical analysis of the glyoxalase II activity data (Tables 15 and 16) confirms: (i) that there was no significant difference in the activity of glyoxalase II in the red blood cells from diabetic patients and controls and (ii) that the activity of glyoxalase II in the red blood cells from diabetic patients with complications was significantly lower than the glyoxalase II activity in the red blood cells from patients without complications (P < 0.05).

Taking the non-insulin-dependent diabetic patients as a group, the statistical analysis revealed that there was no significant difference between the red blood cell glyoxalase activities in diabetic patients with and without complications (Tables 15 and 16). The significant difference that exists between the glyoxalase activities in the red blood cells from patients with and without complications was located in the insulin-dependent diabetic subgroup. If the
insulin-dependent diabetic patients are considered alone, the patients without complications had a significantly lower red blood cell glyoxalase I activity and a significantly higher red blood cell glyoxalase II activity than did the patients with complications (Tables 15 and 16).

The frequency distributions for the activities of glyoxalase I and glyoxalase II in the red blood cells from insulin-dependent diabetic patients are presented in Figures 19 and 20 respectively. In the patients with complications (closed circles), the frequency distributions for the red blood cell glyoxalase activities are skewed to relatively high activities of glyoxalase I and relatively low activities of glyoxalase II. In contrast, in patients without complications (open circles), the frequency curves for the red blood cell glyoxalase activities are skewed to relatively low activities of glyoxalase I and relatively high activities of glyoxalase II.

Examination of Table 17 shows that, with both insulin-dependent and non-insulin-dependent patients, there was a significant bias in the age and duration of diabetes between the subgroups of patients with and without complications. To remove this bias, 14 pairs of patients from the non-insulin-dependent diabetes subgroup, one of each pair with and one without complications, were matched for age (criterion: age difference less than 10 years) and duration of diabetes
Figure 19. Frequency Distribution Curves of Glyoxalase Activity in Red Blood Cells from Insulin-Derived Diabetic Patients with and without complications. The mean activity for diabetic patients with complications ($P < 0.05$)
Figure 20. Frequency Distribution Curves of Glyoxalase II Activity in Red Blood Cells from Insulin-Dependent Diabetic Patients. Key: (---) - diabetic patients without complications, (-----) - diabetic patients with complications. The mean activity for diabetic patients without complications > the mean activity for patients with complications (P < 0.05).
Table 17. The Age and Duration of Diabetes for Subjects in the Diabetes Study

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Complications (+ or -)</th>
<th>Age (yrs)</th>
<th>Duration (yrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Diabetics (85)</td>
<td>±</td>
<td>52.6 ± 17.5</td>
<td>10.8 ± 9.4</td>
</tr>
<tr>
<td>Type I Diabetics (36)</td>
<td>±</td>
<td>43.1 ± 17.4</td>
<td>15.2 ± 11.4</td>
</tr>
<tr>
<td>Type II Diabetics (44)</td>
<td>±</td>
<td>60.3 ± 13.7</td>
<td>7.3 ± 5.3</td>
</tr>
<tr>
<td>All Diabetics (45)</td>
<td>-</td>
<td>45.5 ± 19.4</td>
<td>6.9 ± 4.7</td>
</tr>
<tr>
<td>All Diabetics (40)</td>
<td>+</td>
<td>59.6 ± 12.2</td>
<td>14.8 ± 11.2</td>
</tr>
<tr>
<td>Type I Diabetics (19)</td>
<td>-</td>
<td>34.0 ± 16.9</td>
<td>8.8 ± 5.4</td>
</tr>
<tr>
<td>Type I Diabetics (17)</td>
<td>+</td>
<td>53.4 ± 11.6</td>
<td>22.4 ± 12.0</td>
</tr>
<tr>
<td>Type II Diabetics (21)</td>
<td>-</td>
<td>56.1 ± 15.1</td>
<td>5.2 ± 3.1</td>
</tr>
<tr>
<td>Type II Diabetics (23)</td>
<td>+</td>
<td>64.3 ± 10.6</td>
<td>9.2 ± 6.2</td>
</tr>
</tbody>
</table>
(criterion: duration difference less than 2 years). The results are presented in Table 18. Even after age matching, there was still no significant difference between the activities of glyoxalase I and glyoxalase II in the patients with or without complications. It was more difficult to match the insulin-dependent diabetic patients for age and duration of diabetes. Using the criteria of age difference less than 10 years (except for one pair with a difference of 25 years) and duration difference less than 3 years, there were only 7 suitable pairs of patients with and without complications (the duration of diabetes was considered to be the most important criterion, but large age differences over 60 years were omitted). The results are presented in Table 19. The statistical analysis showed that the patients without complications had a significantly higher glyoxalase II activity ($P < 0.01$) and a significantly lower glyoxalase I activity ($P < 0.05$) than the patients with complications. Matching the insulin-dependent diabetics for age and duration of diabetes maintained and improved the significance of the differences between the red blood cell glyoxalase activities in patients with and without complications.

4.4.2 The Concentration of Methylglyoxal in Whole Human Blood.

The concentration of methylglyoxal in whole blood was determined in 17 normal healthy control individuals and 32 patients with insulin-dependent and
Table 18. The Activity of the Glyoxalase Enzymes in Age-Matched Non-Insulin-Dependent Type II Diabetics With and Without Complications

<table>
<thead>
<tr>
<th>UNCOMPPLICATED</th>
<th>A(d)</th>
<th>Glyoxalase I</th>
<th>Glyoxalase II</th>
<th>COMPLICATED</th>
<th>A(d)</th>
<th>Glyoxalase I</th>
<th>Glyoxalase II</th>
</tr>
</thead>
<tbody>
<tr>
<td>(yrs)</td>
<td>(U/mlRBC)</td>
<td>(U/mlRBC)</td>
<td>(U/mlRBC)</td>
<td>(yrs)</td>
<td>(U/mlRBC)</td>
<td>(U/mlRBC)</td>
<td>(U/mlRBC)</td>
</tr>
<tr>
<td>59(4)</td>
<td>63.7</td>
<td>21.1</td>
<td></td>
<td>57(4)</td>
<td>60.6</td>
<td></td>
<td>9.4</td>
</tr>
<tr>
<td>78(5)</td>
<td>45.6</td>
<td>26.8</td>
<td></td>
<td>72(5)</td>
<td>40.2</td>
<td></td>
<td>18.1</td>
</tr>
<tr>
<td>42(6)</td>
<td>58.1</td>
<td>16.6</td>
<td></td>
<td>70(7)</td>
<td>43.0</td>
<td></td>
<td>14.7</td>
</tr>
<tr>
<td>52(10)</td>
<td>41.2</td>
<td>25.1</td>
<td></td>
<td>56(10)</td>
<td>46.9</td>
<td></td>
<td>17.5</td>
</tr>
<tr>
<td>72(2)</td>
<td>44.9</td>
<td>18.2</td>
<td></td>
<td>78(3)</td>
<td>28.4</td>
<td></td>
<td>15.7</td>
</tr>
<tr>
<td>61(7)</td>
<td>50.3</td>
<td>19.0</td>
<td></td>
<td>57(7)</td>
<td>73.6</td>
<td></td>
<td>15.4</td>
</tr>
<tr>
<td>61(6)</td>
<td>56.4</td>
<td>23.7</td>
<td></td>
<td>58(6)</td>
<td>55.7</td>
<td></td>
<td>16.2</td>
</tr>
<tr>
<td>60(2)</td>
<td>44.1</td>
<td>18.2</td>
<td></td>
<td>61(2)</td>
<td>34.8</td>
<td></td>
<td>24.6</td>
</tr>
<tr>
<td>38(10)</td>
<td>43.3</td>
<td>17.0</td>
<td></td>
<td>44(1)</td>
<td>65.9</td>
<td></td>
<td>25.7</td>
</tr>
<tr>
<td>74(10)</td>
<td>40.2</td>
<td>19.7</td>
<td></td>
<td>79(9)</td>
<td>54.5</td>
<td></td>
<td>17.1</td>
</tr>
<tr>
<td>65(1)</td>
<td>46.6</td>
<td>17.1</td>
<td></td>
<td>63(2)</td>
<td>68.5</td>
<td></td>
<td>16.3</td>
</tr>
<tr>
<td>74(10)</td>
<td>40.2</td>
<td>19.7</td>
<td></td>
<td>68(10)</td>
<td>53.6</td>
<td></td>
<td>19.1</td>
</tr>
<tr>
<td>59(3)</td>
<td>46.8</td>
<td>12.3</td>
<td></td>
<td>60(2)</td>
<td>47.8</td>
<td></td>
<td>21.2</td>
</tr>
<tr>
<td>59(8)</td>
<td>42.6</td>
<td>13.1</td>
<td></td>
<td>59(8)</td>
<td>33.2</td>
<td></td>
<td>18.9</td>
</tr>
</tbody>
</table>

Mean Activity ± S.D

Glyoxalase I: 47.40 ± 6.90
Glyoxalase II: 19.10 ± 4.00

Glyoxalase I: 50.40 ± 13.3
Glyoxalase II: 17.85 ± 3.90

Activity of glyoxalase I and glyoxalase II is expressed as units/ml packed red blood cells as described in the Materials and Methods section. A(d) - age of patient (duration of diabetes). Statistical analysis performed using a Students one-tailed "t" test: P > 0.1 for both enzymes.
Table 19. The Activity of the Glyoxalase Enzymes in Age-Matched Insulin-Dependent Type I Diabetes With and Without Complications

<table>
<thead>
<tr>
<th></th>
<th>UNCOMPLICATED</th>
<th></th>
<th>COMPLICATED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A(d)</td>
<td>Glyoxalase I</td>
<td>Glyoxalase II</td>
</tr>
<tr>
<td></td>
<td>(yrs) (U/mlRBC</td>
<td>(U/mlRBC</td>
<td>(U/mlRBC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65(12)</td>
<td>52.8</td>
<td>21.4</td>
<td></td>
</tr>
<tr>
<td>31(16)</td>
<td>50.7</td>
<td>23.4</td>
<td></td>
</tr>
<tr>
<td>69(14)</td>
<td>45.1</td>
<td>19.3</td>
<td></td>
</tr>
<tr>
<td>22(13)</td>
<td>40.1</td>
<td>18.1</td>
<td></td>
</tr>
<tr>
<td>21(13)</td>
<td>32.2</td>
<td>26.3</td>
<td></td>
</tr>
<tr>
<td>31(15)</td>
<td>37.1</td>
<td>21.4</td>
<td></td>
</tr>
<tr>
<td>34(19)</td>
<td>39.6</td>
<td>24.0</td>
<td></td>
</tr>
</tbody>
</table>

Mean Activity ± S.D

Glyoxalase I: 42.51 ± 6.86
Glyoxalase II: 21.99 ± 2.61

Glyoxalase I: 51.58 ± 9.17
Glyoxalase II: 17.14 ± 2.98

Activity of glyoxalase I and glyoxalase II is expressed as units/ml packed red blood cells as described in the Materials and Methods section. A(d) - age of patients (duration of diabetes). Statistical analysis performed using a Students one-tailed "t" test: Glyoxalase I - P < 0.05; Glyoxalase II - P < 0.01.
non-insulin-dependent diabetes, with and without complications. The data is presented as frequency distribution diagrams in Figure 21, with a statistical analysis in Table 20. In diabetic patients, the distribution of whole blood methylglyoxal concentrations was skewed to the high concentration range, when compared with the concentrations in controls. The increase in the concentration of methylglyoxal in the blood of diabetic patients was statistically significant (P < 0.001). The control subjects had a mean whole blood concentration of methylglyoxal of 1.9 μM, while the concentration approximately doubled in the diabetic patients to 3.5 μM. This indicates that the red blood cell glyoxalase system experienced a substantial elevation in the concentration of methylglyoxal during hyperglycaemia.

4.4.3 The Concentration of S-D-Lactoylglutathione in Whole Human Blood.

The whole blood concentration of S-D-lactoylglutathione was assayed in 24 normal healthy control individuals and in 28 diabetic patients with insulin-dependent and non-insulin-dependent diabetes, with and without complications. The frequency distribution curves of the data are presented in Figure 22, with a statistical analysis in Table 20. In diabetic patients, the frequency distribution was skewed over to the high concentration range of S-D-lactoylglutathione, compared to the frequency
Figure 21. Frequency Distribution Curves of the Concentration of Methylglyoxal in Whole Human Blood. Key: (-●●●-) - diabetic patients, (-O-O-) - normal healthy controls. The mean concentration in diabetic patients > the mean concentration in controls (P < 0.001).
Table 20. The Concentration of Glyoxalase Metabolites in Whole Venous Human Blood

<table>
<thead>
<tr>
<th></th>
<th>Concentration (μM) (n)</th>
<th>Blood Glucose (mM) (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>S-D-lactoylglutathione</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>$12.4 \pm 4.8(24)^a$</td>
<td>$---------$</td>
</tr>
<tr>
<td>Diabetics$^1$</td>
<td>$21.4 \pm 9.3(28)^a$</td>
<td>$9.9 \pm 4.0(27)$</td>
</tr>
<tr>
<td><strong>Methylglyoxal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controls</td>
<td>$1.44 \pm 0.51(17)^a$</td>
<td>$---------$</td>
</tr>
<tr>
<td>Diabetics$^2$</td>
<td>$3.59 \pm 2.33(32)^a$</td>
<td>$10.9 \pm 4.3(30)$</td>
</tr>
</tbody>
</table>

The concentration of S-D-lactoylglutathione and methylglyoxal was determined as described in the Materials and Methods section. Data is the mean ± standard deviation of determinations from n individuals. $^1$ - Diabetic group comprised 13 Type I and 15 Type II patients. $^2$ - Diabetic group comprised 16 Type I and 16 Type II patients. Significance was determined using the Student's two-tailed "t" test: $^a$ - P < 0.001
Figure 22. Frequency Distribution Curves of the Concentration of S-D-Lactoylglutathione in Whole Human Blood. Key: (-●-●-) - diabetic patients, (-O-O-) - normal healthy controls. The mean concentration in diabetic patients > the mean concentration in controls (P < 0.001).
distribution of S-D-lactoylglutathione concentrations in the controls. The statistical analysis shows that the concentration of S-D-lactoylglutathione in the blood of diabetic patients was significantly increased when compared to the controls (\( P < 0.001 \)). The mean whole blood concentration of S-D-lactoylglutathione approximately doubled from 12.4 \( \mu \text{M} \) in the controls to 21.4 \( \mu \text{M} \) in the diabetic patients. This indicates that the red blood cell glyoxalase system experienced a substantial elevation in the concentration of S-D-lactoylglutathione during diabetic hyperglycaemia.
5. DISCUSSION.

5.1 The Glyoxalase Enigma.

The glyoxalase system appears to be present in the cytosol of cells of all life forms. It metabolises the α-oxoaldehyde methylglyoxal to D-lactic acid, via the intermediate S-D-lactoylglutathione. The widespread distribution of the glyoxalase system may suggest a fundamental role in biological metabolism; yet, the major product of the glyoxalase system is D-lactic acid which, although it may be incorporated into the glycolytic metabolism of bacteria, finds very little metabolic use in animals and is largely excreted in the urine (133,134). The ubiquitous occurrence of the glyoxalase system catalysing the formation of a product of minor metabolic importance is the biochemical paradox confronting those who seek to functionally characterise the glyoxalase system. This is the enigma of the glyoxalase system.

The metabolic significance of the glyoxalase metabolic pathway may be assessed by studying tissues which are deficient in one or more components of the glyoxalase system. Rapidly proliferating tumours and immature tissues are characteristically deficient in glyoxalase II activity (3,150,210). Studies of the modification of the glyoxalase system during the differentiation and growth arrest of human tumour cells in culture were major objectives of this work.
The clinical significance of the glyoxalase pathway may be assessed where a disease process gives rise to a modification of the glyoxalase system. A study of the red blood cell glyoxalase system in Diabetes Mellitus was undertaken since it was suspected (114,180) that there is an increase in the metabolic flux through the glyoxalase system during the hyperglycaemia associated with the development of clinical complications.

The results presented here provide further evidence towards the characterisation of the functional role of the glyoxalase system in biological metabolism.

5.2 Modification of the Glyoxalase System During the Differentiation of Human Leukaemia Cells In Vitro.

The human promyelocytic leukaemia HL60 and the human erythroleukaemia K562 cell lines in culture are convenient models for studying in vitro differentiation. The differentiation of the HL60 cell line to neutrophil-like cells can be induced by treatment with several compounds, including NMF (159) and the tetrazinone CCRG 81045. The K562 cell line undergoes transformation to haemoglobin-producing cells after treatment with CCRG 81045 (204), but not with NMF (202). This combination of cell lines and drugs therefore provides a practical test to see if an increase in the activity of glyoxalase II occurs concomitantly with the chemically-induced differentiation process, as is observed during physiological differentiation in embryo
maturation (150).

Optimum differentiation of HL60 cells to neutrophil-like cells occurs after a 4 day incubation with 180 mM NMF. The degree of differentiation is reduced if the cells are treated with 130 mM and 150 mM NMF, or with 180 mM NMF for shorter incubation periods (159). The activity of glyoxalase II increased steadily during the 6 day incubations with 130, 150 and 185 mM NMF (Figure 6). This is consistent with the observed increase in glyoxalase II activity during physiological differentiation. Treatment with CCRG 81045 produced a significant increase in the number of differentiated cells, accompanied by a marked increase in the activity of glyoxalase II (Figure 8). In HL60 cells, the increase in glyoxalase II activity was directly proportional to the number of differentiated cells present (Figure 7). This suggests that there is a direct correlation between differentiation and the increase in glyoxalase II activity.

The differentiation of K562 cells to erythocyte-like cells, induced by CCRG 81045, is dose-dependent and does not occur until 3 days after drug administration (204). The activity of glyoxalase II in K562 cells treated with CCRG 81045 also increased after 3 days of incubation. Although NMF does not induce differentiation in K562 cells, there was an increase in the activity of glyoxalase II after the incubation of K562 cells with NMF (Figure 9).
Therefore, the glyoxalase II activity in K562 cells increased in both differentiation and during non-differentiation conditions.

The significance of the individual changes in the activity of glyoxalase I are more difficult to interpret. Since glyoxalase II is apparently the rate-determining enzyme in the glyoxalase system, changes in the activity of glyoxalase I may be of less metabolic significance than the changes in the activity of glyoxalase II. There is, however, one important feature of the activity changes of glyoxalase I. In HL60 cells, the activity of glyoxalase I decreased and the activity of glyoxalase II increased after treatment with both NMF and CCRG 81045 (Figures 6 and 8). In K562 cells, the activity of both glyoxalase enzymes increased following treatment with these drugs (Figures 9 and 10). This demonstrates that differentiation proceeded with an increase or decrease in the activity of glyoxalase I, and may indicate that changes in the activity of glyoxalase I are indeed of less functional significance than the changes in the activity of glyoxalase II.

The activity of glyoxalase II in K562 cells increased during both differentiating and non-differentiating conditions (Figures 9 and 10). However, the ratio of glyoxalase I to glyoxalase II activity decreased only during differentiation (Tables 11 and 12). The glyoxalase I/glyoxalase II activity ratio also decreased during the differentiation of HL60.
cells by NMF and CCRG 81045 (Figure 23). This ratio may be more important than the absolute changes in enzyme activity during differentiation, due to the expected effects of cell volume changes on the absolute glyoxalase activity per cell number. The relative increase in the activity of glyoxalase II during differentiation suggests that mature, differentiated cells have a greater capacity to metabolise S-D-lactoylglutathione via glyoxalase II than immature, non-differentiated cells.

The differentiation of HL60 cells by 130-185 mM NMF was accompanied by a decrease in the activity of glyoxalase I and an increase in the activity of glyoxalase II (Figure 6). During the differentiation process, the apparent Km of both the glyoxalase I- and glyoxalase II-catalysed reactions was unchanged. However, differentiation of the cells decreased the relative V_{max} for the glyoxalase I-catalysed reaction and increased the relative V_{max} for the glyoxalase II-catalysed reaction (Table 13). This indicates that during the differentiation of HL60 promyelocytes to neutrophils, there was a non-competitive inhibition and/or inactivation of glyoxalase I, and a non-competitive activation and/or de novo synthesis of glyoxalase II. The non-competitive modification of the glyoxalase enzymes has also been reported for the functional activation of neutrophils (211).

These results indicate that there is a major
Figure 23. The Relationship Between the Degree of Differentiation of HL60 Cells and the Decrease in the Glyoxalase I/Glyoxalase II Activity Ratio. Data is for day 4 of treatment with NMF (○) and CCRG 81045 (■).
modification of cellular glyoxalase activity during differentiation. If the flux of metabolites is unchanged, this would be expected to change the cellular concentrations of the glyoxalase metabolites, methylglyoxal and S-D-lactoylglutathione.

Inspection of the Michaelis-Menten kinetics of the glyoxalases in HL60 cell extracts (Figures 11 and 12) reveals that, at similar substrate concentrations, the activity of glyoxalase II is lower than the activity of glyoxalase I. Glyoxalase II is therefore expected to be the rate-determining enzyme of the glyoxalase pathway in HL60 promyelocytes.

Principato et al. have also investigated the changes in the glyoxalase system during differentiation, using chick embryo liver as a model (150). They reported that the glyoxalase I activity, which was initially high, paralleled the mitotic activity of the tissue and decreased as the liver differentiated. The glyoxalase II activity showed the reverse effect - it was initially low and increased as the liver differentiated. Given a constant supply of methylglyoxal, the overall effect of these changes in the activity of the glyoxalase enzymes may be the production of an initially high concentration of S-D-lactoylglutathione, which then decreases as the liver becomes differentiated. These results are very similar to those obtained with the chemically-induced differentiation model used in this study.
5.3 Modification of the Glyoxalase System During Changes in Cell Proliferation Status.

Raji and GM892 cells may be growth-arrested in culture by decreasing the concentration of foetal calf serum in the culture medium. This decreases the proliferation status of the cells without inducing differentiation. This provides a convenient model to study the effect of cell proliferation status on the glyoxalase system.

In GM892 cells, there was a decrease in glyoxalase I activity and an increase in the activity of glyoxalase II during growth arrest (Figure 13). This indicates that the activity of glyoxalase I increases and the activity of glyoxalase II decreases with increasing proliferation of GM892 cells. In Raji cells, there was an increase in the activity of both glyoxalase I and glyoxalase II during growth-arrest (Figure 14). This indicates that the activity of both glyoxalase I and glyoxalase II decrease with increasing proliferation of RAJII cells. Therefore, in both GM892 and Raji cells there was a decrease in the activity of glyoxalase II with increasing cell proliferation. This suggests a consistent inverse relationship between the activity of glyoxalase II and the rate of cell proliferation. However, there was no similar consistent relationship between the activity of glyoxalase I and cell proliferation: the activity of glyoxalase I increased or decreased with increasing cell proliferation. This
suggests that the changes in glyoxalase I activity during growth arrest may not be metabolically significant and the activity of glyoxalase I is not a critical factor in the control of cell proliferation (cf. the Szent-Györgyi hypothesis, Section 1.7).

Removal or depletion of an essential nutrient (e.g. foetal calf serum) from cell culture media is a method routinely employed for growth-arresting cells in culture. During growth arrest, the rate of cell proliferation decreases and the distribution of cells around the cell cycle changes with an accumulation of cells in the non-proliferating $G_0$ phase of the cycle. The observed changes in the activities of glyoxalase I and glyoxalase II in both GM892 and Raji cells suggest that the activities of glyoxalase I and glyoxalase II change round the cell cycle.

If the flux of methylglyoxal metabolised via the glyoxalase system is maintained during growth arrest and round the cell cycle, the observed changes in glyoxalase activities would be expected to produce an increase in the concentration of the glyoxalase intermediate S-D-lactoylglutathione with increasing rate of cell proliferation, although this was not determined. An increased cellular proliferation rate will be reflected by an increased proportion of cells undergoing mitosis. The putative increase in S-D-lactoylglutathione concentration with increased rate of cell proliferation would correlate well with the observed effect of
S-D-lactoylglutathione on microtubular assembly.

Several other studies have investigated the role of the glyoxalase system in cellular proliferation. Experiments with *Saccharomyces cerevisiae* (152,212) and *Datura callus* cells in culture (213) have shown that the activity of glyoxalase I increased with increasing rate of cell proliferation. This is consistent with the changes observed in the GM892 cell study described above. Using a *Datura callus* cell culture, Ramaswamy et al investigated the relationship between the activity of glyoxalase I and the cell proliferation rate (214). Incubation of the cells with a specific mitotic inhibitor (vinblastine) inhibited both cell number (a measure of the proliferation rate) and glyoxalase I activity. Vinblastine acts by binding to the growing end of the microtubule and preventing the formation of the mitotic spindle (215). When the cells were incubated with a specific glyoxalase I inhibitor (squaric acid), both the glyoxalase I activity and the cell number decreased. These results, therefore, indicate that glyoxalase I activity is related to cell proliferation rate, probably via a mechanism linked to the formation of the mitotic spindle.

In contrast, there was found to be no significant difference in the activities of glyoxalase I and glyoxalase II in growth-arrested and proliferating human fibroblasts (154). This conflicts with both the GM892 and Raji studies. Although the reason for this is not
understood, there are two possible explanations. It has been reported that the cell density at which fibroblasts are cultured affects the amount of polymerized tubulin (microtubules) in the cell (216). If the glyoxalase system is involved in the control of microtubule assembly, the activity of glyoxalase I may be dependent on the density at which the cells were cultured, as well as their actual proliferation rate. This may explain why there was no change in the activity of glyoxalase I, even though the proliferation rate of the cell was markedly increased. Alternatively, it is possible that glyoxalase activities in human fibroblasts may be different in individual phases of the cell cycle and yet the mean glyoxalase activities still be similar under proliferating and growth-arrested conditions. Further studies of the glyoxalase activities in cell cycle synchronised fibroblasts are required to resolve this problem.

5.4 The Effect of S-D-Lactoylglutathione on Cell-Free Assembly of Microtubules.

5.4.1 The Cell-Free Assembly of Microtubules.

Microtubules are hollow cylindrical structures, 24 nm in diameter, composed of longitudinally arranged tubulin protofilaments with small amounts of microtubular associated proteins (217). The cytosolic network of microtubules, the microtubular cytoskeleton, provides structural organisation for the cytosol and cell contents. It is particularly important where a
major re-organization of the cytosol occurs. For example, the microtubules form the structural basis for the mitotic spindle, and, as such, are essential for cell division. They also form a cytoplasmic network that may be involved in the control of cell shape, cell growth and intracellular transport.

The cell-free assembly of purified microtubular protein (tubulin + microtubular associated proteins) in this study was pioneered by Weisenberg (172) and further developed by Shelanski et al (218) and Borisy et al (219). The assembly of microtubules is a dynamic process. It can be split into several different phases:

(i) The Nucleation Phase - This is the initial series of reactions between tubulin dimers that lead to the formation of polymerization nuclei. In vivo, the centrosomes act as the nucleation sites for cytoplasmic microtubules, but the exact identity of the nucleation species in vitro is unknown (217).

(ii) The Microtubule Elongation Phase - The microtubule nuclei promote the further assembly of tubulin into microtubules. Elongation involves the sequential net addition of tubulin dimers onto the growing points at the ends of the microtubules. The presence of GTP or ATP is essential for this process. Tubulin and GTP form a complex which actually binds to the end of the microtubule, during which the GTP is hydrolysed to GDP.

As microtubular assembly is a dynamic process, there will be constant addition and loss of tubulin
dimers from the ends of the microtubules. If the concentration of tubulin is below a certain value, termed the "critical concentration", there will be no spontaneous net assembly of tubulin into microtubules (220).

In this study, the assembly of microtubular protein to microtubules was followed by measuring the increase in absorbance of the solution at 350 nm. The increase in absorbance reflects an increase in the turbidity of the solution, caused by the presence of long rods of microtubules (205). Under these conditions, the turbidity of the solution is primarily a measure of the weight of the assembled microtubules and is reasonably insensitive to their length. This method was, therefore, considered as being suitable for simple kinetic analysis of microtubule assembly.

5.4.2 The Effect of S-D-Lactoylglutathione on the Kinetics of Cell-Free Assembly of Microtubules.

The cell-free assembly of purified brain microtubular protein was promoted by GTP and was characterised by an initial 1 – 2 minute lag phase when no increase in absorbance at 350 nm occurred, a 10 minute period of rapid microtubular assembly when there was a rapid increase in absorbance at 350 nm, and followed finally by a slow disassembly when there was a slow decrease in absorbance at 350 nm over a period of several hours (Figure 15, curve d).

S-D-Lactoylglutathione decreased the nucleation lag-time.
(particularly at high concentration) and increased the extent of maximum microtubule assembly - as judged by the maximum absorbance at 350 nm. However, S-D-lactoylglutathione had no significant effect on the rate of microtubule assembly during the rapid assembly phase (Figure 15). The decrease in the nucleation lag-time suggests that S-D-lactoylglutathione either increased the rate of formation of nucleation sites or enhanced the addition of tubulin to the pre-existing nucleation sites. From this experiment, it is impossible to distinguish between these two possibilities. The increase in the maximum absorbance obtained suggests that S-D-lactoylglutathione increased the percentage of total microtubular protein assembled at the steady state where the rates of microtubule assembly and disassembly are equal. In terms of the Weisenberg microtubule assembly notation, the concentration of unassembled tubulin under these conditions is termed the critical subunit concentration. The potentiation of GTP-promoted cell-free assembly of microtubules by S-D-lactoylglutathione may reflect a decrease in the critical subunit concentration, or an increase in the concentration of microtubular protein competent to assemble in the sample. Further experimentation is required to discriminate between these two possibilities.

The slow disassembly of microtubules has been assigned to the phosphorylation of tubulin by an
ATP-dependent kinase which co-purifies with microtubular protein (221). S-D-Lactoylglutathione did not affect the rate of this slow disassembly. This shows that the effect of S-D-lactoylglutathione is independent of the effect of this ATP-dependent phosphorylation.

5.4.3 The Consumption of S-D-Lactoylglutathione During the Cell-Free Assembly of Microtubules.

The assembly of microtubular protein in the presence of S-D-lactoylglutathione lead to a loss of S-D-lactoylglutathione from the solution. This occurred only under conditions necessary for microtubule assembly. This suggests that the potentiation of microtubule assembly leads to a consumption of S-D-lactoylglutathione. The mechanism of this effect is not known. The microtubules produced in the absence and presence of S-D-lactoylglutathione were identical in their instability in the presence of calcium ions, nocodazole and cold - normal features of cell-free assembled microtubules (172,205,209).

Although pig brain microtubules were purified on several occasions, the effect of S-D-lactoylglutathione on the assembly of the microtubules was not consistent. This lack of a consistent effect of S-D-lactoylglutathione has been noted by other workers (129,222). The reason for this inconsistency is currently unknown. However, a recent report has stated that the concentration of magnesium ions in the assembly buffer has an effect on the morphology of the early
intermediates in the microtubular assembly process (206). At low Mg\(^{2+}\) ion concentrations, a large number of polymerisation nuclei are formed, assembly is rapid and the assembled microtubules are short. Conversely, at high magnesium ion concentrations (greater than 1 mM), a small number of polymerisation nuclei are formed and the assembled microtubules are long. Magnesium ions are chelated by GTP, so the concentration of GTP in the solution can affect the final length of the assembled microtubules, by its action on magnesium ion concentration.

The increase in the final absorbance of the assembly solution in the presence of S-D-lactoylglutathione indicates that S-D-lactoylglutathione increases the amount of tubulin assembled into microtubules. It probably exerts this effect by increasing the mean length of microtubules after assembly (217). This increase in mean length will occur to a greater extent if there are a large number of short microtubules in the solution, than if there are a small number of long microtubules (206). The effect of S-D-lactoylglutathione on microtubular assembly would, therefore, be expected to be enhanced when there are a large number of nucleation sites present in the solution. The observed lack of consistency of S-D-lactoylglutathione on microtubule assembly may reflect variations in the number of nucleation sites present in the solution.
5.5 The Red Blood Cell Glyoxalase System During Hyperglycaemia In Vitro

5.5.1 Diabetes Mellitus and Retinopathy

Diabetes Mellitus is a metabolic condition that arises from a deficiency in the action of insulin. The lack of insulin action results in a chronic periodic hyperglycaemia, particularly if the condition is being treated with supplementary insulin injections. Diabetic complications, such as cataract, neuropathy and nephropathy, occur as a direct result of this periodic hyperglycaemia. The development of diabetic complications is frequently correlated with metabolic indicators, such as the formation of glycosylated haemoglobin (185), that are measures of the cumulative exposure of the individual to periodic hyperglycaemia.

The diabetic patients in this study were examined for the presence or absence of retinopathy. Retinopathy is the most common complication of diabetes. Diabetic retinopathy is the major cause of blindness between the ages of 30 and 64 in England and Wales (223). The age of the patient and the duration of diabetes have a marked effect on its time of appearance (224, 225, 226). Few diabetics have detectable retinopathy at the time of diagnosis (224, 226), but most patients have some degree of retinopathy within 25 years. In young diabetics, the mean interval of appearance is approximately 13 years. If diabetes occurs after the age of 60, the mean interval of appearance drops to about 5 years.
5.5.2 Age and Duration of Diabetes

The mean age and duration of diabetes data (Table 17) for the patient groups used in this study shows several significant differences between the groups. In general, the patients with diabetic complications, irrespective of the type of diabetes from which they suffered, were older and had had diabetes for longer than those patients without complications. This is in agreement with other reports that the duration of diabetes is important in the development of diabetic retinopathy (224,226). The difference in the age of the patients with and without complications is important, as older people are prone to develop retinopathy due to old age and not simply due to the occurrence of diabetes.

5.5.3 Glyoxalase Activities

Glyoxalase activity has been detected in neutrophils (145,156) and platelets (227) as well as red blood cells, but the red blood cells are the major source of glyoxalase activity per ml of circulating human blood (Table 21). The results show that the glyoxalase activities in red blood cells from normal healthy control subjects were not significantly different from the glyoxalase activities in red blood cell from a mixed group of diabetic patients, which contained approximately equal numbers of insulin-dependent and non-insulin-dependent diabetics, with and without complications. However, if the diabetic subjects were split into those with
Table 21. The Distribution of Glyoxalase I and Glyoxalase II Activity in 1 ml of Whole Blood

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>Cells/ml Whole Blood</th>
<th>Glyoxalase I (units)</th>
<th>Glyoxalase II (units)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red cells</td>
<td>$4-6 \times 10^9$</td>
<td>23.9</td>
<td>9.55</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>$2.5-7.5 \times 10^6$</td>
<td>0.07</td>
<td>0.007</td>
</tr>
<tr>
<td>Platelets</td>
<td>$2-5 \times 10^8$</td>
<td>0.11</td>
<td>0.01</td>
</tr>
</tbody>
</table>

The activity of glyoxalase I and glyoxalase II is expressed as units as defined in the Materials and Methods section. The red cell glyoxalase activity was calculated using the control data from the diabetic study and adjusted for a 50% haematocrit. The glyoxalase activity for the neutrophils and platelets was calculated using the maximum value of the normal range for the number of cells per ml.
complications (irrespective of Type) and those without complications (irrespective of Type), it was found that the glyoxalase II activity in the red blood cells from those subjects with complications was significantly lower than the red blood cell glyoxalase II activity in diabetics without complications.

The most significant differences in glyoxalase activities in red blood cells occurred in patients with insulin-dependent diabetes. In these patients, the glyoxalase activities were correlated as follows:

Glyoxalase I: Non-complicated < Complicated (P < 0.05)
Glyoxalase II: Non-complicated > Complicated (P < 0.05)

Investigation of the glyoxalase activities in insulin-dependent diabetics matched for age and duration of diabetes improved the statistical significance of these results (Table 19).

The distribution of the red blood cell glyoxalase activities was not significantly affected by diabetes (Figures 17 and 18). The correlation of a high glyoxalase I and a low glyoxalase II activity in the red blood cells of insulin-dependent diabetics suggests that these patients may be genetically disposed to develop diabetic complications. Insulin-dependent diabetes has already been linked to the occurrence of certain alleles of the HLA system (228,229). The most significant
linkage is with alleles on the HLA-D and HLA-DR (D Related) loci. As described in Section 1.2.7, the glyoxalase I locus is located very close to the HLA-D locus on chromosome 6, and has been shown to be linked to the HLA complex as a whole (70). The mechanism by which a genetic disposition to diabetic complications could occur is easy to see for glyoxalase I. The corresponding mechanism for glyoxalase II is harder to envisage, as glyoxalase II does not occur in the form of isozymes, unlike glyoxalase I, and the gene locus is situated on a different chromosome.

If the correlation between glyoxalase activity and insulin-dependent diabetes is repeated in the other tissues where the clinically important complications occur (lens, retina, kidney glomeruli, peripheral neurones), it suggests that the glyoxalase system may be an important factor in the development of diabetic complications.

The non-insulin-dependent diabetic patients did not show any significant correlations between the occurrence of diabetic complications and the red blood cell glyoxalase activities. The reason for this may be two-fold: (a) non-insulin-dependent diabetics do not generally suffer severe hyperglycaemia, and (b) the duration of the disease may not be accurately known (the potentially mild symptoms may prevent immediate diagnosis). In the insulin-dependent diabetic patients, the age of the patient and the duration of diabetes were
important factors in the correlation of glyoxalase activities in the red blood cell with the occurrence of diabetic complications. This is in accord with the correlation of diabetic complications with chronic periodic hyperglycaemia (174,178) and with the view that diabetic complications are an acceleration of the diseases of old age (230).

5.5.4 The Concentration of Methylglyoxal and S-D-Lactoylglutathione in Whole Human Blood

The concentrations of methylglyoxal and S-D-lactoylglutathione in whole blood were significantly increased in diabetic patients, relative to the controls (Table 20). These metabolites are mainly found in the cellular fraction of blood - in plasma, the concentration of methylglyoxal is less than 50 nM and S-D-lactoylglutathione less than 1 μM. In terms of their concentration per ml of whole blood, most of the methylglyoxal and S-D-lactoylglutathione is present in the red cell; the neutrophils (156) and presumably the platelets contain only relatively small amounts.

As there was no significant difference between the red blood cell glyoxalase activities in the control and diabetic groups, the increase in the concentration of the glyoxalase substrates that was observed in the diabetic patients is probably due to an increased flux of intermediates metabolised by the glyoxalase system during hyperglycaemia. The correlation of high glyoxalase I activities and low glyoxalase II activities
with the occurrence of diabetic complications suggests that S-D-lactoylglutathione may play an important role in the development of these complications.

Methyglyoxal may also have a role in the development of diabetic complications. Cataract formation is associated with high molecular weight cross-linked proteins in the eye (231). \(\alpha\)-Oxoaldehydes are capable of cross-linking proteins (232). If the changes demonstrated in blood are replicated in other tissues, such as the eye, methyglyoxal may be envisaged as a factor in the formation of diabetic cataract.
6. CONCLUSION

The aims of this work were to investigate the metabolic functions of the glyoxalase system, and the glyoxalase metabolites methylglyoxal and S-D-lactoylglutathione, in normal and abnormal cellular metabolism. Three specific areas were investigated: (a) the differentiation and proliferation of human tumour cells in vitro; (b) the cell-free assembly of microtubules and (c) the effect of Diabetes Mellitus on the glyoxalase system in vivo.

During the chemically-induced differentiation of human leukaemia cells in vitro, there was a substantial increase in the activity of glyoxalase II, whereas differentiation proceeded with a decrease or an increase in the activity of glyoxalase I. A decrease in the proliferation rate of the GM892 and Raji cell lines, without differentiation, produced an increase in the activity of glyoxalase II, whereas a change in the proliferation status of the cells occurred with an increase or decrease in the activity of glyoxalase I. Therefore, during differentiation and changes in the proliferation status of the cell, there was no consistent change in the activity of glyoxalase I. This indicates that glyoxalase I was not a critical factor in the control of cell proliferation or differentiation. This is contrary to the Szent-Györgyi hypothesis (142,143). The activity of glyoxalase II changed
consistently with changes in cell differentiation and proliferation, and may have a critical role in some regulatory factor in cell differentiation and proliferation. The changes in the glyoxalase activities during differentiation may reflect the removal of cells from progress round the cell cycle.

The cell-free GTP-promoted assembly of microtubules in vitro was potentiated by S-D-lactoylglutathione. The potentiation of assembly was accompanied by the loss of S-D-lactoylglutathione from the solution, which indicates that it may be consumed during the assembly process. The glyoxalase system may have a physiological role in the regulation of microtubular assembly through its control of S-D-lactoylglutathione levels. This suggested role is consistent with the observed changes in the activity of the glyoxalase enzymes during maturation and differentiation. Immature tissues have a high mean microtubular flux for their increased mitotic spindle formation. They also have a decreased capacity to metabolise S-D-lactoylglutathione, via glyoxalase II, and hence may have an increased cellular concentration of S-D-lactoylglutathione.

In diabetes, there was an increase in the whole blood concentration of both S-D-lactoylglutathione and methylglyoxal, but there was no significant change in the activity of the red blood cell glyoxalase enzymes. This may reflect an increased flux of methylglyoxal metabolised via the glyoxalase system during
hyperglycaemia. The occurrence of complications in insulin-dependent Type I diabetics was correlated with a high glyoxalase I activity and a low glyoxalase II activity in the red blood cells. The glyoxalase system may be involved in the development of diabetic complications in red blood cells and possibly in other tissues.

The results presented in this thesis must now be considered in the light of the roles that have been suggested for the glyoxalase system (Section 1.7).

Cooper and Anderson have suggested that the glyoxalase mediated conversion of methylglyoxal to D-lactate may form a glycolytic by-pass route in micro-organisms (139). However, the changes that have been observed in the glyoxalase system during the differentiation and maturation of tissue (150), the functional activation of neutrophils (211) and during diabetes strongly suggest that the glyoxalase system has a different, and more complex role in the cell.

Aronsson and Mannervik proposed that the glyoxalase system was a mammalian detoxification route for methylglyoxal produced by enterobacteria (23). This putative role for the glyoxalase system was supported by the observed high glyoxalase activity in blood and liver. It did not, however, explain the fact that glyoxalase activity has also been detected in plants and in the bacteria themselves. As with the Cooper and
Anderson suggestion, it also fails to explain how tissues, such as immature embryo (150), tumours (3) and regenerating liver (151), can thrive and proliferate, with a deficiency in the activity of glyoxalase II - the pacemaking enzyme of the glyoxalase pathway.

Szent-Györgyi and his co-workers (142,143) suggested that cell growth was controlled by methylglyoxal (the growth inhibitor) and glyoxalase I (the growth promoter). The results presented here demonstrate that the activity of glyoxalase I increased or decreased during cell proliferation and differentiation. Glyoxalase I was not a critical marker or regulatory factor in either of these processes. This is inconsistent with the Szent-Györgyi hypothesis of a methylglyoxal/glyoxalase I growth controlling system.

Gillespie proposed that the glyoxalase system regulated microtubule assembly, by controlling the concentration of S-D-lactoylglutathione (129). This putative role for the glyoxalase system has received support, directly and indirectly, from a number of different investigations. Under conditions in which the assembly of microtubules is elevated, and given a constant supply of methylglyoxal, the activity of glyoxalase II is expected to be relatively low, thus producing a relatively high cellular concentration of S-D-lactoylglutathione. This has been demonstrated in such diverse tissues as differentiating chick liver (150), functionally activated human neutrophils (211),
and regenerating rat liver (151). The two studies on differentiating and proliferating human tumour cells presented in this thesis support this role for the glyoxalase enzymes, assuming that the glyoxalase system controls the microtubular assembly that is required for mitotic spindle formation.

The effect of hyperglycaemia on the glyoxalase system was first proposed by Thornalley (114,180). The results presented in this thesis may represent the first discovery of an involvement of the glyoxalase system with a recognised clinical condition. The modification of the glyoxalase system during diabetes may be an aetiological factor in the development of diabetic complications, and as such, offers a new insight into the prevention of complications.

In the light of the results presented here, it is apposite to reappraise the cellular sites for the metabolism of S-D-lactoylglutathione. From the modifications to the glyoxalase system during the differentiation and proliferation of human tumour cells, and during Diabetes Mellitus, it is possible that there are sites, other than the active site of glyoxalase II, where S-D-lactoylglutathione can be metabolised by the cell, as suggested in the cell-free microtubule assembly experiments. The reaction of S-D-lactoylglutathione at sites other than the active site of glyoxalase II may be a crucial factor in the functional characterisation of
the glyoxalase system.
7. REFERENCES

1. K. Lohmann
   A study of the enzymatic transformation of
   synthetic methylglyoxal to lactic acid
   Biochem. Z. 254 332-354 (1932)

2. E. Racker
   The mechanism of action of glyoxalase
   J. Biol. Chem. 190 685-696 (1951)

3. T. Jerzykowski, R. Winter, W. Matuszewski and
   D. Piskorska
   A re-evaluation of studies on the distribution of
   glyoxalases in animal and tumour tissues
   Int. J. Biochem. 9 853-860 (1978)

4. F.G. Hopkins and E.J. Morgan
   On the distribution of glyoxalase and glutathione
   Biochem. J. 39 320-324 (1945)

5. H.D. Dakin and H.W. Dudley
   An enzyme concerned with the formation of hydroxy
   acids from ketonic aldehydes
   J. Biol. Chem. 14 155-157 (1913)

6. C. Neuberg
   The destruction of lactic aldehyde and
   methylglyoxal by animal organs
   Biochem. Z. 49 502-506 (1913)

7. H.D. Dakin and H.W. Dudley
   On glyoxalase
   J. Biol. Chem. 14 423-431 (1913)

8. M. Jowett and J.H. Quastel
   LXX. The glyoxalase activity of the red blood cell.
   The function of glutathione
   Biochem. J. 27 486-498 (1933)

9. S. Yamazoye
   Glyoxalase and its co-enzyme. III. The mechanism of
   the action of glutathione as the co-enzyme of
   glyoxalase
   J. Biochem. (Tokyo) 23 319-334 (1936)

10. E. Racker
    Glutathione as a coenzyme in intermediary
    metabolism. In "Glutathione" (S. Colowick,
    A. Lazarow, D.R. Schwarz, E. Stadtman, E. Racker
    and H. Waelsch eds), p 165-183, Academic Press, New
    York (1954)

11. K.A. Davis and G.R. Williams
    Cation activation of glyoxalase I
    Biochim. Biophys. Acta 113 393-395 (1966)
12. A-C. Aronsson, E. Marmstål and B. Mannervik
Glyoxalase I, a zinc metalloenzyme of mammals and yeast

13. A-C. Aronsson, S. Sellin, G. Tibbelin and B. Mannervik
Probing the active site of glyoxalase I from human erythrocytes by use of the strong reversible inhibitor S-p-bromobenzylglutathione and metal subsitutions

14. F. Sakuma
Studies on glyoxalase
J. Biochem. (Tokyo) 12 247-249 (1930)

15. J.L. Still
Glyoxalase of Bacterium coli
Biochem. J. 35 390-391 (1941)

16. C. Neuberg and G. Gorr
Mechanism of lactic acid formation by bacteria
Biochem. Z. 162 490-495 (1925)

17. E. Marmstål, A-C. Aronsson and B. Mannervik
Comparison of glyoxalase I purified from yeast (Saccharomyces cerevisiae) with the enzyme from mammalian sources
Biochem. J. 183 23-30 (1979)

18. K. Larsen, A-C. Aronsson, E. Marmstål and B. Mannervik
Immunological comparison of glyoxalase I from yeast and mammals and quantitative determination of the enzyme in human tissues by radioimmunoassay
Comp. Biochem. Physiol. 82B 625-638 (1985)

19. A-C. Aronsson, G. Tibbelin and B. Mannervik
Purification of glyoxalase I from human erythrocytes by the use of affinity chromatography and seperation of the three isoenzymes
Anal. Biochem. 92 390-393 (1979)

20. B. Mannervik
Octahedral metal coordination in the active site of
glyoxalase I as evidenced by the properties of
Co(II)-glyoxalase I
J. Biol. Chem. 258 2091-2093 (1983)

22. L-P.B. Han, C.M. Schimandle, L.M. Davison and
D.L. Vander Jagt
Comparative kinetics of Mg\(^{2+}\), Mn\(^{2+}\),
Co\(^{2+}\), and Ni\(^{2+}\)-activated glyoxalase I.
Evaluation of the role of the metal ion
Biochem. 16 5478-5484 (1977)

23. A-C. Aronsson and B. Mannervik
Characterization of glyoxalase I purified from pig
erythrocytes by affinity chromatography
Biochem. J. 165 503-509 (1977)

24. W.E. Knox
Glutathione. In "The Enzymes. Vol II, 2nd Ed"
(P.D. Poyer, P.D. Lardy and K. Myerback eds),

25. P.R. Carnegie
Structure and properties of a homologue of
 glutathione
Biochem. J. 89 471-478 (1963)

Glyoxalases
Biochem. Z. 327 393-406 (1956)

27. O.K. Behrens
Coenzymes for glyoxalase
J. Biol. Chem. 141 503-508 (1941)

28. H.C. Reeves and S.J. Ajl
Enzymatic synthesis and metabolism of
hydroxypyruvic aldehyde
J. Biol. Chem. 240 569-573 (1965)

29. R.H. Weaver and H.A. Lardy
Synthesis and some biochemical properties of
phosphohydroxypyruvic aldehyde and of
3-phosphoglyceryl glutathione thiol ester
J. Biol. Chem. 236 313-317 (1961)

30. D.L. Vander Jagt, E. Daub, J.A. Krohn and
L-P.B. Han
Effects of pH and thiols on the kinetics of yeast
glyoxalase I. An evaluation of the random pathway
mechanism
Biochem. 14 3669-3675 (1975)
31. L-P.B. Han, L.M. Davison and D.L. Vander Jagt
Purification and kinetic study of glyoxalase-I
from rat liver, erythrocytes, brain and kidney

32. E.E. Cliffe and S.G. Waley
The mechanism of the glyoxalase I reaction, and the
effect of ophthalmic acid as an inhibitor
Biochem. J. 79 475-482 (1961)

33. K.A. Davis and G.R. Williams
Glyoxalase I, a lyase or an oxidoreductive
isomerase?

34. D.L. Vander Jagt, L-P.B. Han and C.H. Lehman
Kinetic evaluation of substrate specificity in the
glyoxalase-I-catalysed disproportionation of
α-ketoaldehydes
Biochem. 11 3735-3740 (1972)

35. E. Marmstål and B. Mannervik
Evaluation of the two-substrate pathway of
glyoxalase I from yeast by use of carbonic
anhydrase and rapid-kinetic studies

36. E. Marmstål and B. Mannervik
Purification, characterization and kinetic studies
of glyoxalase I from rat liver

37. S. Sellin and B. Mannervik
Reversal of the reaction catalysed by glyoxalase I.
Calculation of the equilibrium constant for the
enzymatic reaction
J. Biol. Chem. 258 8872-8875 (1983)

38. K. Ekwall and B. Mannervik
Inhibition of yeast S-lactylglutathione lyase
(glyoxalase I) by sulphydryl reagents

39. B. Mannervik, E. Marmstål, K. Ekwall and
B. Görna-Hall
Inactivation of glyoxalase I from porcine
erthrocytes and yeast by amino-group reagents

40. C.S. Schasteen and D.J. Reed
Involvement of arginine residues in glutathione
binding to yeast glyoxalase I
41. S.J. Carrington and K.T. Douglas  
Glyoxalase I is inactivated by nitration of its tyrosine residues  

42. K.T. Douglas, A.P. Seddon and Y. Nakagawa  
Yeast glyoxalase I. Circular dichroic spectra and pH effects  
Int. J. Biochem. 18 549-555 (1986)

43. S. Sellin and B. Mannervik  
Metal dissociation constants for glyoxalase  
reconstituted with Zn$^{2+}$, Co$^{2+}$, Mn$^{2+}$, and Mg$^{2+}$  

Glyoxalase I : Mechanism-based inhibitors  

45. L. Garcia-Iniguez, L. Powers, B. Chance, S. Sellin, B. Mannervik and A.S. Mildvan  
X-Ray absorption studies of the Zn$^{2+}$ site of glyoxalase I  

46. S. Sellin, P.R. Rosevear, B. Mannervik and A.S. Mildvan  
Nuclear relaxation studies of the role of the essential metal in glyoxalase I  
J. Biol. Chem. 257 10023-10029 (1982)

47. P.R. Rosevear, R.V.J. Chari, J.W. Kozarich, S. Sellin, B. Mannervik and A.S. Mildvan  
C NMR studies of the product complex of glyoxalase I  
J. Biol. Chem. 258 6823-6826 (1983)

48. K. Ueda, S. Shinkai and K.T. Douglas  
Flavin-trapping of the transient enediolate species formed during glyoxalase I catalysis  

49. K.T. Douglas, A.J. Quilter, S. Shinkai and K. Ueda  
Trapping of reactive intermediates in enzymology. Exogenous flavin reduction during catalytic turnover of substrate by glyoxalase I  

50. S.S. Hall, A.M. Doweyko and F. Jordan  
Glyoxalase I enzyme studies. 2. Nuclear magnetic resonance evidence for an enediol-proton transfer mechanism  
J. Amer. Chem. Soc. 98 7460-7461 (1976)
51. R.V.J. Chari and J.W. Kozarich
Glutathiohydroxyacetone $^1$H NMR determination of
the stereochemistry of proton exchange by
glyoxalase I. Evidence for a cis-enediol
intermediate based on mirror-image catalysis

52. R. Vince and W.B. Wadd
Glyoxalase inhibitors as potential anticancer
agents
Biochem. Biophys. Res. Comm. 35 593-598
(1969)

53. R. Vince, S. Daluge and W.B. Wadd
Studies on the inhibition of glyoxalase I by
S-substituted glutathiones

54. A. Al-Timari and K.T. Douglas
Inhibition of mammalian glyoxalase I
(lactoylglutathione lyase) by N-acylated
S-blocked glutathione derivatives as a probe for
the role of the N-site of glutathione in glyoxalase
I mechanism

55. K.T. Douglas, A. Al-Timari, C. D'Silva and
D.I. Gohel
Role of the N-terminus of glutathione in the action
of yeast glyoxalase I

56. K.T. Douglas and J.G. Sharif
pH Dependence of the inhibition of yeast glyoxalase
I by porphyrins

57. K.T. Douglas, I.N. Nadvi and J. Ghotb-Sharif
Porphyrin inhibition of glyoxalase I

58. K.T. Douglas, I.N. Nadvi and N. Thakrar
Lapachol inhibition of alpha-ketoaldehyde
metabolism

59. R.B. Brandt, J. Laux, C. Thomson, M.A. Johnson
and M. Gross
Inhibition of glyoxalase I in vitro by flavones
Int. J. Quantum Chem : Quantum Biol. Symp. 11
195-200 (1984)
60. R.B. Brandt, J.E. Laux, S.W. Yates, M.R. Boots and C. Thomson
Inhibition of glyoxalase I in vitro by coumarin and
coumarin derivatives
155-165 (1986)

Partial transition-state inhibitors of glyoxalase I from human erythrocytes, yeast and rat liver

A glyoxalase I inhibitor of a new structural type produced by Streptomyces
J. Antibiotics 28 737-742 (1975)

63. B. Oray and S.J. Norton
Inhibitors of glyoxalase enzymes

64. R.B. Brandt, M.E. Brandt, M.E. April and C. Thomson
Inhibitors of glyoxalase I in vitro

65. P. Kavathas and R. DeMars
A new variant glyoxalase I allele that is readily
detectable in stimulated lymphocytes and
lymphoblastoid cell lines but not in circulating
lymphocytes or erythrocytes

66. P. Rubinstein, L. de Haas, I.Y. Pevzner and A.W. Nordskog
Glyoxalase I (GLO) in the chicken : Genetic
variation and lack of linkage to the MHC
Immunogen. 13 493-497 (1981)

67. J. Kömpf, S. Bissbort and H. Ritter
Red cell glyoxalase I (E.C. : 4.4.1.5) : Formal
genetics and linkage relations
Humangenet. 28 249-251 (1975)

68. V. Stolc, H.W. Kunz and T.J. Gill III
The linkage of glyoxalase-I to the Major
Histocompatibility Complex in the rat

69. T. Meo, T. Douglas and A-M. Runbeek
Glyoxalase I polymorphism in the mouse : A new
genetic marker linked to H-2
Science 198 311-313 (1977)
70. J. Kömpf and S. Bissbort
Confirmation of linkage between the loci for HL-A and glyoxalase I
Hum. Genet. 32 197-198 (1976)

71. R.L. Stallings and M.J. Siciliano
Confirmational, provisional and/or regional
assignment of 15 enzyme loci onto Chinese hamster
autosomes 1, 2, and 7

72. J. Daussset, L. Legrand, V. Lepage, L. Contu,
A. Marcelli-Barge, I. Wildloecher, A. Benajam,
T. Meo and L. Degos
A haplotype study of HLA complex with special
reference to the HLA-DR series and to Bf. C2 and
glyoxalase I polymorphisms
Tissue Antigens 12 297-307 (1978)

73. C. Lopez-Larrea, A. Bootello and
A. Arnaiz-Villena
Linkage of GLO with HLA in a sample of the Spanish
population

74. P. Rubinstein and N. Suciu-Foca
Glyoxalase I: A possible "null" allele
Hum. Hered. 29 217-220 (1979)

75. Ch. Rittner and W. Weber
Evidence for a "silent allele" GLOO at the
glyoxalase I locus

76. K. Virtaranta-Knowles and H.R. Nevanlinna
Red cell glyoxalase I polymorphism in the Finnish
population

77. K. Bender, R. Frank and H.W. Hitzeroth
Glyoxalase I polymorphism in South African
Bantu-speaking negroids
Hum. Genet. 38 223-226 (1977)

78. M. Hashimoto, S. Harada and K. Omoto
Red cell glyoxalase I polymorphism in Japanese:
Confirmation of a low GLO1 frequency

79. A.K. Ghosh
Polymorphism of red cell glyoxalase I
Hum. Genet. 32 91-95 (1977)
80. E.G. Emes and B.H. Parkin
The determination of glyoxalase I phenotypes in human bloodstains

81. P. Stohlmacher and W. Haferland
Glyoxalase I (GLO) in human tissues
Z. Rechtsmed. 85 165-168 (1980)

82. B. Eriksen
Human red cell glyoxalase I polymorphism in Denmark and its application to paternity cases
Hum. Hered. 29 265-271 (1979)

A comparative study on glyoxalase II from vertebrata
Enzyme 37 164-168 (1987)

84. Y.R. Hsu and S.J. Norton
Multimeric forms of rat liver glyoxalase II
Enzyme 30 259-264 (1983)

85. L. Uotila
Purification and characterization of S-2-hydroxyacylglutathione hydrolase (glyoxalase II) from human liver
Biochem. 12 3944-3950 (1973)

86. G.B. Principato, G. Rosi, V. Talesa and E. Giovannini
Purification and characterization of S-2-hydroxyacylglutathione hydrolase (glyoxalase II) from human brain

87. G.B. Principato, G. Rosi, V. Talesa, E. Giovannini and L. Uotila
Purification and characterization of two forms of glyoxalase II from the liver and brain of Wistar rats

88. J.C. Ball and D.L. Vander Jagt
S-2-Hydroxyacylglutathione hydrolase (glyoxalase II) : Active site mapping of a nonserine thiolesterase
Biochem. 20 899-905 (1981)

89. B. Oray and S.J. Norton
Purification and characterization of mouse liver glyoxalase II
90. P.E. Bush and S.J. Norton
S-(Nitrocarbobenzoxy)glutathiones : Potent competitive inhibitors of mammalian glyoxalase II

91. N.K. Honey and T.B. Shows
Assignment of the glyoxalase II gene (HAGH) to human chromosome 16

92. P.G. Board
Genetic polymorphism of human erythrocyte glyoxalase II

93. L. Uotila
Glutathione thiol esterases of human red blood cells. Fractionation by gel electrophoresis and isoelectric focusing

94. P.G. Board, C.J. Gibbs Jr and D.C. Gajdusek
Polymorphism of erythrocyte glyoxalase II in anthropoid primates
Folia Primatol. 36 138-143 (1981)

95. W.N. Valentine, D.E. Paglia, R.C. Neerhout and P.N. Konrad
Erythrocyte glyoxalase II deficiency with coincidental hereditary elliptocytosis
Blood 36 797-808 (1970)

96. S. Ray and M. Ray
Isolation of methylglyoxal synthase from goat liver
J. Biol. Chem. 256 6230-6233 (1981)

97. R.A. Cooper
Metabolism of methylglyoxal in microorganisms

98. P-K. Tsai and R.W. Gracy
Isolation and characterization of crystalline methylglyoxal synthetase from Proteus vulgaris
J. Biol. Chem. 251 364-367 (1976)

The microbiol metabolism of acetone

100. S. Ray and M. Ray
Formation of methylglyoxal from aminoacetone by amine oxidase from goat plasma
J. Biol. Chem. 258 3461-3462 (1983)
101. M. Ray and S. Ray
L-Threonine dehydrogenase from goat liver.
Feedback inhibition by methyglyoxal
J. Biol. Chem. 260 5913-5918 (1985)

102. C. Monder
α-Keto aldehyde dehydrogenase, an enzyme that
catalyses the enzymic oxidation of methyglyoxal
to pyruvate
J. Biol. Chem. 242 4603-4609 (1967)

103. D.L. Vander Jagt and L.M. Davison
Purification and characterization of 2-oxoaldehyde
dehydrogenase from rat liver

104. I.J. Higgins and J.M. Turner
Enzymes of methyglyoxal metabolism in a
Pseudomonad which rapidly metabolises aminocetone

105. H. Schütte, J. Flossdorf, H. Sahm and M.R. Kula
Purification and properties of formaldehyde
dehydrogenase and formate dehydrogenase from
Candida boidinii

106. L. Uotila and M. Koivusalo
Formaldehyde dehydrogenase from human liver.
Purification, properties and evidence for the
formation of glutathione thiol esters by the enzyme
J. Biol. Chem. 249 7653-7663 (1974)

107. Z.B. Rose and E. Racker
Formaldehyde dehydrogenase from bakers' yeast
J. Biol. Chem. 237 3279-3281 (1962)

108. I. Neben, H. Sahm and M.R. Kula
Studies on an enzyme, S-formylglutathione
hydrolyase, of the dissimilatory pathway of methanol
in Candida boidinii

Formaldehyde dehydrogenase from Candida boidinii
Meth. Enzymol. 89 527-531 (1982)

110. L. Uotila and M. Koivusalo
Purification and properties of S-formylglutathione
hydrolyase from human liver
J. Biol. Chem. 249 7664-7672 (1974)

111. M. Ray and S. Ray
Purification and partial characterization of a
methyglyoxal reductase from goat liver
112. K. Fung and D. Grosjean
Determination of nanogram amounts of carboxyls as 2,4-dinitrophenylhydrazone by high-performance liquid chromatography

113. R.E.J. Mitchel and H.C. Birnboim
The use of Girard-T reagent in a rapid and sensitive method for measuring glyoxal and certain other α-dicarbonyl compounds
Anal. Biochem. 81 47-56 (1977)

114. P.J. Thornalley
Monosaccharide autoxidation in health and disease
Environ. Health Perspect. 64 297-307 (1985)

115. S. Ohmori, M. Mori, M. Kawase and S. Tsuboi
Determination of methylglyoxal as 2-methylquinonioxaline by high performance liquid chromatography and its application to biological samples

Studies on methylglyoxal 1. Fluorometric determination of methylglyoxal using high-performance liquid chromatography

117. N. Krymkiewicz
Reactions of methylglyoxal with nucleic acids
FEBS Lett. 29 51-54 (1973)

118. M. Litt
Structural studies on transfer ribonucleic acid. I. Labelling of exposed guanine sites in yeast phenylalanine transfer ribonucleic acid with ketohexal
Biochem. 8 3249-3253 (1969)

119. C. Furihata, Y. Sato, T. Matsushima and M. Tatematsu
Induction of ornithine decarboxylase and DNA synthesis in rat stomach mucosa by methylglyoxal
Carcinogenesis 6 91-94 (1985)

120. P. Faggin, A.M. Bassi, R. Finollo and G. Brambilla
Induction of sister-chromatid exchanges in Chinese hamster ovary cells by the biotic ketoaldehyde methylglyoxal
Mutation Res. 144 189-191 (1985)
Methylglyoxal-induced DNA-protein cross-links and cytotoxicity in Chinese hamster ovary cells
Carcinogenesis 6 683-686 (1985)

122. G. Leoncini, M. Maresca and A. Bonsignore
The effect of methylglyoxal on the glycolytic enzymes

123. A. Miglietta and L. Gabriel
Methylglyoxal-tubulin interaction: Studies on the aldehyde effects on hepatoma, liver, and purified microtubular protein

124. L.G. Együd and A. Szent-Györgyi
Cell division, SH, ketoaldehydes and cancer

125. H.N.A. Fraval and D.C. McBrien
The effect of methyl glyoxal on cell division and the synthesis of protein and DNA in synchronous and asynchronous cultures of Escherichia coli B/r

126. J.F. Scaife
Mitotic inhibition induced in human kidney cells by methylglyoxal and kethoxal

127. A.M. Lozano and V.A. Mezl
Methylglyoxal inhibits the translation of natural and chemically decapped mRNA

128. F. Hernández, A. López-Rivas, J.A. Pintor-Toro, D. Vázquez and E. Palacian
Implication of arginyl residues in mRNA binding to ribosomes

129. E. Gillespie
Cell-free microtubule assembly: Evidence for control by glyoxalase
Fed. Proc. 4 541 (1975)

130. E. Gillespie
Effects of S-lactoylglutathione and inhibitors of glyoxalase I on histamine release from human leukocytes
Nature 277 135-137 (1979)
131. M.J. Tisdale
Personnal Communication

132. C.F. Cori and G.T. Cori
Glycogen formation in the liver from d- and
l-lactic acid
J. Biol. Chem. 81 389-403 (1929)

133. M. Duran, J.P. van Biervliet, J.P. Kamerling and
S.K. Wadman
D-Lactic aciduria, an inborn error of metabolism?

134. M.A. Judge and J. van Eys
Excretion of D-lactic acid by humans
J. Nutrit. 76 310-313 (1962)

135. E.M. Barnes Jr and H.K. Kaback
β -Galactoside transport in bacterial membrane
preparations: Energy coupling via membrane-bound
D-lactic dehydrogenase
Proc. Natl. Acad. Sci. USA 66 1190-1198
(1970)

136. H.K. Kaback and L.S. Milner
Relationship of a membrane-bound D-(−)-lactic
dehydrogenase to amino acid transport in isolated
bacterial membrane preparations
Proc. Natl. Acad. Sci. USA 66 1008-1015
(1970)

137. R.B. Brandt, S.A. Siegel, M.G. Waters and
M.H. Bloch
Spectrophotometric assay for D-(−)-lactate in
plasma

138. R.B. Brandt and S.A. Siegel
Methylglyoxal production in human blood. In
"Submolecular Biology and Cancer"
(G. Wolstenholme, D.W. Fitzsimmons and J. Whelan
eds.), p 211-223, Ciba Foundation Symposium 67,
Excerpta Medica, Amsterdam (1979)

139. R.A. Cooper and A. Anderson
The formation and catabolism of methylglyoxal
during glycolysis in Escherichia coli

140. A. Böck and F.C. Neidhardt
Properties of a mutant of Escherichia coli with
a temperature-sensitive fructose-1,6-diphosphate
aldolase
141. D. Mazia

142. A. Szent-Györgyi
Cell division and cancer
Science 149 34-37 (1965)

143. A. Szent-Györgyi
On retine

144. M.P. Schubert
Combination of thiol acids with methylglyoxal
J. Biol. Chem. 111 671-678 (1935)

145. E. Gillespie
The tumour promoting phorbol diester, 12-0-tetradecanoylphorbol-13-acetate (TPA) increases glyoxalase I and decreases glyoxalase II activity in human polymorphonuclear leukocytes

146. L.G. Együd and A. Szent-Györgyi
Cancerostatic action of methylglyoxal
Science 160 1140 (1968)

147. R.A. Reiffen and F. Schneider
A comparative study on proliferation, macromolecular synthesis and energy metabolism of in vitro-grown Ehrlich ascites tumour cells in the presence of glucosone, galactosone and methylglyoxal

148. T. Jerzykowski, W. Matuszewski, N. Otrzonsek and R. Winter
Antineoplastic action of methylglyoxal
Neoplasma 17 25-35 (1970)

149. P.J. Conroy
150. G.B. Principato, M. Bodo, M.G. Biagioni, G. Rosi and F.S. Liotti
Glyoxalases and glutathione reductase activity changes in chicken liver during embryo development and after hatching

151. G.B. Principato, P. Locci, G. Rosi, V. Talesa and E. Giovannini
Activity changes of glyoxalases I-II and glutathione reductase in regenerating rat liver
Biochem. Int. 6 249-255 (1983)

152. A.K. Dudani, L.K. Srivastava and R. Prasad
Glyoxalase-I activity and cell cycle regulation in yeast

153. P. Sutrave and A.R. Rao
Studies on glyoxalase I in regenerating mammalian spleen

Glyoxalase activity in quiescent and proliferating human fibroblasts

155. E. Wieczorek and T. Dobosz
The blood group enzymes systems' phenotypes (AK, ADA, 6PGD, PGM, EsD and GLO) in the fetal life in man
Ginekol. Pol. 50 23-29 (1979)

156. P.J. Thornalley, V. Della Bianca, P. Bellavite and F. Rossi
S-D-Lactoylglutathione in resting and activated human neutrophils

157. S.J. Collins, R.C. Gallo and R.E. Gallagher
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture
Nature 270 347-349 (1977)

158. S.J. Collins, F.W. Ruscetti, R.E. Gallagher and R.C. Gallo
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds
159. S.P. Langon and J.A. Hickman  
Correlation between the molecular weight and  
potency of polar compounds which induce the  
differentiation of HL-60 human promyelocytic  
leukemia cells  
Cancer Res. 47 140-144 (1987)

160. G.R. Pullen and C.S. Hosking  
Differentiated HL60 promyelocytic leukaemia cells  
have a deficient myeloperoxidase/halide killing  
system  

161. P.E. Newburger, C. Speier, N. Borregaard,  
C.E. Walsh, J.C. Whitin and E.R. Simons  
Development of the superoxide-generating system  
during differentiation of the HL-60 human  
 promyelocytic leukemia cell line  

162. G. Rovera, D. Santoli and C. Damsky  
Human promyelocytic leukemia cells in culture  
differentiate into macrophage-like cells when  
treated with a phorbol diester  
Proc. Natl. Acad. Sci. USA 76 2777-2784  
(1979)

163. A.S. Tsiftsoglou, W. Wong, R. Hyman, M. Minden  
and S.H. Robinson  
Analysis of commitment of human leukemia HL-60  
cells to terminal granulocytic maturation  
Cancer Res. 45 2334-2339 (1985)

164. G. Rovera, N. Olashaw and P. Meo  
Terminal differentiation in human promyelocytic  
leukaemic cells in the absence of DNA synthesis  

165. C.B. Lozzio and B.B. Lozzio  
Human chronic myelogenous leukemia cell-line with  
positive Philadelphia chromosome  
Blood 45 321-334 (1975)

166. E. Klein, H. Ben-Bassat, H. Neumann, P. Ralph,  
J. Zeuthen, A. Polliack and F. Vánky  
Properties of the K562 cell line, derived from a  
patient with chronic myeloid leukemia  
Int. J. Cancer 18 421-431 (1976)

167. L.C. Andersson, K. Nilsson and C.G. Gahmberg  
K562 - a human erythroleukemic cell line  
Int. J. Cancer 23 143-147 (1979)
168. T.R. Rutherford, J.B. Clegg and D.J. Weatherall
K562 human leukaemic cells synthesise embryonic
haemoglobin in response to haemin
Nature 280 164-165 (1979)

169. R.J.V. Pulvertaft
Cytology of Burkitt's tumour (African lymphoma)
Lancet 1 238-240 (1964)

170. "Burkitt's Lymphoma : A human cancer model"
(G.M. Lenoir, G.T. O'Conor and C.L.M. Olweny
eds), International Agency for Research on Cancer
(IARC) Scientific Publication 60, Lyon (1985)

171. R.B. Mann and C.W. Berad
Burkitt's tumour : Lessons from mice, monkeys and man
Lancet 2 84 (1977)

172. R.C. Weisenberg
Microtubule formation in vitro in solutions
containing low calcium concentrations
Science 177 1104-1105 (1972)

173. M.B. Davidson
"Diabetes Mellitus : Diagnosis and Treatment.

174. K.M. West
Hyperglycaemia as a cause of long-term
complications. In "Complications of Diabetes,
2nd Ed" (H. Keen and J. Jarrett eds), p 13-18,

175. J.H. Karam, G.M. Grodsky and P.H. Forsham
Excessive insulin response to glucose in obese subjects as measured by immunochemical assay
Diabetes 12 197-204 (1963)

176. J. Bornstein and R.D. Lawrence
Two types of diabetes mellitus with and without available plasma insulin
Brit. Med. J. 1 732 (1951)

177. P.F. Kador and J.H. Kinoshita
Diabetic and galactosaemic cataracts. In "Human Cataract Formation" (J. Nugent and J. Whelan eds), p 110-131, Ciba Foundation Symposium 106,

178. K.H. Gabbay
Hyperglycaemia, polyol metabolism and complications of diabetes mellitus
179. L. Kennedy and J.W. Baynes
Non-enzymatic glycosylation and the chronic complications of diabetes: An overview
Diabetologia 26 93-98 (1984)

180. P.J. Thornalley

181. E. Beutler

182. B. Das and S.K. Srivastava
Activation of aldose reductase from human tissues
Diabetes 34 1145-1151 (1985)

183. M. Brownlee, H. Vlassara and A. Cerami
Nonenzymatic glycosylation products on collagen covalently trap low-density lipoproteins
Diabetes 34 938-941 (1985)

184. J.I. Malone, G. Knox, S. Benford and T.A. Tedesco
Red cell sorbitol: An indicator of diabetic control
Diabetes 29 861-864 (1980)

Haemoglobin A1: An indicator of the metabolic control of diabetic patients
Lancet 2 734-737 (1977)

186. A. Cerami
Aging of proteins and nucleic acids: What is the role of glucose?

187. S. Pongor, P.C. Ulrich, F.A. Bencsath and A. Cerami
Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose

188. A. Bono, G. Caimi, A. Catania, A. Sarno and L. Pandolfo
Red cell peroxide metabolism in Diabetes Mellitus
189. N. Uzel, A. Sivas, M. Uysal and H. Oz
Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus

190. F.B. Davis, P.J. Davis, G. Nat, S.D. Blas,
M. MacGillivray, S. Gutman and M.J. Feldman
The effect of in vitro glucose administration on human erythrocyte Ca$^{2+}$-ATPase activity and on
enzyme responsiveness in vitro to thyroid hormone
and calmodulin
Diabetes 34 639-646 (1985)

191. T. Kamada and S. Otsuji
Lower levels of erythrocyte membrane fluidity in
diabetic patients. A spin label study
Diabetes 32 585-591 (1983)

192. D.E. McMillan, N.G. Utterback and J. La Puma
Reduced erythrocyte deformability in diabetes
Diabetes 27 895-901 (1978)

193. C.M. Peterson, R.L. Jones, R.J. Koenig, E.T. Melvin
and M.L. Lehrman
Reversible hematologic sequelae of diabetes mellitus

194. G.P. Pescarmona, A. Bosia and D. Ghigo
Shortened red cell life span in diabetes : Mechanism of hemolysis. In "Advances in Red Blood
(1982)

195. B. Mannervik, A-C. Aronsson and G. Tibbelin
Glyoxalase I from human erythrocytes

Purification and characterization of glyoxalase I from Pseudomonas putida
(1986)

197. J.C. Ball and D.L. Vander Jagt
Purification of S-2-hydroxyacylglutathione
hydrolase (glyoxalase II) from rat erythrocytes

198. G.B. Principato, G. Rosi, V. Talesa, V. Bocchini
and E. Giovannini
Purification of S-2-hydroxyacylglutathione
hydrolase (glyoxalase II) from calf brain
199. S.S. Hall, A.M. Doweyko and F. Jordan
Glyoxalase I enzyme studies. 4. General base
catalysed enediol proton transfer rearrangement of
methyl- and phenylglyoxalglutathionylhemithiol
acetal to S-lactoyl- and S-mandeloylglutathione
followed by hydrolysis. A model for the glyoxalase
enzyme system
J. Amer. Chem. Soc. 100 5934-5939 (1978)

200. M.H. Davis, D.F. Birt and R.C. Schnell
Direct enzymatic assay for reduced and oxidised
glutathione

201. E. Beutler
"Red Cell Metabolism. A Manual of Biochemical
Methods. 2nd Ed", Grune and Stratton, New York
(1975)

and S. LaBella
Inducers of erythroid differentiation in K562 human
leukemia cells

203. N. Mendelsohn, H.S. Gilbert, J.K. Christman and
G. Acs
Effect of maturation on the response of human
promyelocytic leukemia cells (HL-60) to the tumour
promoter 12-O-tetradecanoylphorbol-13-acetate
Cancer Res. 40 1469-1474 (1980)

204. M.J. Tisdale
Induction of haemoglobin in the human leukaemia
cell line K562 by monomethyltriazenes and
imidazotetrazinones
Biochem. Pharmac. 43 2077-2082 (1985)

205. F. Gaskin, C.R. Cantor and M.L. Shelanski
Biochemical studies on the in vitro assembly and
disassembly of microtubules

206. C. Heusel, D. Bonne and M-F. Carlier
Is microtubule assembly a biphasic process? A
fluorimetric study using
4',6-diamidino-2-phenylindole as a probe

207. R. Palomares, V. Prasad, R.F. Luduena and
R. Manso-Martinez
Mechanism of endogenous phosphorylation of
microtubule proteins during GTP-induced microtubule
assembly and implications for stability of the
assembled structures
208. A.D. Bershadsky and V.I. Gelfand
ATP-dependent regulation of cytoplasmic microtubule
disassembly
Proc. Natl. Acad. Sci. USA 78 3610-3613
(1981)

209. M.J. De Brabander, R. Van de Veire, F. Aerts,
M. Borgers and P.A.J. Janssen
The effects of methyl[5-(2-thienylcarbonyl)-1H-
benzimidazol-2-yl]carbamate (R 17 934; NSC 238159),
a new synthetic antitumoral drug interfering with
microtubules, on mammalian cells cultured in
vitro
Cancer Res. 36 905-916 (1976)

210. T. Jerzykowski, R. Winter, W. Matuszewski
and Z. Szczurek
Glyoxalase II activity in tumours
Experientia 15 32-33 (1975)

211. P.J. Thornalley and P. Bellavite
Modification of the glyoxalase system during the
functional activation of human neutrophils
Biochim. Biophys. Acta in press

212. K. Murata, Y. Inoue, T. Saikusa, K. Watanabe,
Y. Fukuda, M. Shimosaka and A. Kimura
Metabolism of \( \alpha \)-ketoaldehydes in yeast: Inducible
formation of methylglyoxal reductase and
its relation to growth arrest of Saccharomyces
cerevisiae
J. Ferment. Technol. 64 1-4 (1986)

213. O. Ramaswamy, S. Pal, S.K. Sopory and
S.G. Mukherjee
Effect of squaric acid and isoascorbate on
glyoxalase-I cell division and DNA synthesis in
Datura callus
Basic Life Sci. 22 43-46 (1983)

214. O. Ramaswamy, S. Pal, S. Guha-Mukherjee
and S.K. Sopory
Correlation of glyoxalase I activity with cell
proliferation in Datura callus culture

215. L. Wilson, K. Anderson, L. Grisham and D. Chin
Biochemical mechanisms of action of microtubule
inhibitors. In "Microtubules and Microtubule
Inhibitors" (M. Borgers and M. de Brabander eds),
p 103-113, North-Holland, Amsterdam (1975)

216. R.E. Ostlund Jr, J.T. Leung and S.V. Hajek
Regulation of microtubule assembly in cultured
fibroblasts
217. D.L. Purich and D. Kristofferson
Microtubule assembly: A review of progress, principles, and perspectives.
Advam. Protein Chem. 36 133-212 (1984)

218. M.L. Shelanski, F. Gaskin and C.R. Cantor
Microtubule assembly in the absence of added nucleotides
Proc. Natl. Acad. Sci. USA 70 765-768 (1973)

Purification of tubulin and associated high molecular weight proteins from porcine brain and
characterization of microtubules assembly in vitro

220. R.C. Weisenberg
Kinetic and steady state analysis of microtubule assembly

221. R.D. Sloboda, S.A. Rudolph, J.T. Rosenbaum and
P. Greengard
Cyclic AMP-dependent endogenous phosphorylation of a microtubule-associated protein

222. S.J. Norton
Personnal Communication

223. M.I. Dury

The natural history of retinopathy in insulin-dependent juvenile-onset diabetes
Ophthalmol. 88 613-618 (1981)

Diabetic retinopathy in Joslin clinic patients with adult-onset diabetes

226. P.F. Palmberg
Diabetic retinopathy
Diabetes 26 703-709 (1977)
227. G. Leoncini, M. Maresca, F. Balestrero, U. Armani and A. Piana
Platelet glyoxalases in thrombocytosis

Type I diabetes and the HLA-D locus
Diabetologia 18 41-43 (1980)

229. A.G. Cudworth
Type I Diabetes Mellitus
Diabetologia 14 281-291 (1978)

230. V.M. Monnier, R.R. Kohn and A. Cerami
Accelerated age-related browning of collagen in Diabetes Mellitus


232. E. Schauenstein, H. Esterbauer and H. Zollner
"Aldehydes in Biological Systems. Their Natural Occurrence and Biological Activities.", Pion, London (1977)